

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2018239433 B2**

(54) Title
A genetically modified mouse expressing human APOE4p and mouse Trem2 p.R47H and methods of use thereof

(51) International Patent Classification(s)
A01K 67/027 (2006.01) **C07K 14/775** (2006.01)
C07K 14/705 (2006.01) **G01N 33/48** (2006.01)

(21) Application No: **2018239433** (22) Date of Filing: **2018.03.21**

(87) WIPO No: **WO18/175581**

(30) Priority Data

(31)	Number	(32)	Date	(33)	Country
	62/474,358		2017.03.21		US

(43) Publication Date: **2018.09.27**

(44) Accepted Journal Date: **2024.02.01**

(71) Applicant(s)
The Jackson Laboratory;Indiana University Research and Technology Corporation

(72) Inventor(s)
Howell, Gareth;Sasner, Michael;Carter, Gregory;Lamb, Bruce

(74) Agent / Attorney
Spruson & Ferguson, Level 24, Tower 2 Darling Park, 201 Sussex Street, Sydney, NSW, 2000, AU

(56) Related Art
US 6046381 A
TENG JIANG ET AL.: "Upregulation of TREM2 Ameliorates Neuropathology and Rescues Spatial Cognitive Impairment in a Transgenic Mouse Model of Alzheimer Disease", NEUROPSYCHOPHARMACOLOGY, vol. 39, 2014, pages 2949 - 2962, XP055543947
"Building Better Mouse Models for Late-Onset Alzheimer's", ALZFORUM, 20 January 2017 (2017-01-20), pages 1 - 8, XP055543957, Retrieved from the Internet
JP 2001017028 A
EP 1063298 A2

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 September 2018 (27.09.2018)



(10) International Publication Number
WO 2018/175581 A8

(51) International Patent Classification:

A01K 67/027 (2006.01) *C07K 14/775* (2006.01)
G01N 33/48 (2006.01) *C07K 14/705* (2006.01)

(21) International Application Number:

PCT/US2018/023565

(22) International Filing Date:

21 March 2018 (21.03.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/474,358 21 March 2017 (21.03.2017) US

(71) Applicants: **THE JACKSON LABORATORY** [US/US];
610 Main Street, Bar Harbor, ME 04609 (US). **INDIANA
UNIVERSITY RESEARCH AND TECHNOLOGY**

CORPORATION [US/US]; 518 Indiana Avenue, Indianapolis, IN 46202 (US).

(72) Inventors: **HOWELL, Gareth**; 10 Brendun Lane, Mount Desert, ME 04660 (US). **SASNER, Michael**; 116 Ledge lawn Ave., Bar Harbor, ME 04609 (US). **CARTER, Gregory**; Po Box 432, Seal Harbor, ME 04675 (US). **LAMB, Bruce**; 10487 Windermere, Carmel, IN 46032 (US).

(74) Agent: **DIPIETRANTONIO, Heather, J.** et al.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, Massachusetts 02210 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,

(54) Title: A GENETICALLY MODIFIED MOUSE EXPRESSING HUMAN APOE4 AND MOUSE Trem2 p.R47H AND METHODS OF USE THEREOF




FIG. 3A

(57) Abstract: Genetically modified mice characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease are provided wherein the genome of the mouse includes: 1) a DNA sequence encoding a human APOE4 protein (APOE4p) operably linked to a promoter; and 2) a DNA sequence encoding a mouse Trem2 protein having a mutation p.R47H (Trem2p) operably linked to a promoter, such that the mouse expresses human APOE4p and mouse Trem2p. Methods are provided for screening for a compound for use in the treatment of Alzheimer's disease using such genetically modified mice.



KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(48) Date of publication of this corrected version:

27 December 2018 (27.12.2018)

(15) Information about Correction:

see Notice of 27 December 2018 (27.12.2018)

Previous Correction:

see Notice of 01 November 2018 (01.11.2018)

~ 1 ~

A GENETICALLY MODIFIED MOUSE EXPRESSING HUMAN APOE4 AND MOUSE Trem2 p.R47H AND METHODS OF USE THEREOF

REFERENCE TO RELATED APPLICATION

[0001] This application claims priority from U.S. Provisional Patent Application Serial No. 62/474,358, filed March 21, 2017, the entire content of which is incorporated herein by reference.

5

GOVERNMENT SUPPORT

[0002] This invention was made with government support under AG054345 awarded by the National Institutes of Health. The government has certain rights in the invention.

10

FIELD OF THE INVENTION

[0003] The present invention relates generally to genetically modified mice useful as models of human Alzheimer disease. In specific aspects, the present invention relates to genetically modified mice expressing human APOE4 and mouse Trem2 p.R47H and methods of use thereof.

15

BACKGROUND OF THE INVENTION

[0004] One of the major obstacles to developing therapies for Alzheimer's disease (AD) is the lack of animal models to be used in preclinical trials. One reason for this may be that existing models are based on familial mutations, while the vast majority of the clinical population has non-familial late-onset AD.

20

[0005] Familial or early-onset Alzheimer's disease is caused by mutations in, or overexpression of, the amyloid precursor protein (*APP*) gene or mutations in presenilin genes (*PSEN1* or *PSEN2*). All of these lead to increased production of the Abeta42 peptide, which is thought to be neurotoxic. Dozens if not hundreds of mouse models that mimic aspects of familial Alzheimer's disease have been created. Many treatments have been shown to be effective in these familial Alzheimer's disease mouse models, but none have been effective when tested in clinical trials.

25

[0006] In contrast, late-onset Alzheimer's disease, which accounts for 95-98% of the human Alzheimer's disease patient population, does not have a simple and defined genetic etiology. Late-onset Alzheimer's disease is thought to be a multifactorial syndrome caused

30

by a variety of genetic and environmental causes interacting with the aging process. Because of this complexity, the genetic causes are still not fully understood and no useful mouse models of late-onset Alzheimer's disease in humans have been reported to date.

[0006a] Reference to any prior art in the specification is not an acknowledgement or suggestion that this prior art forms part of the common general knowledge in any jurisdiction or that this prior art could reasonably be expected to be combined with any other piece of prior art by a skilled person in the art.

SUMMARY OF THE INVENTION

[0006b] In a first aspect of the invention, there is provided a genetically modified mouse comprising:

a transgene encoding a humanized APOE4 protein (APOE4p), wherein the transgene comprises exon 1 of a mouse *Apoe4* gene and exons 2, 3 and 4 of a human *APOE4* gene; and

a mouse gene encoding a mouse Trem2 protein comprising a p.R47H mutation (Trem2p),

wherein the humanized APOEp and mouse Trem2p are expressed in the genetically modified mouse, and the genetically modified mouse exhibits one or more characteristic(s) of non-familial late-onset Alzheimer's disease selected from (a) microglia, amyloid plaques, tau aggregates, inflammation, synaptic and/or neuronal loss, cognitive deficit, or blood flow deficit in the brain of the genetically modified mouse (b) cerebrovascular leakage and (c) cholesterol metabolism.

[0006c] In a second aspect of the invention, there is provided a method for screening a putative treatment for human Alzheimer's disease, comprising:

administering a compound to a genetically modified mouse of the first aspect;

assessing an effect of the compound on one or more characteristic(s) of non-familial late-onset Alzheimer's disease selected from (a) microglia, amyloid plaques, tau aggregates, inflammation, synaptic and/or neuronal loss, cognitive deficit, or blood flow deficit in the brain of the genetically modified mouse, (b) cerebrovascular leakage, and (c) cholesterol metabolism; and

comparing the effect to a control mouse.

[0007] A genetically modified mouse characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease is provided according to aspects of the present invention wherein the genome of the mouse includes: 1) a DNA sequence encoding a human APOE4

2018239433 11 Jan 2024

protein (APOE4p), the DNA sequence encoding APOE4p operably linked to a promoter; and 2) a DNA sequence encoding a mouse Trem2 protein having a mutation p.R47H (Trem2p), the DNA sequence encoding Trem2p operably linked to a promoter, and wherein the mouse expresses human APOE4p and mouse Trem2p. According to aspects of the present invention, the mouse is homozygous for the DNA sequence encoding APOE4p and for the DNA sequence encoding Trem2p.

[0008] A genetically modified mouse characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease is provided according to aspects of the present invention wherein the genome of the mouse includes: 1) a DNA sequence encoding a human APOE4 protein (APOE4p), the DNA sequence encoding APOE4p operably linked to a promoter; and 2) a DNA sequence encoding a mouse Trem2 protein having a mutation p.R47H (Trem2p), the DNA sequence encoding Trem2p operably linked to a promoter, wherein the mouse expresses human APOE4p and mouse Trem2p, and wherein the APOE4p includes an amino acid sequence of: SEQ ID NO:1, or the APOE4p is encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:2 under highly stringent hybridization conditions. According to aspects of the present invention, the mouse is homozygous for the DNA sequence encoding APOE4p and for the DNA sequence encoding Trem2p.

[0009] A genetically modified mouse characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease is provided according to aspects of the present invention wherein the genome of the mouse includes: 1) a DNA sequence encoding a human APOE4 protein (APOE4p), the DNA sequence encoding APOE4p operably linked to a

- 3 -

promoter; and 2) a DNA sequence encoding a mouse Trem2 protein having a mutation p.R47H (Trem2p), the DNA sequence encoding Trem2p operably linked to a promoter, wherein the mouse expresses human APOE4p and mouse Trem2p, and wherein the mouse Trem2p includes an amino acid sequence of: SEQ ID NO:3, or the mouse Trem2p is encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:4 under highly stringent hybridization conditions. According to aspects of the present invention, the mouse is homozygous for the DNA sequence encoding APOE4p and for the DNA sequence encoding Trem2p.

[0010] A genetically modified mouse characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease is provided according to aspects of the present invention wherein the genome of the mouse includes: 1) a DNA sequence encoding a human APOE4 protein (APOE4p), the DNA sequence encoding APOE4p operably linked to a promoter; and 2) a DNA sequence encoding a mouse Trem2 protein having a mutation p.R47H (Trem2p), the DNA sequence encoding Trem2p operably linked to a promoter, wherein the mouse expresses human APOE4p and mouse Trem2p, wherein the APOE4p includes an amino acid sequence of: SEQ ID NO:1, or the APOE4p is encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:2 under highly stringent hybridization conditions, and wherein the mouse Trem2p includes an amino acid sequence of: SEQ ID NO:3, or the mouse Trem2p is encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:4 under highly stringent hybridization conditions. According to aspects of the present invention, the mouse is homozygous for the DNA sequence encoding APOE4p and for the DNA sequence encoding Trem2p.

[0011] A genetically modified mouse characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease is provided according to aspects of the present invention wherein the genetically modified mouse is a B6(SJL)-*ApoE*^{tm1.1(APOE*4)Adng/Trem2^{em1Adng}/J mouse whose genome includes: 1) a DNA sequence encoding human APOE4 protein (APOE4p), the DNA sequence encoding APOE4p operably linked to a promoter; and 2) a DNA sequence encoding mouse Trem2 protein having a mutation p.R47H (Trem2p), the DNA sequence encoding Trem2p operably linked to a promoter, wherein the mouse is homozygous for the DNA sequence encoding APOE4p and for the DNA sequence encoding Trem2p, and wherein the mouse expresses human APOE4p and mouse Trem2p.}

[0012] A method for screening for a treatment for use in the treatment of Alzheimer's disease is provided according to aspects of the present invention, including administering a treatment to a genetically modified mouse characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease is provided according to aspects of the present invention wherein the genome of the mouse includes: 1) a DNA sequence encoding a human APOE4 protein (APOE4p), the DNA sequence encoding APOE4p operably linked to a promoter; and 2) a DNA sequence encoding a mouse Trem2 protein having a mutation p.R47H (Trem2p), the DNA sequence encoding Trem2p operably linked to a promoter, and wherein the mouse expresses human APOE4p and mouse Trem2p; and assessing an effect of the treatment on one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p relevant to non-familial late-onset Alzheimer's disease on the mouse. According to aspects of the present invention, the mouse is homozygous for the DNA sequence encoding APOE4p and for the DNA sequence encoding Trem2p. According to aspects of the present invention, assessing an effect of the treatment includes comparing the effect of the treatment on the genetically modified mouse with a control. According to aspects of the present invention, the control includes administering the treatment to a mouse which does not express human APOE4p and mouse Trem2p and assessing an effect of the treatment on the mouse which does not express human APOE4p and mouse Trem2p. According to aspects of the present invention, the control includes administering the treatment to a wild-type C57BL/6J mouse and assessing an effect of the treatment on the wild-type C57BL/6J mouse. According to aspects of the present invention, the control includes administering the treatment to an APOE3-expressing mouse and assessing an effect of the treatment on the APOE3-expressing mouse.

[0013] A method for screening for a treatment for use in the treatment of Alzheimer's disease is provided according to aspects of the present invention, including administering a treatment to a genetically modified mouse characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease is provided according to aspects of the present invention wherein the genome of the mouse includes: 1) a DNA sequence encoding a human APOE4 protein (APOE4p), the DNA sequence encoding APOE4p operably linked to a promoter; and 2) a DNA sequence encoding a mouse Trem2 protein having a mutation p.R47H (Trem2p), the DNA sequence encoding Trem2p operably linked to a promoter,

- 5 -

wherein the mouse expresses human APOE4p and mouse Trem2p, and wherein the APOE4p includes an amino acid sequence of: SEQ ID NO:1, or the APOE4p is encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:2 under highly stringent hybridization conditions; and assessing an effect of the treatment on one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p relevant to non-familial late-onset Alzheimer's disease on the mouse. According to aspects of the present invention, the mouse is homozygous for the DNA sequence encoding APOE4p and for the DNA sequence encoding Trem2p. According to aspects of the present invention, assessing an effect of the treatment includes comparing the effect of the treatment on the genetically modified mouse with a control. According to aspects of the present invention, the control includes administering the treatment to a mouse which does not express human APOE4p and mouse Trem2p and assessing an effect of the treatment on the mouse which does not express human APOE4p and mouse Trem2p. According to aspects of the present invention, the control includes administering the treatment to a wild-type C57BL/6J mouse and assessing an effect of the treatment on the wild-type C57BL/6J mouse. According to aspects of the present invention, the control includes administering the treatment to an APOE3-expressing mouse and assessing an effect of the treatment on the APOE3-expressing mouse.

[0014] A method for screening for a treatment for use in the treatment of Alzheimer's disease is provided according to aspects of the present invention, including administering a treatment to a genetically modified mouse characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease is provided according to aspects of the present invention wherein the genome of the mouse includes: 1) a DNA sequence encoding a human APOE4 protein (APOE4p), the DNA sequence encoding APOE4p operably linked to a promoter; and 2) a DNA sequence encoding a mouse Trem2 protein having a mutation p.R47H (Trem2p), the DNA sequence encoding Trem2p operably linked to a promoter, wherein the mouse expresses human APOE4p and mouse Trem2p, and wherein the mouse Trem2p includes an amino acid sequence of: SEQ ID NO:3, or the mouse Trem2p is encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:4 under highly stringent hybridization conditions; and assessing an effect of the treatment on one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p relevant to non-familial late-onset Alzheimer's disease on the mouse. According to aspects of the present invention, the mouse is homozygous for the DNA sequence encoding APOE4p

and for the DNA sequence encoding Trem2p. According to aspects of the present invention, assessing an effect of the treatment includes comparing the effect of the treatment on the genetically modified mouse with a control. According to aspects of the present invention, the control includes administering the treatment to a mouse which does not express human APOE4p and mouse Trem2p and assessing an effect of the treatment on the mouse which does not express human APOE4p and mouse Trem2p. According to aspects of the present invention, the control includes administering the treatment to a wild-type C57BL/6J mouse and assessing an effect of the treatment on the wild-type C57BL/6J mouse. According to aspects of the present invention, the control includes administering the treatment to an APOE3-expressing mouse and assessing an effect of the treatment on the APOE3-expressing mouse.

[0015] A method for screening for a treatment for use in the treatment of Alzheimer's disease is provided according to aspects of the present invention, including administering a treatment to a genetically modified mouse characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease is provided according to aspects of the present invention wherein the genome of the mouse includes: 1) a DNA sequence encoding a human APOE4 protein (APOE4p), the DNA sequence encoding APOE4p operably linked to a promoter; and 2) a DNA sequence encoding a mouse Trem2 protein having a mutation p.R47H (Trem2p), the DNA sequence encoding Trem2p operably linked to a promoter, wherein the mouse expresses human APOE4p and mouse Trem2p, wherein the APOE4p includes an amino acid sequence of: SEQ ID NO:1, or the APOE4p is encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:2 under highly stringent hybridization conditions, and wherein the mouse Trem2p includes an amino acid sequence of: SEQ ID NO:3, or the mouse Trem2p is encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:4 under highly stringent hybridization conditions; and assessing an effect of the treatment on one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p relevant to non-familial late-onset Alzheimer's disease on the mouse. According to aspects of the present invention, the mouse is homozygous for the DNA sequence encoding APOE4p and for the DNA sequence encoding Trem2p. According to aspects of the present invention, assessing an effect of the treatment includes comparing the effect of the treatment on the genetically modified mouse with a control. According to aspects of the present invention, the control includes

administering the treatment to a mouse which does not express human APOE4p and mouse Trem2p and assessing an effect of the treatment on the mouse which does not express human APOE4p and mouse Trem2p. According to aspects of the present invention, the control includes administering the treatment to a wild-type C57BL/6J mouse and assessing an effect of the treatment on the wild-type C57BL/6J mouse. According to aspects of the present invention, the control includes administering the treatment to an APOE3-expressing mouse and assessing an effect of the treatment on the APOE3-expressing mouse.

[0016] A method for screening for a treatment for use in the treatment of Alzheimer's disease is provided according to aspects of the present invention, including administering a treatment to a genetically modified mouse characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease is provided according to aspects of the present invention wherein the genetically modified mouse is a B6(SJL)-*ApoE^{tm1.1(APOE*4)AdinJ}* Trem2^{em1AdinJ}/J mouse whose genome includes: 1) a DNA sequence encoding human APOE4 protein (APOE4p), the DNA sequence encoding APOE4p operably linked to a promoter; and 2) a DNA sequence encoding mouse Trem2 protein having a mutation p.R47H (Trem2p), the DNA sequence encoding Trem2p operably linked to a promoter, wherein the mouse is homozygous for the DNA sequence encoding APOE4p and for the DNA sequence encoding Trem2p, and wherein the mouse expresses human APOE4p and mouse Trem2p; and assessing an effect of the treatment on one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p relevant to non-familial late-onset Alzheimer's disease on the mouse. According to aspects of the present invention, assessing an effect of the treatment includes comparing the effect of the treatment on the genetically modified mouse with a control. According to aspects of the present invention, the control includes administering the treatment to a mouse which does not express human APOE4p and mouse Trem2p and assessing an effect of the treatment on the mouse which does not express human APOE4p and mouse Trem2p. According to aspects of the present invention, the control includes administering the treatment to a wild-type C57BL/6J mouse and assessing an effect of the treatment on the wild-type C57BL/6J mouse. According to aspects of the present invention, the control includes administering the treatment to an APOE3-expressing mouse and assessing an effect of the treatment on the APOE3-expressing mouse.

[0017] A method for screening for a compound for use in the treatment of Alzheimer's disease is provided according to aspects of the present invention, including administering a

compound to a genetically modified mouse characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease is provided according to aspects of the present invention wherein the genome of the mouse includes: 1) a DNA sequence encoding a human APOE4 protein (APOE4p), the DNA sequence encoding APOE4p operably linked to a promoter; and 2) a DNA sequence encoding a mouse Trem2 protein having a mutation p.R47H (Trem2p), the DNA sequence encoding Trem2p operably linked to a promoter, and wherein the mouse expresses human APOE4p and mouse Trem2p; and assessing an effect of the compound on one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p relevant to non-familial late-onset Alzheimer's disease on the mouse. According to aspects of the present invention, the mouse is homozygous for the DNA sequence encoding APOE4p and for the DNA sequence encoding Trem2p. According to aspects of the present invention, assessing an effect of the compound includes comparing the effect of the compound on the genetically modified mouse with a control. According to aspects of the present invention, the control includes administering the compound to a mouse which does not express human APOE4p and mouse Trem2p and assessing an effect of the compound on the mouse which does not express human APOE4p and mouse Trem2p. According to aspects of the present invention, the control includes administering the compound to a wild-type C57BL/6J mouse and assessing an effect of the compound on the wild-type C57BL/6J mouse. According to aspects of the present invention, the control includes administering the compound to an APOE3-expressing mouse and assessing an effect of the compound on the APOE3-expressing mouse.

[0018] A method for screening for a compound for use in the treatment of Alzheimer's disease is provided according to aspects of the present invention, including administering a compound to a genetically modified mouse characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease is provided according to aspects of the present invention wherein the genome of the mouse includes: 1) a DNA sequence encoding a human APOE4 protein (APOE4p), the DNA sequence encoding APOE4p operably linked to a promoter; and 2) a DNA sequence encoding a mouse Trem2 protein having a mutation p.R47H (Trem2p), the DNA sequence encoding Trem2p operably linked to a promoter, wherein the mouse expresses human APOE4p and mouse Trem2p, and wherein the APOE4p includes an amino acid sequence of: SEQ ID NO:1, or the APOE4p is encoded by the

complement of a nucleic acid which hybridizes to SEQ ID NO:2 under highly stringent hybridization conditions; and assessing an effect of the compound on one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p relevant to non-familial late-onset Alzheimer's disease on the mouse. According to aspects of the present invention, the mouse is homozygous for the DNA sequence encoding APOE4p and for the DNA sequence encoding Trem2p. According to aspects of the present invention, assessing an effect of the compound includes comparing the effect of the compound on the genetically modified mouse with a control. According to aspects of the present invention, the control includes administering the compound to a mouse which does not express human APOE4p and mouse Trem2p and assessing an effect of the compound on the mouse which does not express human APOE4p and mouse Trem2p. According to aspects of the present invention, the control includes administering the compound to a wild-type C57BL/6J mouse and assessing an effect of the compound on the wild-type C57BL/6J mouse. According to aspects of the present invention, the control includes administering the compound to an APOE3-expressing mouse and assessing an effect of the compound on the APOE3-expressing mouse.

[0019] A method for screening for a compound for use in the treatment of Alzheimer's disease is provided according to aspects of the present invention, including administering a compound to a genetically modified mouse characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease is provided according to aspects of the present invention wherein the genome of the mouse includes: 1) a DNA sequence encoding a human APOE4 protein (APOE4p), the DNA sequence encoding APOE4p operably linked to a promoter; and 2) a DNA sequence encoding a mouse Trem2 protein having a mutation p.R47H (Trem2p), the DNA sequence encoding Trem2p operably linked to a promoter, wherein the mouse expresses human APOE4p and mouse Trem2p, and wherein the mouse Trem2p includes an amino acid sequence of: SEQ ID NO:3, or the mouse Trem2p is encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:4 under highly stringent hybridization conditions; and assessing an effect of the compound on one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p relevant to non-familial late-onset Alzheimer's disease on the mouse. According to aspects of the present invention, the mouse is homozygous for the DNA sequence encoding APOE4p and for the DNA sequence encoding Trem2p. According to aspects of the present invention, assessing an effect of the compound includes comparing the effect of the compound on the

genetically modified mouse with a control. According to aspects of the present invention, the control includes administering the compound to a mouse which does not express human APOE4p and mouse Trem2p and assessing an effect of the compound on the mouse which does not express human APOE4p and mouse Trem2p. According to aspects of the present invention, the control includes administering the compound to a wild-type C57BL/6J mouse and assessing an effect of the compound on the wild-type C57BL/6J mouse. According to aspects of the present invention, the control includes administering the compound to an APOE3-expressing mouse and assessing an effect of the compound on the APOE3-expressing mouse.

[0020] A method for screening for a compound for use in the treatment of Alzheimer's disease is provided according to aspects of the present invention, including administering a compound to a genetically modified mouse characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease is provided according to aspects of the present invention wherein the genome of the mouse includes: 1) a DNA sequence encoding a human APOE4 protein (APOE4p), the DNA sequence encoding APOE4p operably linked to a promoter; and 2) a DNA sequence encoding a mouse Trem2 protein having a mutation p.R47H (Trem2p), the DNA sequence encoding Trem2p operably linked to a promoter, wherein the mouse expresses human APOE4p and mouse Trem2p, wherein the APOE4p includes an amino acid sequence of: SEQ ID NO:1, or the APOE4p is encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:2 under highly stringent hybridization conditions, and wherein the mouse Trem2p includes an amino acid sequence of: SEQ ID NO:3, or the mouse Trem2p is encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:4 under highly stringent hybridization conditions; and assessing an effect of the compound on one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p relevant to non-familial late-onset Alzheimer's disease on the mouse. According to aspects of the present invention, the mouse is homozygous for the DNA sequence encoding APOE4p and for the DNA sequence encoding Trem2p. According to aspects of the present invention, assessing an effect of the compound includes comparing the effect of the compound on the genetically modified mouse with a control. According to aspects of the present invention, the control includes administering the compound to a mouse which does not express human APOE4p and mouse Trem2p and assessing an effect of the compound on the mouse which does not express

human APOE4p and mouse Trem2p. According to aspects of the present invention, the control includes administering the compound to a wild-type C57BL/6J mouse and assessing an effect of the compound on the wild-type C57BL/6J mouse. According to aspects of the present invention, the control includes administering the compound to an APOE3-expressing mouse and assessing an effect of the compound on the APOE3-expressing mouse.

[0021] A method for screening for a compound for use in the treatment of Alzheimer's disease is provided according to aspects of the present invention, including administering a compound to a genetically modified mouse characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease is provided according to aspects of the present invention wherein the genetically modified mouse is a B6(SJL)-*ApoE^{tm1.1(APOE*4)}Adinuj Trem2^{em1Adinuj}/J* mouse whose genome includes: 1) a DNA sequence encoding human APOE4 protein (APOE4p), the DNA sequence encoding APOE4p operably linked to a promoter; and 2) a DNA sequence encoding mouse Trem2 protein having a mutation p.R47H (Trem2p), the DNA sequence encoding Trem2p operably linked to a promoter, wherein the mouse is homozygous for the DNA sequence encoding APOE4p and for the DNA sequence encoding Trem2p, and wherein the mouse expresses human APOE4p and mouse Trem2p; and assessing an effect of the compound on one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p relevant to non-familial late-onset Alzheimer's disease on the mouse. According to aspects of the present invention, the mouse is homozygous for the DNA sequence encoding APOE4p and for the DNA sequence encoding Trem2p. According to aspects of the present invention, assessing an effect of the compound includes comparing the effect of the compound on the genetically modified mouse with a control. According to aspects of the present invention, the control includes administering the compound to a mouse which does not express human APOE4p and mouse Trem2p and assessing an effect of the compound on the mouse which does not express human APOE4p and mouse Trem2p. According to aspects of the present invention, the control includes administering the compound to a wild-type C57BL/6J mouse and assessing an effect of the compound on the wild-type C57BL/6J mouse. According to aspects of the present invention, the control includes administering the compound to an APOE3-expressing mouse and assessing an effect of the compound on the APOE3-expressing mouse.

BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 is a schematic diagram of a humanized ApoE4 expression construct described in detail in examples herein.

5 [0023] Figure 2 is an image of a Western blot of brain tissue from B6(SJL)-*ApoE*^{tm1.1(APOE*4)AdinJ} *Trem2*^{em1AdinJ}/J (common name: B6J.APOE4/Trem2) mice (lanes 4-6) and control (wild-type (WT) C57BL/6J (abbreviated B6J) mice (lanes 1-3) brain tissue.

[0024] Figure 3A is a graph showing results of an assay for high density lipoprotein (HDL) in blood samples obtained from 12 month old B6J.APOE4/Trem2 mice and 12 month
10 old C57BL/6J control mice.

[0025] Figure 3B is a graph showing results of an assay for low density lipoprotein (LDL) in blood samples obtained from 12 month old B6J.APOE4/Trem2 mice and 12 month old C57BL/6J control mice.

[0026] Figure 3C is a graph showing results of an assay for total cholesterol in blood
15 samples obtained from 12 month old B6J.APOE4/Trem2 mice and 12 month old C57BL/6J control mice.

[0027] Figure 4 shows representative images of B6J.APOE4/Trem2 tissue at 7-8 months of age immunostained to show Collagen IV (Col IV) and Fibrin(ogen) along with representative images from similar sagittal sections of brain from control C57BL/6J
20 (abbreviated B6J) mice which were similarly immunostained.

[0028] Figure 5 is a gene expression heatmap of differentially-expressed genes in B6J.APOE4/Trem2 mice compared to wild-type control B6J mice.

DETAILED DESCRIPTION OF THE INVENTION

25 [0029] The present invention relates generally to a genetically modified mouse which is a model of non-familial late-onset Alzheimer's disease and which encodes two exogenously introduced risk factors for non-familial late-onset AD in its genome, such that the mouse produces human apolipoprotein E4 (APOE4) and mouse Trem2 p.R47H proteins.

[0030] Human apolipoprotein is a polymorphic protein with three isoforms designated
30 ApoE2, ApoE3 and ApoE4. These three isoforms differ from each other with respect to the identity of amino acids at positions 130 and 176 in the amino acid sequence of the proteins (corresponding to positions 112 and 158 in the mature APOE protein without the 18 amino acid signal peptide). ApoE2 is characterized by cysteine at both 130 and 176, ApoE3 is

characterized by cysteine at 130 and arginine at 176 and ApoE4 is characterized by arginine at both 130 and 176. Individuals having one or more ApoE4 alleles are at greater risk for developing non-familial late-onset AD and a number of mechanisms relating to pathology have been proposed, see for example, DiBattista *et al.*, 2016, Exp. Neurol. 280:97-105; Bu *et al.*, Nature Reviews Neuroscience, 2009, 10:333-344; Huang *et al.*, Cell, 2017, 168:1-15; and Tambini *et al.*, EMBO Reports, 2016, 17:27-36.

[0031] Trem2 (triggering receptor expressed on myeloid cells 2) is an immune phagocytic receptor expressed by brain microglia. Trem2 triggers phagocytosis of cell debris and regulates aspects of the inflammatory response. A rare variant in *TREM2*, p.R47H, is significantly associated with Alzheimer's disease in humans.

[0032] In specific embodiments, the present invention relates to a genetically modified mouse whose genome includes a DNA sequence encoding human APOE4 protein and a DNA sequence encoding mouse Trem2 protein having the R47H point mutation.

[0033] A human *APOE4* DNA sequence (hereinafter APOE4g) encoding human APOE4 protein (hereinafter APOE4p or "human APOE4") is shown herein as SEQ ID NO:2. An encoded APOE4p is shown herein as SEQ ID NO:1.

[0034] A mouse mutant *Trem2* DNA sequence (hereinafter Trem2g) encoding mouse Trem2 protein having the R47H point mutation (hereinafter Trem2p or "mouse Trem2p") is shown herein as SEQ ID NO:4. An encoded Trem2p is shown herein as SEQ ID NO:3.

[0035] One or more genetic modifications can be introduced into a mouse genome to encode a variant of APOE4p and/or a variant of Trem2p in a genetically modified mouse according to embodiments of methods of the present invention.

[0036] As used herein, the term "variant" refers to APOE4p or Trem2p containing one or more mutations in its amino acid sequence compared to the corresponding protein of SEQ ID NO:1 or SEQ ID NO:3. For example, such mutations can be one or more amino acid substitutions, additions, and/or deletions, so long as the variant of APOE4p or Trem2p retains the functional characteristics of APOE4p or Trem2p of SEQ ID NO:1 or SEQ ID NO:3, respectively.

[0037] In particular embodiments, a variant APOE4p according to embodiments of the present invention has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater identity to SEQ ID NO:1 over its entire length, and has R (Arginine) and R (Arginine) as amino acids 130 and 176 of the APOE4 protein including an 18 amino acid signal peptide,

shown herein as SEQ ID NO:1, as well as retains the functional characteristics of APOE4p of SEQ ID NO:1.

[0038] In particular embodiments, a variant APOE4p according to embodiments of the present invention has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater identity to SEQ ID NO:15 over its entire length, and has R (Arginine) and R (Arginine) as amino acids 112 and 158 of the APOE4 protein not including the 18 amino acid signal peptide, shown herein as SEQ ID NO:15, as well as retains the functional characteristics of APOE4p of SEQ ID NO:15.

[0039] In particular embodiments, a variant Trem2p according to embodiments of the present invention has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater identity to SEQ ID NO:3 over its entire length and retains the functional characteristics of Trem2p of SEQ ID NO:3.

[0040] Mutations can be introduced using standard molecular biology techniques, such as CRISPR technology. Alternative techniques include site-directed mutagenesis and PCR-mediated mutagenesis and the like. One of skill in the art will recognize that one or more amino acid mutations can be introduced without altering the functional properties of APOE4p and mouse Trem2p proteins.

[0041] Assays for assessment of functional properties of APOE4p, Trem2p and variants are known in the art.

[0042] Conservative amino acid substitutions can be made in APOE4p and Trem2p proteins to produce APOE4p and Trem2p variants. Conservative amino acid substitutions are art recognized substitutions of one amino acid for another amino acid having similar characteristics. For example, each amino acid may be described as having one or more of the following characteristics: electropositive, electronegative, aliphatic, aromatic, polar, hydrophobic and hydrophilic. A conservative substitution is a substitution of one amino acid having a specified structural or functional characteristic for another amino acid having the same characteristic. Acidic amino acids include aspartate, glutamate; basic amino acids include histidine, lysine, arginine; aliphatic amino acids include isoleucine, leucine and valine; aromatic amino acids include phenylalanine, glycine, tyrosine and tryptophan; polar amino acids include aspartate, glutamate, histidine, lysine, asparagine, glutamine, arginine, serine, threonine and tyrosine; and hydrophobic amino acids include alanine, cysteine, phenylalanine, glycine, isoleucine, leucine, methionine, proline, valine and tryptophan; and conservative substitutions include substitution among amino acids within each group. Amino

acids may also be described in terms of relative size, alanine, cysteine, aspartate, glycine, asparagine, proline, threonine, serine, valine, all typically considered to be small.

[0043] APOE4p and Trem2p variants can include synthetic amino acid analogs, amino acid derivatives and/or non-standard amino acids, illustratively including, without limitation, 5 alpha-aminobutyric acid, citrulline, canavanine, cyanoalanine, diaminobutyric acid, diaminopimelic acid, dihydroxy-phenylalanine, djenkolic acid, homoarginine, hydroxyproline, norleucine, norvaline, 3-phosphoserine, homoserine, 5-hydroxytryptophan, 1-methylhistidine, 3-methylhistidine, and ornithine.

[0044] It will be appreciated by those of ordinary skill in the art that, due to the 10 degenerate nature of the genetic code, nucleic acid sequences other than SEQ ID NO:2 and SEQ ID NO:4 encode APOE4p and Trem2p, respectively, and that such alternate nucleic acids may be introduced into a mouse genome to produce a genetically modified mouse expressing APOE4p and Trem2p of the disclosure.

[0045] The singular terms "a," "an," and "the" are not intended to be limiting and include 15 plural referents unless explicitly stated otherwise or the context clearly indicates otherwise.

[0046] The terms "expressing" and "expresses" refer to transcription of a gene to produce a corresponding mRNA and/or translation of the mRNA to produce the corresponding protein.

[0047] APOE4p and Trem2p variants are encoded by nucleic acids having a high degree 20 of identity with SEQ ID NO:2 or SEQ ID NO:4, respectively. The complement of a nucleic acid encoding an APOE4p variant specifically hybridizes with SEQ ID NO:2 encoding APOE4p under high stringency conditions. The complement of a nucleic acid encoding a Trem2p variant specifically hybridizes with SEQ ID NO:4 encoding Trem2p under high stringency conditions.

[0048] The term "nucleic acid" refers to RNA or DNA molecules having more than one 25 nucleotide in any form including single-stranded, double-stranded, oligonucleotide or polynucleotide. The term "nucleotide sequence" refers to the ordering of nucleotides in an oligonucleotide or polynucleotide in a single-stranded form of nucleic acid.

[0049] The terms "hybridization" and "hybridizes" refer to pairing and binding of 30 complementary nucleic acids. Hybridization occurs to varying extents between two nucleic acids depending on factors such as the degree of complementarity of the nucleic acids, the melting temperature, T_m , of the nucleic acids and the stringency of hybridization conditions, as is well known in the art.

[0050] The term “stringency of hybridization conditions” refers to conditions of temperature, ionic strength, and composition of a hybridization medium with respect to particular common additives such as formamide and Denhardt’s solution. Determination of particular hybridization conditions relating to a specified nucleic acid is routine and is well known in the art, for instance, as described in J. Sambrook and D.W. Russell, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press; 3rd Ed., 2001; and F.M. Ausubel, Ed., *Short Protocols in Molecular Biology*, Current Protocols; 5th Ed., 2002. High stringency hybridization conditions are those which only allow hybridization of substantially complementary nucleic acids. Typically, nucleic acids having about 85-100% complementarity are considered highly complementary and hybridize under high stringency conditions. Intermediate stringency conditions are exemplified by conditions under which nucleic acids having intermediate complementarity, about 50-84% complementarity, as well as those having a high degree of complementarity, hybridize. In contrast, low stringency hybridization conditions are those in which nucleic acids having a low degree of complementarity hybridize.

[0051] The terms “specific hybridization” and “specifically hybridizes” refer to hybridization of a particular nucleic acid to a target nucleic acid without substantial hybridization to nucleic acids other than the target nucleic acid in a sample.

[0052] Stringency of hybridization and washing conditions depends on several factors, including the T_m of the probe and target and ionic strength of the hybridization and wash conditions, as is well-known to the skilled artisan. Hybridization and conditions to achieve a desired hybridization stringency are described, for example, in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, 2001; and Ausubel, F. *et al.*, (Eds.), *Short Protocols in Molecular Biology*, Wiley, 2002.

[0053] An example of high stringency hybridization conditions is hybridization of nucleic acids over about 100 nucleotides in length in a solution containing 6X SSC, 5X Denhardt’s solution, 30% formamide, and 100 micrograms/ml denatured salmon sperm at 37°C overnight followed by washing in a solution of 0.1X SSC and 0.1% SDS at 60°C for 15 minutes. SSC is 0.15M NaCl/0.015M Na citrate. Denhardt’s solution is 0.02% bovine serum albumin/0.02% FICOLL/0.02% polyvinylpyrrolidone.

[0054] The term “complementary” refers to Watson-Crick base pairing between nucleotides and specifically refers to nucleotides hydrogen bonded to one another with thymine or uracil residues linked to adenine residues by two hydrogen bonds and cytosine

and guanine residues linked by three hydrogen bonds. In general, a nucleic acid includes a nucleotide sequence described as having a "percent complementarity" to a specified second nucleotide sequence. For example, a nucleotide sequence may have 80%, 90%, or 100% complementarity to a specified second nucleotide sequence, indicating that 8 of 10, 9 of 10 or 10 of 10 nucleotides of a sequence are complementary to the specified second nucleotide sequence. For instance, the nucleotide sequence 3'-TCGA-5' is 100% complementary to the nucleotide sequence 5'-AGCT-3'. Further, the nucleotide sequence 3'-TCGA- is 100% complementary to a region of the nucleotide sequence 5'-TTAGCTGG-3'.

[0055] To determine the percent identity of two amino acid sequences or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino acid or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % identity=number of identical overlapping positions/total number of positions X100%). In one embodiment, the two sequences are the same length or differ in length by no more than 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9% or 10% of the total length of the reference sequence.

[0056] The determination of percent identity between two sequences can also be accomplished using a mathematical algorithm. A preferred, non-limiting example of a mathematical algorithm utilized for the comparison of two sequences is the algorithm of Karlin and Altschul, 1990, PNAS 87:2264 2268, modified as in Karlin and Altschul, 1993, PNAS. 90:5873 5877. Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul *et al.*, 1990, J. Mol. Biol. 215:403. BLAST nucleotide searches are performed with the NBLAST nucleotide program parameters set, e.g., for score=100, wordlength=12 to obtain nucleotide sequences homologous to a nucleic acid molecules of the present invention. BLAST protein searches are performed with the XBLAST program parameters set, e.g., to score 50, wordlength=3 to obtain amino acid sequences homologous to a protein molecule of the present invention. To obtain gapped alignments for comparison purposes, Gapped BLAST are utilized as described in Altschul *et al.*, 1997, Nucleic Acids Res. 25:3389 3402. Alternatively, PSI BLAST is used to perform an iterated search which

detects distant relationships between molecules (Id.). When utilizing BLAST, Gapped BLAST, and PSI Blast programs, the default parameters of the respective programs (e.g., of XBLAST and NBLAST) are used (see, e.g., the NCBI website). Another preferred, non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the
5 algorithm of Myers and Miller, 1988, CABIOS 4:11 17. Such an algorithm is incorporated in the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 is used.

[0057] The percent identity between two sequences is determined using techniques
10 similar to those described above, with or without allowing gaps. In calculating percent identity, typically only exact matches are counted.

[0058] Nucleic acids encoding APOE4p, Trem2p or a variant of either thereof can be isolated from natural sources, generated recombinantly or made by chemical synthetic techniques using well-known methodology.

15 [0059] Genetically modified mice

[0060] A genetically modified mouse is provided according to embodiments of the present invention whose genome includes a nucleic acid encoding APOE4p operably linked to a promoter, wherein the animal expresses the encoded APOE4p, and whose genome includes a nucleic acid encoding Trem2p operably linked to a promoter, wherein the animal
20 expresses the encoded Trem2p.

[0061] A genetically modified mouse is provided according to embodiments of the present invention whose genome includes a nucleic acid encoding APOE4p operably linked to the endogenous mouse Apoe promoter, wherein the animal expresses the encoded APOE4p and whose genome includes a nucleic acid encoding Trem2p operably linked to the
25 endogenous mouse Trem2 promoter, wherein the animal expresses the encoded Trem2p.

[0062] Any of various methods can be used to introduce a genetic modification into a mouse genome to produce a genetically modified mouse expressing APOE4p and Trem2p.

[0063] Genome editing methods for generating a genetically modified mouse according to embodiments of the present invention whose genome includes a nucleic acid encoding
30 APOE4p operably linked to a promoter, wherein the animal expresses the encoded APOE4p and whose genome includes a nucleic acid encoding Trem2p operably linked to a promoter, wherein the animal expresses the encoded Trem2p, include, but are not limited to, site directed mutagenesis, recombination-based methods and nuclease genome editing techniques.

[0064] Genome editing techniques can be used to modify a genomic sequence by introduction of a discrete mutation at a predetermined target site in the genome.

[0065] For example, one or more nucleotides in a genomic sequence can be replaced with one or more different nucleotides using a genome editing technique so that the genomic
5 sequence encodes a protein with a single amino acid difference, or multiple amino acid differences, compared to the unmodified genomic sequence.

[0066] Genome editing techniques can also be used to modify a genomic sequence by insertion of a coding sequence into the genome at a predetermined target site, a “knock-in” technique.

10 [0067] As used herein, the terms “target site” and “target sequence” in the general context of a genetic editing technique refer to a nucleic acid sequence that defines a portion of a chromosomal sequence to be edited.

[0068] For example, a nucleic acid sequence encoding a protein can be inserted at a predetermined target site in the genome so that the genome includes a nucleic acid encoding
15 the protein and the protein is expressed. The nucleic acid sequence can also contain a promoter to drive expression of the encoded protein or expression of the encoded protein can be driven by an endogenous promoter when the nucleic acid is inserted in a position so that it is operably linked to the endogenous promoter.

[0069] According to particular aspects of the present invention, a point mutation is
20 introduced into the genome of a first mouse using a genome editing technique so that the mouse encodes Trem2p, and a nucleic acid encoding human APOE4 is inserted into the Apoe4 gene in the genome of a second mouse by a “knock-in” genome editing technique so that the genome of the second mouse contains a “humanized” APOE4 gene as shown in Figure 1, containing exon 1 of the mouse Apoe4 gene and exons 2, 3 and 4 of the human
25 APOE4 gene. The first and second mice are then bred, naturally or by artificial methods, to obtain a genetically modified mouse whose genome includes a DNA sequence encoding APOE4p and a DNA sequence encoding Trem2p.

[0070] According to particular aspects of the present invention, a point mutation is
30 introduced into the genome of a first mouse using CRISPR genome editing technique so that the mouse encodes Trem2p, and a nucleic acid encoding human APOE4 is introduced into the Apoe4 gene in the genome of a second mouse by a “knock-in” CRISPR genome editing technique so that the genome of the second mouse contains a “humanized” APOE4 gene as shown in Figure 1, containing exon 1 of the mouse Apoe4 gene and exons 2, 3 and 4 of the

human APOE4 gene. The first and second mice are then bred naturally or by artificial methods to produce a genetically modified mouse whose genome includes a DNA sequence encoding APOE4p and a DNA sequence encoding Trem2p.

[0071] Genomic editing is performed, for example, by methods described herein, and as detailed in J. P. Sundberg and T. Ichiki, Eds., *Genetically Engineered Mice Handbook*, CRC Press; 2006; M. H. Hofker and J. van Deursen, Eds., *Transgenic Mouse Methods and Protocols*, Humana Press, 2002; A. L. Joyner, *Gene Targeting: A Practical Approach*, Oxford University Press, 2000; *Manipulating the Mouse Embryo: A Laboratory Manual*, 3rd edition, Cold Spring Harbor Laboratory Press; December 15, 2002, ISBN-10: 0879695919; Kursad Turksen (Ed.), *Embryonic stem cells: methods and protocols in Methods Mol Biol.* 2002;185, Humana Press; *Current Protocols in Stem Cell Biology*, ISBN: 978047015180; Meyer et al., *PNAS USA*, 2010, vol. 107 (34), 15022–15026; and Doudna, J. et al. (eds.) *CRISPR-Cas: A Laboratory Manual*, 2016, CSHP. A brief description of several genomic editing techniques is described herein.

[0072] Nuclease Techniques for Genetic Modification of Mice

[0073] A genetic modification method, such as but not limited to, a nuclease genetic editing technique, can be used to introduce a desired DNA sequence into the genome at a predetermined target site, such as methods using a homing endonuclease, integrase, meganuclease, transposon, nuclease-mediated process using a zinc finger nuclease (ZFN), a Transcription Activator-Like (TAL), a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas, or Drosophila Recombination-Associated Protein (DRAP). Briefly, a genetic modification method that can be used includes introducing into an ES cell, iPS cell, somatic cell, fertilized oocyte or embryo, RNA molecules encoding a targeted TALEN, ZFN, CRISPR or DRAP and at least one oligonucleotide, then selecting for an ES cell, iPS cell, somatic cell, fertilized oocyte or embryo with the desired genetic modification.

[0074] For example, a desired nucleic acid sequence can be introduced into the genome of a mouse at a predetermined target site by a nuclease technique, such as, but not limited to, CRISPR methodology, TAL (transcription activator-like) Effector methodology, Zinc Finger-Mediated Genome Editing or DRAP to produce a genetically modified mouse provided according to embodiments of the present invention whose genome includes a nucleic acid encoding APOE4p operably linked to a promoter, wherein the animal expresses the encoded APOE4p and whose genome includes a nucleic acid encoding Trem2p operably linked to a promoter, wherein the animal expresses the encoded Trem2p.

[0075] As used herein, the terms “target site” and “target sequence” in the context of a nuclease genetic editing technique refer to a nucleic acid sequence that defines a portion of a chromosomal sequence to be edited and to which a nuclease is engineered to recognize and bind, provided sufficient conditions for binding exist.

5 [0076] *CRISPR-Cas System*

[0077] CRISPRs (Clustered Regularly Interspaced Short Palindromic Repeats) are loci containing multiple short direct repeats that are found in the genomes of approximately 40% of sequenced bacteria and 90% of sequenced archaea and confer resistance to foreign DNA elements, see Horvath, 2010, Science, 327: 167–170; Barrangou *et al*, 2007, Science, 315: 10 1709-1712; and Makarova *et al*, 2011, Nature Reviews Microbiology, 9: 467-477.

[0078] CRISPR repeats range in size from 24 to 48 base pairs. They usually show some dyad symmetry, implying the formation of a secondary structure such as a hairpin, but are not truly palindromic. CRISPR repeats are separated by spacers of similar length.

[0079] The CRISPR-associated (cas) genes are often associated with CRISPR repeat-spacer arrays. More than forty different Cas protein families have been described (Haft *et al*. 15 2005, PLoS Comput Biol. 1 (6): e60). Particular combinations of cas genes and repeat structures have been used to define 8 CRISPR subtypes, some of which are associated with an additional gene module encoding repeat-associated mysterious proteins (RAMPs).

[0080] There are diverse CRISPR systems in different organisms, and one of the simplest is the type II CRISPR system from *Streptococcus pyogenes*: only a single gene encoding the Cas9 protein and two RNAs, a mature CRISPR RNA (crRNA) and a partially complementary trans-acting RNA (tracrRNA), are necessary and sufficient for RNA-guided silencing of foreign DNAs (Gasiunas *et al*, 2012, PNAS 109: E2579-E2586; Jinek *et al*, 20 2012, Science 337: 816-821). Maturation of crRNA requires tracrRNA and RNase III (Deltcheva *et al*, 2011, Nature 471: 602-607). However, this requirement can be bypassed by using an engineered small guide RNA (sgRNA) containing a designed hairpin that mimics the tracrRNA-crRNA complex (Jinek *et al*, 2012, Science 337: 816-821). Base pairing between the sgRNA and target DNA causes double-strand breaks (DSBs) due to the endonuclease activity of Cas9. Binding specificity is determined by both sgRNA-DNA base pairing and a short DNA motif (protospacer adjacent motif [PAM] sequence: NGG) 25 juxtaposed to the DNA complementary region (Marraffini & Sontheimer, 2010, Nature Reviews Genetics, 11: 181-190). For example, the CRISPR system requires a minimal set of two molecules, the Cas9 protein and the sgRNA, and therefore can be used as a host-

30

independent gene-targeting platform. The Cas9/CRISPR can be harnessed for site-selective RNA-guided genome editing, such as targeting insertion see for example, Carroll, 2012, Molecular Therapy 20: 1658-1660; Chang *et al*, 2013, Cell Research 23: 465-472; Cho *et al*, 2013, Nature Biotechnol 31: 230-232; Cong *et al*, 2013, Science 339: 819-823; Hwang *et al*, 2013, Nature Biotechnol 31: 227-229; Jiang *et al*, 2013, Nature Biotechnol 31: 233-239; Mali *et al*, 2013, Science 339: 823-826; Qi *et al*, 2013, Cell 152: 1173-1183; Shen *et al*, 2013, Cell Research 23: 720-723; and Wang *et al*, 2013, Cell 153: 910-918). In particular, Wang *et al*, 2013, Cell 153: 910-918 describe targeted insertion using the CRISPR/Cas9 system combined with oligonucleotides.

10 [0081] *TAL (transcription activator-like) Effectors*

[0082] Transcription activator-like (TAL) effectors or TALE (transcription activator-like effector) are derived from a plant pathogenic bacteria genus, *Xanthomonas*, and these proteins mimic plant transcriptional activators and manipulate the plant transcript, see Kay *et al.*, 2007, Science, 318:648-651.

15 [0083] TAL effectors contain a centralized domain of tandem repeats, each repeat containing approximately 34 amino acids, which are key to the DNA binding specificity of these proteins. In addition, they contain a nuclear localization sequence and an acidic transcriptional activation domain, for a review see Schornack *et al* 2006, J. Plant Physiol., 163(3): 256-272; Scholze and Boch, 2011, Curr Opin Microbiol, 14:47-53.

20 [0084] Specificity of TAL effectors depends on the sequences found in the tandem repeats. The repeated sequence includes approximately 102 bp and the repeats are typically 91-100% homologous with each other (Bonas *et al*, 1989, Mol Gen Genet 218: 127-136). Polymorphism of the repeats is usually located at positions 12 and 13 and there appears to be a one-to-one correspondence between the identity of the hypervariable diresidues at positions
25 12 and 13 with the identity of the contiguous nucleotides in the TAL-effector's target sequence, see Moscou and Bogdanove 2009, Science 326: 1501; and Boch *et al.* 2009, Science 326:1509-1512. The two hypervariable residues are known as repeat variable diresidues (RVDs), whereby one RVD recognizes one nucleotide of DNA sequence and ensures that the DNA binding domain of each TAL-effector can target large recognition sites
30 with high precision (15 - 30nt). Experimentally, the code for DNA recognition of these TAL-effectors has been determined such that an HD sequence at positions 12 and 13 leads to a binding to cytosine (C), NG binds to T, NI to A, C, G or T, NN binds to A or G, and IG binds to T. These DNA binding repeats have been assembled into proteins with new combinations

and numbers of repeats, to make artificial transcription factors that are able to interact with new sequences and activate the expression of a reporter gene in plant cells (Boch *et al.* 2009, Science 326:1509-1512). These DNA binding domains have been shown to have general applicability in the field of targeted genomic editing or targeted gene regulation in all cell types, see Gaj *et al.*, Trends in Biotechnol, 2013, 31(7):397-405. Moreover, engineered TAL effectors have been shown to function in association with exogenous functional protein effector domains such as a nuclease, not naturally found in natural Xanthomonas TAL-effect or proteins in mammalian cells. TAL nucleases (TALNs or TALENs) can be constructed by combining TALs with a nuclease, e.g. FokI nuclease domain at the N-terminus or C-terminus, Kim *et al.* 1996, PNAS 93:1156-1160; Christian *et al.* 2010, Genetics 186:757-761; Li *et al.*, 2011, Nucleic Acids Res 39: 6315-6325; and Miller *et al.*, 2011, Nat Biotechnol 29: 143-148. The functionality of TALENs to cause deletions by NHEJ has been shown in rat, mouse, zebrafish, Xenopus, medaka, rat and human cells, Ansai *et al.*, 2013, Genetics, 193: 739-749; Carlson *et al.*, 2012, PNAS, 109: 17382-17387; Hockemeyer *et al.*, 2011, Nature Biotechnol., 29: 731-734; Lei *et al.*, 2012, PNAS, 109: 17484-17489; Moore *et al.*, 2012, PLoS ONE, 7: e37877; Stroud *et al.*, 2013, J. Biol. Chem., 288: 1685-1690; Sung *et al.*, 2013, Nature Biotechnol 31: 23-24; Wefers *et al.*, 2013, PNAS 110: 3782-3787.

[0085] For TALEN, methods of making such are further described in the US Pat. Nos. 8,420,782, 8,450,471, 8,450,107, 8,440,432 and 8,440,431, and US patent application publications 2013/0137161 and 2013/0137174.

[0086] Other useful endonucleases may include, for example, HhaI, HindIII, NotI, BbvCI, EcoRI, BglI, and AlwI. The fact that some endonucleases (e.g., FokI) only function as dimers can be capitalized upon to enhance the target specificity of the TAL effector. For example, in some cases each FokI monomer can be fused to a TAL effector sequence that recognizes a different DNA target sequence, and only when the two recognition sites are in close proximity do the inactive monomers come together to create a functional enzyme. By requiring DNA binding to activate the nuclease, a highly site-specific restriction enzyme can be created.

[0087] In some embodiments, the TALEN may further include a nuclear localization signal or sequence (NLS). A NLS is an amino acid sequence that facilitates targeting the TALEN nuclease protein into the nucleus to introduce a double stranded break at the target sequence in the chromosome.

[0088] Nuclear localization signals are known in the art, see, for example, Makkerh *et al.* 1996, *Curr Biol.* 6:1025-1027. NLS include the sequence PKKKRKV (SEQ ID NO:16) from SV40 Large T-antigen, Kalderon 1984, *Cell*, 39: 499-509; RPAATKKAGQAKKK (SEQ ID NO:17) from nucleoplasmin, Dingwall *et al.*, 1988, *J Cell Biol.*, 107, 841-9. Further
5 examples are described in McLane and Corbett 2009, *IUBMB Life*, 61, 697-70; Dopie *et al.* 2012, *PNAS*, 109, E544-E552.

[0089] The cleavage domain may be obtained from any endonuclease or exonuclease. Non-limiting examples of endonucleases from which a cleavage domain may be derived include, but are not limited to, restriction endonucleases and homing endonucleases. See, for
10 example, 2002-2003 Catalog, New England Biolabs, Beverly, Mass.; and Belfort *et al.* (1997) *Nucleic Acids Res.* 25:3379-3388. Additional enzymes that cleave DNA are known, e.g., SI Nuclease; mung bean nuclease; pancreatic DNase I; micrococcal nuclease; yeast HO endonuclease. See also Linn *et al.* (eds.) *Nucleases*, Cold Spring Harbor Laboratory Press, 1993. One or more of these enzymes, or functional fragments thereof, may be used as a
15 source of cleavage domains.

[0090] Zinc Finger-Mediated Genome Editing

[0091] The use of zinc finger nucleases (ZFN) for gene editing, such as for targeted insertion via a homology-directed repair process, has been well established. For example, see
20 Carbery *et al.*, 2010, *Genetics*, 186: 451-459; Cui *et al.*, 2011, *Nature Biotechnol.*, 29: 64-68; Hauschild *et al.*, 2011, *PNAS*, 108: 12013-12017; Orlando *et al.*, 2010, *Nucleic Acids Res.*, 38: e152-e152; and Porteus & Carroll, 2005, *Nature Biotechnology*, 23: 967-973.

[0092] Components of the ZFN-mediated process include a zinc finger nuclease with a DNA binding domain and a cleavage domain. Such are described for example in Beerli *et al.* (2002) *Nature Biotechnol.*, 20:135-141; Pabo *et al.* (2001) *Ann. Rev. Biochem.*, 70:313-340;
25 Isalan *et al.* (2001) *Nature Biotechnol.* 19:656-660; Segal *et al.* (2001) *Curr Opin. Biotechnol.*, 12:632-637; and Choo *et al.* (2000) *Curr Opin. Struct. Biol.*, 10:411-416; and U.S. Pat. Nos. 6,453,242 and 6,534,261. Methods to design and select a zinc finger binding domain to a target sequence are known in the art, see for example Sera, *et al.*, *Biochemistry* 2002,41,7074-7081; U.S. Pat. Nos. 6,607,882; 6,534,261 and 6,453,242.

30 [0093] In some embodiments, the zinc finger nuclease may further include a nuclear localization signal or sequence (NLS). A NLS is an amino acid sequence that facilitates targeting the zinc finger nuclease protein into the nucleus to introduce a double stranded

break at the target sequence in the chromosome. Nuclear localization signals are known in the art. See, for example, Makkerh *et al.* (1996) *Current Biology* 6:1025-1027.

[0094] The cleavage domain may be obtained from any endonuclease or exonuclease. Non-limiting examples of endonucleases from which a cleavage domain may be derived include, but are not limited to, restriction endonucleases and homing endonucleases. See, for example, 2002-2003 Catalog, New England Biolabs, Beverly, Mass.; and Belfort *et al.* (1997) *Nucleic Acids Res.* 25:3379-3388. Additional enzymes that cleave DNA are known (e.g., SI Nuclease; mung bean nuclease; pancreatic DNase I; micrococcal nuclease; yeast HO endonuclease). See also Linn *et al.* (eds.) *Nucleases*, Cold Spring Harbor Laboratory Press, 1993. One or more of these enzymes (or functional fragments thereof) may be used as a source of cleavage domains. A cleavage domain also may be derived from an enzyme or portion thereof, as described above, that requires dimerization for cleavage activity.

[0095] Two zinc finger nucleases may be required for cleavage, as each nuclease includes a monomer of the active enzyme dimer. Alternatively, a single zinc finger nuclease may include both monomers to create an active enzyme dimer. Restriction endonucleases (restriction enzymes) are present in many species and are capable of sequence-specific binding to DNA (at a recognition site), and cleaving DNA at or near the site of binding. Certain restriction enzymes (e.g., Type IIS) cleave DNA at sites removed from the recognition site and have separable binding and cleavage domains. For example, the Type IIS enzyme FokI catalyzes double stranded cleavage of DNA, at 9 nucleotides from its recognition site on one strand and 13 nucleotides from its recognition site on the other. See, for example, U.S. Pat. Nos. 5,356,802; 5,436,150 and 5,487,994; as well as Li *et al.* (1992) *PNAS* 89:4275-4279; Li *et al.* (1993) *PNAS* 90:2764-2768; Kim *et al.* (1994) *PNAS* 91:883-887; Kim *et al.* (1994) *J. Biol. Chem.* 269:31, 978-31, 982. Thus, a zinc finger nuclease may include the cleavage domain from at least one Type IIS restriction enzyme and one or more zinc finger binding domains, which may or may not be engineered. Exemplary Type IIS restriction enzymes are described for example in International Publication WO 07/014275, the disclosure of which is incorporated by reference herein in its entirety. Additional restriction enzymes also contain separable binding and cleavage domains, and these also are contemplated by the present disclosure. See, for example, Roberts *et al.* (2003) *Nucleic Acids Res.* 31: 418-420. An exemplary Type IIS restriction enzyme, whose cleavage domain is separable from the binding domain, is FokI. This particular enzyme is active as a dimer (Bitinaite *et al.* 1998, *PNAS* 95: 10,570-10,575). Accordingly, for the purposes of the present

- 26 -

disclosure, the portion of the FokI enzyme used in a zinc finger nuclease is considered a cleavage monomer. Thus, for targeted double stranded cleavage using a FokI cleavage domain, two zinc finger nucleases, each including a FokI cleavage monomer, may be used to reconstitute an active enzyme dimer. Alternatively, a single polypeptide molecule containing a zinc finger binding domain and two FokI cleavage monomers may also be used. In certain embodiments, the cleavage domain may include one or more engineered cleavage monomers that minimize or prevent homodimerization, as described, for example, in U.S. Patent Publication Nos. 2005/0064474, 2006/0188987, and 2008/0131962, each of which is incorporated by reference herein in its entirety. By way of non-limiting example, amino acid residues at positions 446, 447, 479, 483, 484, 486, 487, 490, 491, 496, 498, 499, 500, 531, 534, 537 and 538 of FokI are all targets for influencing dimerization of the FokI cleavage half-domains. Exemplary engineered cleavage monomers of FokI that form obligate heterodimers include a pair in which a first cleavage monomer includes mutations at amino acid residue positions 490 and 538 of FokI and a second cleavage monomer that includes mutations at amino-acid residue positions 486 and 499. Thus, in one embodiment, a mutation at amino acid position 490 replaces Glu (E) with Lys (K); a mutation at amino acid residue 538 replaces Ile (I) with Lys (K); a mutation at amino acid residue 486 replaces Gln (Q) with Glu (E); and a mutation at position 499 replaces Ile (I) with Lys (K). Specifically, the engineered cleavage monomers may be prepared by mutating positions 490 from E to K and 538 from I to K in one cleavage monomer to produce an engineered cleavage monomer designated "E490K:I538K" and by mutating positions 486 from Q to E and 499 from I to L in another cleavage monomer to produce an engineered cleavage monomer designated "Q486E:I499L." The above described engineered cleavage monomers are obligate heterodimer mutants in which aberrant cleavage is minimized or abolished. Engineered cleavage monomers may be prepared using a suitable method, for example, by site-directed mutagenesis of wild-type cleavage monomers (FokI) as described in U.S. Patent Publication No. 2005/0064474.

[0096] The zinc finger nuclease described above may be engineered to introduce a double stranded break at the targeted site of integration. The double stranded break may be at the targeted site of integration, or it may be up to 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100 or 1000 nucleotides away from the site of integration. In some embodiments, the double stranded break may be up to 1, 2, 3, 4, 5, 10, 15, or 20 nucleotides away from the site of integration. In other embodiments, the double stranded break may be up to 10, 15, 20, 25,

30, 35, 40, 45 or 50 nucleotides away from the site of integration. In yet other embodiments, the double stranded break may be up to 50, 100 or 1000 nucleotides away from the site of integration.

[0097] The DRAP technology has been described in US Pat. Nos. 6,534,643, 6,858,716
5 and 6,830,910 and Watt *et al.*, 2006.

[0098] Optionally, a nucleic acid sequence encoding a protein can be inserted at a random target site in the genome so that the genome includes a nucleic acid encoding the protein. Typically, for random insertion, the nucleic acid sequence also contains a promoter to drive expression of the inserted nucleic acid.

10 [0099] In a further option, a nucleic acid encoding the desired protein, APOE4p, Trem2p or both APOE4p and Trem2p, is inserted into a predetermined target site in the genome other than the Apoe4 gene or the Trem2 gene.

[00100] For example, a nucleic acid encoding the desired protein, APOE4p, Trem2p or both APOE4p and Trem2p, is inserted into a predetermined target site in the genome known
15 to result in reliable expression, such as the Hprt or the Rosa26 locus.

[00101] According to aspects, for genomic editing at a predetermined target site, a targeting construct is made using recombinant DNA techniques and includes 5' and 3' sequences which are homologous to the targeted endogenous gene in the cell. The targeting construct further includes a selectable marker such as neomycin phosphotransferase,
20 hygromycin or puromycin, a nucleic acid encoding the desired protein, APOE4p, Trem2p or both APOE4p and Trem2p, and optionally a polyadenylation signal. To insure correct transcription and translation of the nucleic acid encoding the desired protein, the nucleic acid encoding the desired protein is either in frame with the endogenous gene locus, or a splice acceptor site and internal ribosome entry site (IRES) sequences can be included.

25 [00102] Such a targeting construct is transfected into a desired cell type, such as but not limited to, stem cells and the cells are screened to detect the correct genomic editing event using PCR, Southern blot or sequencing analysis. Cells with the correct genomic editing event can be further analyzed for expression of the encoded protein by protein analysis, such as ELISA or Western blot analysis. If desired, the nucleic acid encoding the selectable marker
30 can be configured to be removed by treating the stem cells with a recombinase such as Cre recombinase or Flippase (Flp). After recombinase treatment, the cells are analyzed for the presence of the nucleic acid encoding the desired protein.

[00103] Cells with the correct genomic editing event are selected and injected into preimplantation embryos as described above. Chimeric males are selected for breeding. Offspring can be analyzed for transmission of the ES cell genome by coat color and genetic analysis, such as PCR, Southern blot or sequencing and can be tested for expression of the
5 desired protein, such as by protein analysis (Western blot, ELISA) or other functional assays. Offspring expressing the correct proteins are intercrossed to create mice homozygous for the genetic modification(s).

[00104] Generation of a genetically modified mouse expressing APOE4p and Trem2p may include injection or transfection of appropriate nucleic acids, such as one or more one or
10 more nucleic acids encoding a desired protein and/or one or more expression constructs, such as an expression construct encoding a protein or RNA (such as cas9 or a guide RNA for use in CRISPR), into a preimplantation embryo or stem cells, such as embryonic stem (ES) cells or induced pluripotent stem (iPS) cells.

[00105] The terms “expression construct” and “expression cassette” are used herein to refer to a double-stranded recombinant DNA molecule containing a desired nucleic acid
15 coding sequence and containing one or more regulatory elements necessary or desirable for the expression of the operably linked coding sequence.

[00106] The term “regulatory element” as used herein refers to a nucleotide sequence which controls some aspect of the expression of nucleic acid sequences. Exemplary
20 regulatory elements illustratively include an enhancer, an internal ribosome entry site (IRES), an intron; an origin of replication, a polyadenylation signal (pA), a promoter, a transcription termination sequence, and an upstream regulatory domain, which contribute to the replication, transcription, post-transcriptional processing of a nucleic acid sequence. Those of ordinary skill in the art are capable of selecting and using these and other regulatory
25 elements in an expression construct with no more than routine experimentation. Expression constructs can be generated recombinantly or synthetically using well-known methodology.

[00107] The term “operably linked” as used herein refers to a nucleic acid in functional relationship with a second nucleic acid.

[00108] A regulatory element is included in an expression cassette is a promoter in
30 particular embodiments. The term “promoter” as used herein refers to a DNA sequence operably linked to a nucleic acid sequence to be transcribed such as a nucleic acid sequence encoding a desired molecule. A promoter is generally positioned upstream of a nucleic acid sequence to be transcribed and provides a site for specific binding by RNA polymerase and

other transcription factors. In specific embodiments, a promoter is generally positioned upstream of the nucleic acid sequence transcribed to produce the desired molecule, and provides a site for specific binding by RNA polymerase and other transcription factors. An included promoter can be a constitutive promoter or can provide inducible expression; and
5 can provide ubiquitous, tissue-specific or cell-type specific expression.

[00109] Ubiquitous promoters that can be included in an expression construct include, but are not limited to, a 3-phosphoglycerate kinase (PGK-1) promoter, a beta-actin promoter, a ROSA26 promoter, a heat shock protein 70 (Hsp70) promoter, an EF-1 alpha gene encoding elongation factor 1 alpha (EF1) promoter, an eukaryotic initiation factor 4A (eIF-4A1)
10 promoter, a chloramphenicol acetyltransferase (CAT) promoter and a CMV (cytomegalovirus) promoter.

[00110] These and other promoters are known in the art as exemplified in Abboud, S. L. et al, *J. Histochem & Cytochem.*, 51(7):941-949, 2003; Schorpp *et al.*, *Nucl. Acids Res.*, 24(9):1787-1788, 1996; McBurney, M. W. *et al.*, *Devel. Dynamics*, 200:278-293, 1994; and
15 Majumder, M. *et al.*, *Blood*, 87(8):3203-3211, 1996.

[00111] In addition to a promoter, one or more enhancer sequences may be included such as, but not limited to, cytomegalovirus (CMV) early enhancer element and an SV40 enhancer element.

[00112] Additional included sequences include an intron sequence such as the beta globin intron or a generic intron, a transcription termination sequence, and an mRNA
20 polyadenylation (pA) sequence such as, but not limited to SV40-pA, beta-globin-pA and SCF-pA.

[00113] An expression construct may include sequences necessary for amplification in bacterial cells, such as a selection marker (e.g. kanamycin or ampicillin resistance gene) and
25 a replicon.

[00114] For methods of DNA injection of an expression construct into a preimplantation embryo, the expression construct is optionally linearized before injection into mouse preimplantation embryos. Preferably the expression construct is injected into fertilized oocytes. Fertilized oocytes are collected from superovulated females the day after mating (0.5
30 dpc) and injected with the expression construct. The injected oocytes are either cultured overnight or transferred directly into oviducts of 0.5-day p.c. pseudopregnant females.

[00115] Methods for superovulation, harvesting of oocytes, expression construct injection and embryo transfer are known in the art and described in *Manipulating the Mouse Embryo*:

A Laboratory Manual, 3rd edition, Cold Spring Harbor Laboratory Press; December 15, 2002, ISBN-10: 0879695919.

[00116] Offspring can be tested for the presence of the desired mutation or inserted sequence by DNA analysis, such as PCR, Southern blot or sequencing. Mice which are carrying the desired mutation or inserted sequence can be tested for protein expression such as for example, by ELISA or Western blot analysis.

[00117] Alternatively, a nucleic acid or expression construct may be transfected into stem cells (ES cells or iPS cells) using well-known methods, such as electroporation, calcium-phosphate precipitation and lipofection. The cells are screened for the presence of the desired mutation or inserted sequence by DNA analysis, such as PCR, Southern blot or sequencing. Cells with the desired mutation or inserted sequence by can be tested for functional expression by protein analysis, such as for example, by ELISA or Western blot analysis.

[00118] Mouse ES cells are grown in media optimized for the particular line. Typically ES media contains 15% fetal bovine serum (FBS) or synthetic or semi-synthetic equivalents, 2 mM glutamine, 1 mM Na pyruvate, 0.1 mM non-essential amino acids, 50 U/ml penicillin and streptomycin, 0.1 mM 2-mercaptoethanol and 1000 U/ml LIF (plus, for some cell lines chemical inhibitors of differentiation) in Dulbecco's Modified Eagle Media (DMEM). A detailed description is known in the art (Tremml et al., 2008, Current Protocols in Stem Cell Biology, Chapter 1:Unit 1C.4. For review of inhibitors of ES cell differentiation, see Buehr, M., et al. (2003). Genesis of embryonic stem cells. Philosophical Transactions of the Royal Society B: Biological Sciences 358, 1397-1402.

[00119] Selected cells incorporating the desired mutation or inserted sequence can be injected into preimplantation embryos. For microinjection, ES or iPS cell are rendered to single cells using a mixture of trypsin and EDTA, followed by resuspension in ES media. Groups of single cells are selected using a finely drawn-out glass needle (20-25 micrometer inside diameter) and introduced through the embryo's zona pellucida and into the blastocysts cavity (blastocoel) using an inverted microscope fitted with micromanipulators.

[00120] Alternatively, to blastocyst injection, stem cells can be injected into early stage embryos (e.g. 2-cell, 4-cell, 8-cell, premorula or morula). Injection may be assisted with a laser or piezo pulses drilled opening the zona pellucida. Approximately 9-10 selected stem cells (ES or iPS cells) are injected per blastocysts, or 8-cell stage embryo, 6-9 stem cells per 4-cell stage embryo, and about 6 stem cells per 2-cell stage embryo. Following stem cell introduction, embryos are allowed to recover for a few hours at 37 °C in 5% CO₂, 5% O₂ in

nitrogen or cultured overnight before transfer into pseudopregnant recipient females. In a further alternative to stem cell injection, stem cells can be aggregated with morula stage embryos. All these methods are well established and can be used to produce stem cell chimeras. For a more detailed description see *Manipulating the Mouse Embryo: A Laboratory Manual*, 3rd edition (A. Nagy, M. Gertsenstein, K. Vintersten, R. Behringer, Cold Spring Harbor Laboratory Press; December 15, 2002, ISBN-10: 0879695919, Nagy *et al.*, 1990, Development 110, 815-821; US 7,576,259; Method for making genetic modifications, US7659442, US 7,294,754, and Kraus *et al.* 2010, Genesis 48, 394-399.

[00121] Pseudopregnant embryo recipients are prepared using methods known in the art.

Briefly, fertile female mice between 6-8 weeks of age are mated with vasectomized or sterile males to induce a hormonal state conducive to supporting surgically introduced embryos. At 2.5 days post coitum (dpc) up to 15 of the stem cell containing blastocysts are introduced into the uterine horn very near to the uterus-oviduct junction. For early stage embryos and morula, such embryos are either cultured in vitro into blastocysts or implanted into 0.5 dpc or 1.5 dpc pseudopregnant females according to the embryo stage into the oviduct. Chimeric pups from the implanted embryos are born 16-20 days after the transfer depending on the embryo age at implantation. Chimeric males are selected for breeding. Offspring can be analyzed for transmission of the ES cell genome by coat color and genetic analysis, such as PCR, Southern blot or sequencing. Further the expression of the encoded protein(s) can be analyzed by protein analysis (Western blot, ELISA) or other functional assays.

[00122] A genetically modified mouse of the present invention may be heterozygous or homozygous for the genetic modification.

[00123] According to aspects of the present invention, a genetically modified mouse of the present invention may be heterozygous or homozygous for the "knock-in" humanized APOE4 modification wherein the mouse expresses APOE4p and also may be heterozygous or homozygous for the mutated genomic sequence encoding Trem2p wherein the mouse expresses Trem2p.

[00124] Homozygous genetically modified mice expressing APOE4p can be crossed with homozygous genetically modified mice expressing Trem2p to create a congenic strain homozygous for both modifications and expressing both APOE4p and Trem2p according to embodiments.

[00125] Genetically modified mice of the present invention can be any of various strains.

[00126] A genetic modification can be introduced into the genome of an isolated mouse embryonic stem (ES) cell, a mouse induced pluripotent stem (iPS) cell, a mouse somatic cell, a fertilized mouse oocyte (zygote) or a mouse embryo in a knock-in strategy to produce a genetically modified mouse of the present invention.

5 [00127] Embodiments of the invention provide a genetically modified mouse that includes a desired genetic modification in all or substantially all of its cells, as well as a genetically modified mouse that includes a desired genetic modification in some, but not all its cells.

[00128] A genetically modified mouse according to aspects of the present invention can
10 include one or more additional genetic variants associated with increased risk of late-onset Alzheimer disease in humans.

[00129] Identification of Treatments and Compounds

[00130] Methods for screening for putative treatments for human Alzheimer's disease are provided according to embodiments of the present invention which include: administering a
15 putative treatment for Alzheimer's disease to a genetically modified mouse, wherein the genome of the mouse includes: 1) a DNA sequence encoding human APOE4 protein (APOE4p) operably linked to a promoter; and 2) a DNA sequence encoding mouse Trem2 protein having a mutation p.R47H (Trem2p) operably linked to a promoter, wherein the mouse expresses APOE4p and Trem2p and wherein the mouse is characterized by one or
20 more symptoms or signs associated with expression of APOE4p and Trem2p relevant to non-familial late-onset Alzheimer's disease of the present invention; and assessing an effect of the putative treatment on the mouse.

[00131] Methods for screening for putative treatments for human Alzheimer's disease are provided according to embodiments of the present invention which include: administering a
25 putative treatment for Alzheimer's disease to a B6(SJL)-*Apoe*^{tm1.1(APOE*4)AdinJ} *Trem2*^{em1AdinJ/J} mouse whose genome includes: 1) a DNA sequence encoding human APOE4 protein (APOE4p) operably linked to a promoter; and 2) a DNA sequence encoding mouse Trem2 protein having a mutation p.R47H (Trem2p) operably linked to a promoter, wherein the mouse is homozygous for the DNA sequence encoding APOE4p and for the DNA sequence
30 encoding Trem2p, and wherein the mouse expresses human APOE4p and mouse Trem2p; and assessing an effect of the putative treatment on the mouse.

[00132] Methods for screening for a compound for use in the treatment of Alzheimer's disease, are provided according to aspects of the present invention which include

administering a compound to a genetically modified mouse of the present invention; and assessing an effect of the compound in the treatment of one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p relevant to non-familial late-onset Alzheimer's disease. Assessing an effect of the compound in the treatment of one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p relevant to non-familial late-onset Alzheimer's disease preferably includes comparing the result of the assessment with a suitable control, such as, but not limited to, the effect of the compound on a control, such as an APOE3-expressing mouse or a wild-type mouse (e.g. a mouse carrying the *ApoE* gene).

[00133] Such signs and symptoms include, but are not limited to, any one or more of: 1) presence of significantly more microglia in the brain of a genetically modified mouse of the present invention compared to a control, such as an APOE3-expressing mouse or wild-type control mouse; 2) presence of significantly more amyloid plaques in the brain of a genetically modified mouse of the present invention compared to a control, such as an APOE3-expressing mouse or wild-type control mouse; 3) presence of significantly more tau aggregates in the brain of a genetically modified mouse of the present invention compared to a control, such as an APOE3-expressing mouse or wild-type control mouse; 4) presence of significantly more inflammation in the brain of a genetically modified mouse of the present invention compared to a control, such as an APOE3-expressing mouse or wild-type control mouse; 5) presence of significantly more synaptic and/or neuronal loss in the brain of a genetically modified mouse of the present invention compared to a control, such as an APOE3-expressing mouse or wild-type control mouse; 6) presence of significantly more cognitive deficit in the brain of a genetically modified mouse of the present invention compared to a control, such as an APOE3-expressing mouse or wild-type control mouse; 7) presence of significantly more indications of frailty in an aging genetically modified mouse of the present invention compared to a control, such as an APOE3-expressing mouse or wild-type control mouse; 8) presence of significantly more blood flow deficit in the brain of a genetically modified mouse of the present invention compared to a control, such as an APOE3-expressing mouse or wild-type control mouse; 9) a significant difference in presence, level, and/or function of one or more biomarkers of non-familial late-onset Alzheimer's disease in blood, serum, or tissue of a genetically modified mouse of the present invention compared to a control, such as an APOE3-expressing mouse or wild-type control mouse; 10) cerebrovascular leakage in a genetically modified mouse of the present invention compared

to a control, such as an APOE3-expressing mouse or wild-type control mouse; and 11) levels of one or more blood lipoproteins, such as high density lipoprotein, and low density lipoprotein, and/or cholesterol, in a genetically modified mouse of the present invention compared to a control, such as an APOE3-expressing mouse or wild-type control mouse.

5 [00134] According to aspects of the present invention, methods for screening for putative treatments for human Alzheimer's disease are provided wherein assessing an effect of a compound includes comparing the effect of the compound on the genetically modified mouse, wherein the genome of the mouse includes: 1) a DNA sequence encoding human APOE4 protein (APOE4p) operably linked to a promoter; and 2) a DNA sequence encoding
10 mouse Trem2 protein having a mutation p.R47H (Trem2p) operably linked to a promoter, wherein the mouse expresses APOE4p and Trem2p and wherein the mouse is characterized by one or more symptoms or signs associated with expression of APOE4p and Trem2p relevant to non-familial late-onset Alzheimer's disease of the present invention, with a control.

15 [00135] According to aspects of the present invention, methods for screening for putative treatments for human Alzheimer's disease are provided wherein assessing an effect of the compound includes comparing the effect of the compound on a B6(SJL)-*ApoE^{tm1.1}(APOE*4)Adng Trem2^{em1}Adng/J* mouse with a control.

[00136] A suitable control includes, for example, administering the compound to a
20 mouse which does not express human APOE4p and mouse Trem2p and assessing an effect of the compound on the mouse. A suitable control includes, for example, administering the compound to an APOE3-expressing mouse or wild-type control mouse. A wild-type control mouse can be any mouse which does not express human APOE4p and mouse Trem2p. A suitable control includes, for example, administering the compound to a wild-type C57BL/6J
25 mouse; and assessing an effect of the compound on the wild-type C57BL/6J mouse.

[00137] Symptoms or signs associated with expression of human APOE4p and mouse Trem2p relevant to non-familial late-onset Alzheimer's disease can be assessed by methods well-known in the art including, but not limited to, immunoassay, nucleic acid assay, histochemical staining, cognitive assays, *in vivo* imaging, physical assessment of the animals,
30 cerebrovascular leakage assessment, and morphological assessment of tissues and/or cells.

[00138] Immunoassays that can be used are well-known in the art and include, but are not limited to, enzyme-linked immunosorbent assay (ELISA) such as but not limited to, antigen capture ELISA, indirect ELISA, fixed cell ELISA; immunochromatography; antigen capture;

- 35 -

flow cytometry; immunoblot; immunoprecipitation; immunodiffusion; competitive immunoassays, immunocytochemistry; radioimmunoassay; and combinations of any of these. Generalized details of immunoassays are described in standard references, illustratively including Wild, D., *The Immunoassay Handbook*, 3rd Ed., Elsevier Science, 2005; Gosling, J. P., *Immunoassays: A Practical Approach*, Practical Approach Series, Oxford University Press, 2005; E. Harlow and D. Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, 1988; F. Breitling and S. Dübel, *Recombinant Antibodies*, John Wiley & Sons, New York, 1999; H. Zola, *Monoclonal Antibodies: Preparation and Use of Monoclonal Antibodies and Engineered Antibody Derivatives*, Basics: From Background to Bench, BIOS Scientific Publishers, 2000; B.K.C. Lo, *Antibody Engineering: Methods and Protocols*, Methods in Molecular Biology, Humana Press, 2003; F. M. Ausubel et al., Eds., *Short Protocols in Molecular Biology*, Current Protocols, Wiley, 2002; Ormerod, M. G., *Flow Cytometry: a practical approach*, Oxford University Press, 2000; and Givan, A. L., *Flow Cytometry: first principles*, Wiley, New York, 2001.

[00139] According to aspects of the present invention, nucleic acid assays to detect a nucleic acid analyte relevant to non-familial late-onset Alzheimer's disease in a genetically modified mouse of the present invention compared to a wild-type mouse includes, but is not limited to, nucleic acid amplification techniques such as, but not limited to, PCR, RT-PCR ligation-mediated PCR and phi-29 PCR; nucleic acid hybridization techniques such as, but not limited to, Northern blot, Southern blot, RNase protection assay, dot blot, transcriptome analysis, and *in situ* hybridization. Nucleic acid assays for both qualitative and quantitative assay of a nucleic acid in a sample are described in detail in standard references, illustratively including J. Sambrook and D.W. Russell, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press; 3rd Ed., 2001; F. M. Ausubel et al., Eds., *Short Protocols in Molecular Biology*, Current Protocols, Wiley, 2002; C.W. Dieffenbach et al., *PCR Primer: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, 2003; and V. Demidov et al., *DNA Amplification: Current Technologies and Applications*, Taylor & Francis, 2004.

[00140] Biomarker assays that can be used are well-known in the art and include, but are not limited to, assays of A β and tau species, neurofilaments, neurogranin, interleukins, TNF α , GM-CSF, and soluble Trem2 in cerebrospinal fluid (CSF), blood, serum, or tissue.

[00141] Cognitive assays that can be used are well-known in the art and include, but are not limited to, assays of spatial memory, short-term memory, long-term memory, assays of executive function, attentional tasks such as 3 and 5 choice serial reaction time tests, tests of

processing speed, set shifting tests, reversal learning tasks, assays of object memory, assays of pattern recognition, assays of passive avoidance memory, assays of habituation, and assays of novel object recognition, water maze testing, fear conditioning tests, radial arm water maze testing, Y-maze testing, T-maze testing, and open field habituation tests.

5 [00142] Physical assessment methods of the animals that can be used are well-known in the art and include, but are not limited to, assessment of indices of frailty in a genetically modified mouse of the present invention compared to a control, such as an APOE3-expressing mouse or a wild-type mouse as a comparison to normal aging.

[00143] *In vivo* imaging methods that can be used are well-known in the art and include,
10 but are not limited to, magnetic resonance imaging (MRI), computed tomography (CT) imaging, X-ray, optical imaging, and ultrasound imaging. Such imaging techniques can be used to assess one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p relevant to non-familial late-onset Alzheimer's disease including, but not limited to, amyloid or tau aggregation, abnormal blood flow, pathological neuronal loss, and
15 abnormal glucose metabolism.

[00144] Assessment of changes to one or more of: a transcriptomic profile, a proteomic profile, and a metabolic profile of a genetically modified mouse of the present invention compared to a wild-type mouse and/or compared to clinical samples can be performed using methods that are well-known in the art.

20 [00145] Assessment of inflammation can be performed by assay of one or more biomarkers of inflammation, such as, but not limited to, IL-8, IL-11, TNF-alpha, granulocyte-macrophage colony stimulating factor (GM-CSF), TGF-beta, VEGF, monocyte chemotactic factor-1, macrophage migratory inhibitory factor, s100B, fibrinogen, and interferon gamma-inducible protein 10. Such assays can be performed on samples obtained from a genetically
25 modified mouse of the present invention and a wild-type mouse, such as a sample of brain, spinal cord, blood, plasma, serum, cerebrospinal fluid or other relevant tissue or body fluid.

[00146] Morphological assessment of tissues and/or cells can include physical examination of gross anatomy and/or microscopic examination of tissues and/or cells with or without histochemical or cytochemical staining of the tissues and/or cells. Morphological
30 assessment of tissues and/or cells can include assessment of synaptic and neuronal loss.

[00147] A method for screening for a compound for use in the treatment of Alzheimer's disease in an individual human subject having or suspected of having Alzheimer's disease is provided according to aspects of the present invention which include administering a

- 37 -

compound to a genetically modified mouse of the present invention; and assessing an effect of the compound on amyloid and/or tau which are associated with expression of human APOE4p and mouse Trem2p relevant to non-familial late-onset Alzheimer's disease on the mouse. According to particular embodiments, assessing an effect of the compound on amyloid and/or tau includes assessing the level and/or localization of amyloid and/or tau. According to particular embodiments, assessing an effect of the compound on amyloid and/or tau includes assessing amyloid and/or tau aggregates in a genetically modified mouse of the present invention, such as assessment of aggregate size, number, location or a combination of any two or more thereof.

[00148] Cerebrovascular leakage is a key aspect of non-familial late-onset Alzheimer's disease and it is a surprising and unexpected finding of the present invention that expression of human APOE4p and mouse Trem2p results in cerebrovascular leakage.

[00149] A method for screening for a compound for use in the treatment of non-familial late-onset Alzheimer's disease in an individual human subject having or suspected of having non-familial late-onset Alzheimer's disease is provided according to aspects of the present invention which include administering a compound to a genetically modified mouse of the present invention; and assessing an effect of the compound on cerebrovascular leakage which is associated with expression of human APOE4p and mouse Trem2p relevant to non-familial late-onset Alzheimer's disease in the mouse. Assessing an effect of the compound on cerebrovascular leakage includes, but is not limited to, assessment of cerebrovascular permeability. The term "cerebrovascular permeability" refers to the capacity of a blood vessel wall to allow for normal movement of small molecules or substances such as water, ions, certain drugs and nutrients across the blood vessel wall while acting as a barrier to movement of larger molecules and substances, such as fibrinogen, and albumin. The term "cerebrovascular leakage" refers to an abnormality of blood vessels which results in leakage of larger molecules and substances, such as fibrinogen, and albumin, through blood vessel walls. Assays for assessing cerebrovascular leakage are well-known in the art, including *in vitro* assays using cells or tissues isolated from a genetically modified mouse of the present invention, and *in vivo* assays. A non-limiting example of an *in vivo* assay of cerebrovascular leakage includes intravenous injection of a labeled protein (e.g. Evans Blue-labeled albumin) and assessment of appearance of the dye-labeled protein in brain tissues, see for example, Radu et al., An *in vivo* Assay to Test Blood Vessel Permeability., J. Vis. Exp. 2013, (73):50062.

[00150] The putative treatment can be any treatment modality such as, but not limited to, administration of a compound. The term "compound" as used herein is not limited and encompasses small molecule chemicals and biologicals such as peptides, proteins, glycoproteins, including antibodies, for example.

5 [00151] Embodiments of inventive compositions and methods are illustrated in the following examples. These examples are provided for illustrative purposes and are not considered limitations on the scope of inventive compositions and methods.

[00152] Examples

[00153] Generation of a Genetically Modified Mouse Having a DNA Sequence

10 Encoding APOE4p in Its Genome

[00154] The mouse Apoe4 gene is located on chromosome 7 at 19,696,109 – 19,699,166. An APOE4 gene-targeting construct was made that included 4980 bp (SEQ ID NO:9) of mouse sequence, which defined the mouse 5' homology arm including exon 1 of mouse ApoE, 4292 bp (SEQ ID NO:10) of human APOE4 sequence including human protein coding
15 exons 2-4 of the human gene as well as an additional 1.5 kb of flanking human sequence after the 3'UTR to include any potential regulatory sequences.

[00155] Figure 1 shows a schematic diagram of the humanized ApoE4 construct (see "m/hAPOE targeting vector E4"). On Figure 1, (C C) above exon 4' shows the nt present in exon 4 for arginine at p.R310 and R176, respectively, isoform E4. Isoform E2 with (T T)
20 codes for cysteine at both C130 and C176, while E3 (T C) codes for cysteine at C130R and arginine at R176 sites.

[00156] Human APOE4 exon 4 contains sequence that codes for the ApoE4 isoform of the gene and encodes the nucleotide sequence for arginine at R130 and R176. It is noted that APOE4 includes an 18 amino acid signal peptide at the N-terminus of the protein such that
25 APOE4 including the signal peptide is 317 amino acids and the variant amino acids which differ among APOE2, APOE3 and APOE4 are at positions 130 and 176. In the mature APOE proteins (299 amino acids), the variant amino acids which differ among APOE2, APOE3 and APOE4 are at positions 112 and 158.

[00157] A Frt neo Frt selection cassette (FNF cassette, SEQ ID NO:11) was inserted after
30 the human sequence followed by a NdeI restriction site (for ease of Southern screening). The FNF cassette is followed by 5166 bp of mouse sequence (SEQ ID NO:12), the 3' homology arm. The resulting 14,438 bp synthesized construct was cloned into pBlight vector using

recombineering techniques, producing a construct called mApoE_hAPOE4_PGKneo_mAPOE for gene targeting in embryonic stem cells.

[00158] The ApoE4 gene-targeting construct was introduced into cultured embryonic stem (ES) cells of a C57Bl6 mouse strain by electroporation. Homologous recombination produced loci that retained all normal mouse regulatory sequences (plus non-coding exon one) together with the human APOE4 protein-encoding exons 2-4. Transfected ES cells were screened by Southern blot to ensure correct targeting. Three clones were identified that were correctly targeted. ES cells containing the correctly targeted locus were introduced into C57BL/6J embryos, and the resultant chimeric mice were bred with C57BL/6J mice. Offspring carrying the modified locus in the germ-line were interbred to generate the homozygous genetically modified genome. All F1 matings produced normal litter sizes with a Mendelian distribution of the locus.

[00159] Generation of a Genetically Modified Mouse Having a DNA Sequence Encoding Trem2p in Its Genome

[00160] The Trem2 R47H KI allele was generated at The Jackson Laboratory by pronuclear injection of Cas9 RNA (100 ng) and a single guide sequence (50 ng) GAAGCACTGGGGGAGACGCA (SEQ ID NO:7) with 183 nt donor oligo (40 ng) (GCCCTCAACACCACGGTGCTGCAGGGCATGGCCGGCCAGTCCTTGAGGGTGTCA TGTACTTATGACGCCTTGAAGCACTGGGGGAGACACAaGCaTGGTGTCTGGCAGC TGGGTGAGGAGGGCCCATGCCAGCGTGTGGTGAGCACACACGGTGTGTGGCTGC TGGCCTTCCTGAAGAAGCGG, SEQ ID NO:8) containing a nucleotide G>A point mutation (underlined uppercase "A" at nt 89 in SEQ ID NO:8) for amino acid sequence change at R47H and 2 silent mutations (lysine AAG>AAA (underlined lower case "a" at nt 93 in SEQ ID NO:8) and alanine GCC>GCA (underlined lower case "a" at nt 96 in SEQ ID NO:8)) into the gene (to prevent re-cutting of the donor sequence in homologous directed repair). The CRISPR strategy resulted in the specific R47H knock in, and silent mutations present in the Trem2 gene of founder mice.

[00161] Offspring carrying the modified allele in the germ-line were interbred to generate the homozygous genetically modified genome. All F1 matings produced normal litter sizes with a Mendelian distribution of the locus. The resulting inbred strain of mouse is designated C57BL/6J-Trem2^{em1Adpnc}/J (common name Trem2 R47H KI (JAX)) and expresses Trem2p.

[00162] Generation of A Genetically Modified Mouse Having a DNA Sequence Encoding APOE4p and a DNA Sequence Encoding Trem2p in Its Genome

[00163] In this example, a genetically modified mouse was generated by crossing an inbred strain of mouse, B6(SJL)-Apoe^{tm1.1(APOE*4)Adpnc}/J (common name APOE*4 KI (JAX)) expressing human APOE4p with an inbred strain of mouse, C57BL/6J-Trem2^{em1Adpnc}/J (common name Trem2 R47H KI (JAX)) expressing mouse Trem2p. The resulting genetically modified mice, homozygous for both the humanized *APOE4* allele and the R47H allele of the mouse *Trem2* gene, are designated B6(SJL)-Apoe^{tm1.1(APOE*4)Adnj} Trem2^{em1Adnj}/J (formerly B6(SJL)-Apoe^{tm1.1(APOE*4)Adpnc} Trem2^{em1Adpnc}/J, abbreviated as APOE4 X Trem2 R47H (JAX) mice), common name: B6J.APOE4/Trem2, which express both human APOE4 and mouse Trem2p.

[00164] Validation of Genetically Modified Mouse Model of Non-Familial Late-Onset Alzheimer's Disease

[00165] Tissue Harvesting, Protein Isolation and Sectioning

[00166] Mice were administered a lethal dose of Ketamine/Xylazine by intraperitoneal injection, and transcardially perfused with 1xPBS (phosphate buffered saline). Brains were dissected, and the right hemisphere was snap frozen for protein isolation, while the left hemisphere was fixed in 4% paraformaldehyde overnight at 4°C. The fixed hemispheres were rinsed with 1xPBS, cryoprotected in 10% sucrose, followed by 30% sucrose at 4°C, and finally embedded in OCT (optimal cutting temperature compound). Frozen brains were sectioned at 25 µm and stored at -80°C until required. Protein was extracted with Trizol Reagent (Life Technologies, Cat#15596-018) following manufacturer's guidelines. Protein pellets were resuspended in a solution of 1:1 8M urea and 1% SDS.

[00167] Immunofluorescence, Thioflavin S Staining, and Image Capture

[00168] Cryosections were rinsed with PBT (1xPBS with 1% TritonX-100) for 5 minutes (mins) then incubated with 500 µL of Liberate Antibody Binding Solution (L.A.B. - Polysciences Inc.) solution for 20 minutes at room temperature (RT) for antigen retrieval. Slides were then incubated overnight at 4°C in the following primary antibodies: rabbit polyclonal anti-GFAP (1:200, Dako); rabbit polyclonal anti-IBA1 (1:250, Wako); rabbit polyclonal anti-NeuN (1:100, Cell Signaling Inc); mouse monoclonal anti-non-phosphorylated neurofilament (1:200, Covance) and sheep polyclonal anti-TREM2 (1:200, RD Systems). The sheep polyclonal anti-TREM2 antibody was previously verified using Trem2 deficient mice. All antibodies were diluted in PBTB (1xPBS, 1% TritonX-100 and 1% BSA) containing 10% normal goat or donkey serum. After primary incubation, sections were

- 41 -

washed 3 times in PBT and incubated with appropriate secondary antibodies (goat anti-rabbit Alexa Fluor 488/594/633, goat anti-mouse Alexa Fluor 488, donkey anti-sheep Alexa Fluor 594, 1:1000 dilution, Life Technologies) for 2 hrs at RT.

[00169] All sections were then counterstained with DAPI and mounted with Aqua PolyMount (Polysciences). For Thioflavin S staining, sections stained with IBA1 and GFAP were further counterstained with 1% Thioflavin S (diluted in a 1:1 water:ethanol ratio). Slides were incubated for 8 mins at RT in 1% Thioflavin-S, washed in 80% ethanol, then 95% ethanol and finally in dH₂O and mounted. Images were taken using either the Leica SP5 confocal microscope or the Zeiss Axio Imager.Z2. For each antibody, all images were captured using identical parameters for accurate quantification.

[00170] Initial observations were performed in sections from both males and females. Quantification of cell numbers was performed on brain sections from at least 4–6 male mice, as there was no overt difference between sexes. For plaque counts, the number of plaques present in the entorhinal cortical region for each mouse was determined. For IBA1+ cells, 5 equally spaced images were captured (using 20× optical lens) of either the cortex, in the region of the entorhinal cortex, or the hippocampus, from a central brain section of each mouse. For NeuN+ cells, 5 equally spaced images were captured (using 20× optical lens). For IBA1+ cells associated with plaques, images of 8+ plaques per brain were imaged (using 20× optical lens).

[00171] Images were processed and all cells in the 20× image were counted using the cell counter plugin for ImageJ/FIJI. A single cell was determined as a DAPI stained nucleus associated with a cell specific antibody stain (e.g. IBA1 or NEUN). Cell numbers in the 5 images from each mouse were totaled and then averaged across mice. Mouse number and diet were masked to the investigator for all cell counting assays.

[00172] Western blot analysis demonstrates expression of human APOE4 in B6(SJL)-*Apoe*^{tm1.1(APOE*4)Adng} *Trem2*^{em1Adng}/J (common name: B6J.APOE4/Trem2) mice

[00173] Brain extracts (~25 micrograms protein) were diluted in 2x Laemmli sample buffer (Bio-Rad 1610737) and run on a 4-20% gradient (BioRad mini-protean TGX 456-1096) and transferred to a nitrocellulose membrane (InVitrogen IB301001).

[00174] Blots were blocked with 5% non-fat milk powder and probed overnight at +4°C with a human APOE4-specific antibody (Novus Biologicals NBP1-49529) at 1:100 dilution. Blots were then probed with secondary antibody (Millipore goat anti-mouse HRP AP191P) at 1:30,000 dilution for 2 hours at room temperature. Blots were detected using ECL.

chemiluminescent reagents (GE Healthcare RPN 2109) on Amersham Hyperfilm ECL (GE Healthcare 28906838).

[00175] An antibody that is specific for the human APOE4 variant (Novus Biologicals NBP1-49529 at 1:100 dilution) was used to probe Western blots of about 25 micrograms of protein from C57BL/6J (abbreviated B6J) or B6J.APOE4/Trem2 brain tissue. Figure 2 is an image of a Western blot of brain tissue from B6J.APOE4/Trem2 (lanes 4-6) and control (WT (B6J); lanes 1-3) brain tissue. As shown in Figure 2, human APOE4 protein expression was detected only in the protein from B6J.APOE4/Trem2 mice.

[00176] Blood chemistry shows altered metabolism in the B6J.APOE4/Trem2 mice

[00177] APOE variants have been shown to differentially regulate lipoprotein and cholesterol metabolism. Although the mechanisms by which the APOE4 variant increases the risk for Alzheimer's disease is not known, these effects on altered metabolism are thought to play a role. Blood samples obtained from 12 month old B6J.APOE4/Trem2 (abbreviated APOE4/Trem2 in Figures 3A, 3B and 3C) mice and 12 month old C57BL/6J control mice were assayed for high density lipoprotein (HDL), low density lipoprotein (LDL) and total cholesterol according to standard blood chemistry methods.

[00178] Blood, extracted at harvest, was stored in EDTA coated vials on ice and further centrifuged at 5000 RPM for 15mins. The plasma was removed and aliquoted for long term storage at -80°C. Plasma aliquots were profiled for the following: Total cholesterol (mg/dL), LDL (mg/dL), HDL (mg/dL). High density lipoprotein cholesterol (HDL) was assayed using the Wako L-Type HDL-C kit (Wako 99100101) as per manufacturer's instructions. LDL was assayed using Beckman Coulter LDL-Cholesterol kit (Beckman Coulter OSR6196) as per manufacturer's instructions. Total cholesterol was assayed using the Beckman Coulter Cholesterol kit (Beckman Coulter OSR6116).

[00179] Results are shown in Figures 3A, 3B, and 3C, respectively. These data show that the B6J.APOE4/Trem2 mouse has APOE4-dependent alterations in cholesterol metabolism, including reduced total cholesterol and reduced levels of both LDL and HDL.

[00180] Immunohistochemistry shows cerebrovascular leakage and inflammation in the B6J.APOE4/Trem2 mice

[00181] All mice were bred and housed in a 12/12 hours light/dark cycle. Eight month old mice were injected intraperitoneally with a lethal quantity of ketamine/xylazine according to IACUC approved procedures. Mice were perfused with 1X PBS (phosphate buffered saline) and whole brains were removed. One hemisphere was fixed in 4% paraformaldehyde

overnight at +4°C. Following fixation, the tissue was rinsed in 1X PBS, incubated in 10% sucrose overnight at +4°C, then incubated in 30% sucrose overnight at 4°C. Brains were then frozen in optimal cutting temperature (OCT) compound and stored at -80°C until sectioned. Frozen brains were sectioned at 25 microns and mounted on glass slides, and stored at -80°C until required for immunofluorescence staining.

[00182] Slides were dried and post fixed in 4% PFA. Sections were subsequently immersed in diH₂O for 3mins at 37°C, then transferred and incubated in 0.5mg/mL pepsin in 0.2N HCl for 15mins at 37°C. Sections were further washed in diH₂O for 3mins, transferred to a humidified chamber, and washed in 1xPBS. Sections were incubated overnight in Rabbit anti-fibrin (1:200) and Goat anti-ColIV (anti-collagen IV) (1:40) at +4°C in 1xPBT. Slides were washed in 1xPBT and incubated in the appropriate secondary antibodies at a concentration of 1:1000 (Donkey anti-rabbit IgG 594, Donkey anti-goat 488) for 2 hours at room temperature. Tissue was counterstained with DAPI and mounted using Aqua-Poly mount (Polyscience Inc). Staining was imaged on the Zeiss AxioImager at a magnification of 20x.

[00183] Sagittal brain sections of B6J.APOE4/Trem2 mice were immunostained for fibrinogen (fibrin) to detect cerebrovascular leakage. Representative images of B6J.APOE4/Trem2 tissue at 7-8 months of age are shown in Figure 4 along with representative images from similar sagittal sections of brain from control C57BL/6J (abbreviated B6J) mice. Arrows indicate cerebrovascular leakage as indicated by fibrin immunostaining outside of blood vessels. Blood vessels are shown by immunostaining for collagen IV (Col IV).

[00184] Vascular damage may be a key aspect of late-onset Alzheimer's disease pathology. Some existing mouse models of familial Alzheimer's disease have demonstrated cerebral amyloid angiopathy (CAA), but B6J.APOE4/Trem2 mice are the first model that does not over-express familial Alzheimer's disease mutations to show vascular deficits.

[00185] Transcriptional analysis demonstrates AD-relevant changes in gene expression in the B6J.APOE4/Trem2 model

[00186] Gene expression analysis was carried out with the NanoString Neuropathology gene panel. This assay measures the expression of 770 neuropathology-related genes. Female mice around eight months of age were assayed for the B6J.APOE4/Trem2 strain and the C57BL/6J (abbreviated B6J) strain, with three biological replicates of each strain.

[00187] Total RNA was extracted from brain homogenates. Tissues were lysed and homogenized in TRIzol Reagent (Ambion), then RNA was isolated using the miRNeasy Mini kit (Qiagen), according to manufacturers' protocols, including the optional DNase digest step. Sample concentration and quality were assessed using the Nanodrop 2000 spectrophotometer (Thermo Scientific) and the RNA 6000 Nano LabChip assay (Agilent Technologies).

[00188] RNA was hybridized and multiplexed with NanoString probes according to manufacturer's instructions. Counts for target genes were normalized to housekeeping genes to account for variability in RNA content. Data were analyzed using Nanostring nSolver Analysis Software.

[00189] Expression of each gene in the B6J.APOE4/Trem2 strain was compared to the control C57BL/6J strain and genes with significant ($p < 0.05$) expression were identified with a linear regression model as shown in Figure 5. Figure 5 is a gene expression heatmap of differentially-expressed genes in B6J.APOE4/Trem2 compared to C57BL/6J. Expression values are in Log2 fold change relative to the C57BL/6J average of each gene.

[00190] The probe used in this panel detects mouse Apoe but not human APOE. Because in this model mouse Apoe has been replaced by the human APOE4 variant, no Apoe expression is detected and this is shown as the most strongly down-regulated transcript.

[00191] The list of differentially-expressed genes contains multiple genes related to brain function and neurodegeneration. The Gene Ontology Biological Process and Panther Pathway annotations database was queried to identify processes and pathways represented by these genes. The relevant processes include, but are not limited to, the results in Table I which shows pathways and processes represented by the differentially-expressed genes in the B6J.APOE4/Trem2 strain. Notably, these interlinked processes and pathways include many highly relevant to neurodegeneration.

TABLE I	
Process or Pathway	Genes
Alzheimer's disease-amyloid secretase pathway	Pcsk2, Mapk10, Mapk9, Prkcq
5HT2 type receptor mediated signaling pathway	Slc18a2, Plcb2, Slc6a4, Gng2, Prkcq
Inflammation mediated by chemokine and cytokine signaling pathway	Akt3, Gnao1, Plcb3, Arrb2, Il6, Myh10, Gng2
Modulation of chemical synaptic transmission	Cnr1, Stx1a, Arrb2, Unc13a, Cdk5, Calb1, Slc6a4, Gria4

- 45 -

Neuron development	Cnr1, Thy1, Mapk10, Hcn1, Cdk5, Chl1, Il6, Mapk9, Myh10, Uchl1
Cognition	Cnr1, Amph, Cdk5, Calb1, Chl1, Slc6a4, Chmp2b
Apoptosis signaling	Akt3, Mapk10, Mapk9, Casp7, Prkcq
Aging	Cnr1, Slc18a2, Gnao1

[00192] Scientific and technical terms used herein are intended to have the meanings commonly understood by those of ordinary skill in the art. Such terms are found defined and used in context in various standard references illustratively including J. Sambrook and D.W.

- 5 Russell, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press; 3rd Ed., 2001; F.M. Ausubel, Ed., Short Protocols in Molecular Biology, Current Protocols; 5th Ed., 2002; B. Alberts et al., Molecular Biology of the Cell, 4th Ed., Garland, 2002; D.L. Nelson and M.M. Cox, Lehninger Principles of Biochemistry, 4th Ed., W.H. Freeman & Company, 2004; Herdewijn, P. (Ed.), Oligonucleotide Synthesis: Methods and Applications,
- 10 Methods in Molecular Biology, Humana Press, 2004; A. Nagy, M. Gertsenstein, K. Vintersten, R. Behringer (Eds) 2002, Manipulating the Mouse Embryo: A Laboratory Manual, 3rd edition, Cold Spring Harbor Laboratory Press, ISBN-10: 0879695919; and K. Turksen (Ed.), Embryonic stem cells: methods and protocols in Methods in Molecular Biology, 2002; 185, Humana Press; Current Protocols in Stem Cell Biology, ISBN:
- 15 9780470151808.

- 46 -

SEQUENCES

[00193] The amino acid sequence of APOE4p is shown along with exemplary nucleic acid sequences encoding APOE4p.

[00194] SEQ ID NO:1: APOE4p (317 amino acids)

5 MKVLWAALLVTFLAGCQAKVEQAVETEPEPELQQTEWQSGQRWELALGRFWDY
LRWVQTLSEQVQEELLSSQVTQELRALMDETMKELKAYKSELEEQLTPVAEETRAR
LSKELQAAQARLGADMEDVRGRLVQYRGEVQAMLGQSTEELRVRLASHLRKLRKR
LLRDADDLQKRLAVYQAGAREGAERGLSAIRERLGPLVEQGRVRAATVGSAGQPL
QERAQAWGERLRARMEEMGSRTRDRLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQ
10 ARLKSWFEPLVEDMQRQWAGLVEKVQAAVGTSAAPVPSDNH

[00195] SEQ ID NO:2: Exons 2, 3 and 4 of the human APOE4 genomic DNA sequence encoding human APOE4p including the 18 amino acid signal peptide

ACTGGCCAATCACAGGCAGGAAGATGAAGGTTCTGTGGGCTGCGTTGCTGGTCA
15 CATTCCTGGCAGGTATGGGGGCGGGGCTTGCTCGGTTCCCCCGCTCCTCCCCCT
CTCATCCTCACCTCAACCTCCTGGCCCCATTCAGGCAGACCCTGGGCCCCCTCTTC
TGAGGCTTCTGTGCTGCTTCCTGGCTCTGAACAGCGATTGACGCTCTCTGGGCCCT
CGGTTTCCCCCATCCTTGAGATAGGAGTTAGAAGTTGTTTTGTTGTTGTTGTTGTTGTT
TGTTGTTGTTTGTGTTTTTTTGAGATGAAGTCTCGCTCTGTGCGCCAGGCTGGAGTG
20 CAGTGGCGGGATCTCGGCTCACTGCAAGCTCCGCCCTCCAGGTCCACGCCATTCT
CCTGCCTCAGCCTCCCAAGTAGCTGGGACTACAGGCACATGCCACCACACCCGA
CTAACTTTTTTGTATTTTCAGTAGAGACGGGGTTTCACCATGTTGGCCAGGCTGGT
CTGGAACCTCCTGACCTCAGGTGATCTGCCCGTTTCGATCTCCCAAAGTGCTGGGA
TTACAGGCGTGAGCCACCGCACCTGGCTGGGAGTTAGAGGTTTCTAATGCATTGC
25 AGGCAGATAGTGAATACCAGACACGGGGCAGCTGTGATCTTTATTCTCCATCACC
CCCACACAGCCCTGCCTGGGGCACACAAGGACACTCAATACATGCTTTTCCGCTG
GGCGCGGTGGCTCACCCCTGTAATCCCAGCACTTTGGGAGGCCAAGGTGGGAGG
ATCACTTGAGCCCAGGAGTTCAACACCAGCCTGGGCAACATAGTGAGACCCTGT
CTCTACTAAAAATACAAAAATTAGCCAGGCATGGTGCCACACACCTGTGCTCTCA
30 GCTACTCAGGAGGCTGAGGCAGGAGGATCGCTTGAGCCCAGAAGGTCAAGGTTG
CAGTGAACCATGTTTCAGGCCGCTGCACTCCAGCCTGGGTGACAGAGCAAGACCC
TGTTTATAAATACATAATGCTTTCCAAGTGATTAAACCGACTCCCCCTCACCCCTG
CCCACCATGGCTCCAAAGAAGCATTTGTGGAGCACCTTCTGTGTGCCCTAGGTA
CTAGATGCCTGGACGGGGTCAGAAGGACCCTGACCCACCTTGAACCTTGTTCCACA
35 CAGGATGCCAGGCCAAGGTGGAGCAAGCGGTGGAGACAGAGCCGGAGCCCGAG
CTGCGCCAGCAGACCGAGTGGCAGAGCGGCCAGCGCTGGGAACTGGCACTGGGT
CGCTTTTGGGATTACCTGCGCTGGGTGCAGACACTGTCTGAGCAGGTGCAGGAGG
AGCTGCTCAGCTCCCAGGTCAACCCAGGAAGTGGAGTGAGTGTCCTCATCCTGGCC
CTTGACCCTCCTGGTGGGCGGCTATACCTCCCCAGGTCCAGGTTTCTATTCTGCCCC
40 TGTCGCTAAGTCTTGGGGGGCCTGGGTCTCTGCTGGTTCTAGCTTCCTCTTCCCAT
TTCTGACTCCTGGCTTTAGCTCTCTGGATATCTCTCTCTCAGCTTTGTCTCTCTCTC
TTCCCTTCTGACTCAGTCTCTCACACTCGTCTGGCTCTGTCTCTGTCTCTCCCTAG
CTCTTTTATATAGAGACAGAGAGATGGGGTCTCACTGTGTTGCCAGGCTGGTCT
TGAACCTTCTGGGCTCAAGCGATCCTCCCGCCTCGGCCTCCCAAAGTGCTGGGATT
45 AGAGGCATGAGCCACCTTGCCCGGCCTCCTAGCTCCTTCTTCGTCTCTGCCTCTGC
CCTCTGCATCTGCTCTCTGCATCTGTCTCTGTCTCCTTCTCTCGGCCTCTGCCCCGT

- 47 -

TCCTTCTCTCCCTCTTGGGTCTCTCTGGGCTCATCCCCATCTCGCCCGCCCCATCCC
 AGCCCTTCTCCCCGCCTCCCACTGTGCGACACCCTCCCGCCCTCTCGGCCGCAGG
 GCGCTGATGGACGAGACCATGAAGGAGTTGAAGGCCTACAAATCGGAACTGGAG
 GAACAACTGACCCCGGTGGCGGAGGAGACGCGGGCACGGCTGTCCAAGGAGCT
 5 GCAGGCGGCGCAGGCCCGGTGGGCGCGGACATGGAGGACGTGCGCGGCCGCC
 TGGTGCAGTACCGCGGCGAGGTGCAGGCCATGCTCGGCCAGAGCACCGAGGAGC
 TGGCGGTGCGCCTCGCCTCCACCTGCGCAAGCTGCGTAAGCGGCTCCTCCGCGA
 TGCCGATGACCTGCAGAAGCGCCTGGCAGTGTACCAGGCCGGGGCCCGCGAGGG
 CGCCGAGCGCGGCCCTCAGCGCCATCCGCGAGCGCCTGGGGCCCCCTGGTGGAACA
 10 GGGCCGCGTGCGGGGCCCACTGTGGGCTCCCTGGCCGGCCAGCCGCTACAGGA
 GCGGGCCAGGCCTGGGGCGAGCGGCTGCGCGCGCGGATGGAGGAGATGGGCA
 GCCGGACCCGCGACCGCCTGGACGAGGTGAAGGAGCAGGTGGCGGAGGTGCGC
 GCCAAGCTGGAGGAGCAGGCCCAGCAGATACGCCTGCAGGCCGAGGCCTTCCAG
 GCCCGCCTCAAGAGCTGGTTCGAGCCCCCTGGTGGAAGACATGCAGCGCCAGTGG
 15 GCCGGGCTGGTGGAAGAAGGTGCAGGCTGCCGTGGGCACCAGCGCCGCCCTGTG
 CCCAGCGACAATCACTGAACGCCGAAGCCTGCAGCCATGCGACCCACGCCACC
 CCGTGCCTCCTGCCTCCGCGCAGCCTGCAGCGGGAGACCCTGTCCCCGCCCCAGC
 CGTCCTCCTGGGGTGGACCCTAGTTTAATAAAGATTACCAAGTTTCACGCA

20 [00196] SEQ ID NO:3: Trem2p (249 amino acids, R47H mutation)

MGPLHQFLLLLITALSQALNTTVLQGMAGQSLRVSTYDALKHWGRHKAWCRQLG
 EEGPCQRVVSTHGVWLLAFLKKRNGSTVIADDTLAGTVTITLKNLQAGDAGLYQCQ
 SLRGREAELVQKVLVEVLEDPLDDQDAGDLWVPEESSSFEGAQVEHSTSRQVSSCGS
 PLAYHLPLSKESRDLLPHTLHSSPPGLRSPEQVSCSQHPLGCGQGQAEAGNTCGQR
 25 AGLWPRCWAPTSDPHWTRRYVREF

[00197] SEQ ID NO:4: mutated mouse genomic DNA sequence encoding Trem2p (1056 nucleotides)

ACTTCAAGGGAAAAGCAAGATCTTGCACAAGGTCCCCTCCGGCTGGCTGCTGGC
 30 AAAGGAAAGGTGCCATGGGACCTCTCCACCAGTTTCTCCTGCTGCTGATCACAGC
 CCTGTCCCAAGCCCTCAACACCACGGTGCTGCAGGGCATGGCCGGCCAGTCCTTG
 AGGGTGTCATGTACTTATGACGCCTTGAAGCACTGGGGGAGACACAAaGCaTGGT
 GTCGGCAGCTGGGTGAGGAGGGCCCATGCCAGCGTGTGGTGAGCACACACGGTG
 TGTGGCTGCTGGCCTTCTGAAGAAGCGGAATGGGAGCACAGTCATCGCAGATG
 35 ACACCCCTTGCTGGAACCGTCACCATCACTCTGAAGAACCTCCAAGCCGGTGACGC
 GGGCCTCTACCAGTGTCAGAGTCTCCGAGGCCGAGAGGCTGAGGTCCTGCAGAA
 AGTACTGGTGAGGTGCTGGAGGACCCTCTAGATGACCAAGATGCTGGAGATCT
 CTGGGTCCCCGAGGAGTCATCGAGTTTCGAGGGTGCCCAAGTGGAACACAGCAC
 CTCCAGGCAGGTTTCATCCTGTGGGTACCTCTAGCCTACCACCTTCTCCTCTTT
 40 CCAAGGAATCAAGAGACCTCCTTCCACCCACCTCCATTCTTCTCCTCCTGGCCT
 GCGTTCTCCTGAGCAAGTTTCTTGCAGCCAGCATCCTCTGGGCTGTGGCCAGGGG
 CAGGCAGAAGCCGGGAACACCTGTGGTCAGAGGGCTGGACTGTGGCCAAGATGC
 TGGGCACCAACTTCAGATCCTCACTGGACCCGGAGGTACGTGAGAGAATTCTGA
 GTGGGAGGAGAACTACAGCTTAAGTCCAGCCAGGAGTCAATCCAGCCTGCATGC
 45 TCTCCCCTCCTCCACCAAGACTTCTGTTTCTGCTACTTTTGCTTCAGAGGCCGCCT
 CTGCCTCAAGCCACCTATCCTGGGAGCAGGAATACTGGTGTGTACATCTGTGTT
 GAGTGGGGAAGACAGCTGGATGGTTGTCTGTCAACTTCTGCACTTTGGACATTAA

- 48 -

ACATTCTCCACACACCAA

[00198] SEQ ID NO:5: Trem2p (249 amino acids, mouse wild type protein, no R47H mutation)

5 MGPLHQFLLLLITALSQALNTTVLQGMAGQSLRVSCITYDALKHWGRRKAWCRQLG
EEGPCQRVVSTHGVWLLAFLKKRNGSTVIADDTLAGTVTITLKNLQAGDAGLYQCQ
SLRGREAQVLEVLQKVLVEVLEDPLDDQDAGDLWVPEESSFEGAQVEHSTSRQVSSCGS
PLAYHLPPLSKESRDLLPTHLHSSPPGLRSPEQVSCSQHPLGCGQGQAEAGNTCCGQR
AGLWPRCWAPTSDPHWTRRYVREF

10

[00199] SEQ ID NO:6: mouse wild type genomic DNA sequence encoding Trem2 mouse wild type protein (1056 nucleotides)

ACTTCAAGGGAAAAGCAAGATCTTGCACAAGGTCCCCTCCGGCTGGCTGCTGGC
AAAGGAAAGGTGCCATGGGACCTCTCCACCAGTTTCTCCTGCTGCTGATCACAGC
15 CCTGTCCCAAGCCCTCAACACCACGGTGCTGCAGGGCATGGCCGGCCAGTCCTTG
AGGGTGTCATGTACTTATGACGCCTTGAAGCACTGGGGGAGACGCAAGGCCTGG
TGTCGGCAGCTGGGTGAGGAGGGCCCATGCCAGCGTGTGGTGAGCACACACGGT
GTGTGGCTGCTGGCCTTCCCTGAAGAAGCGGAATGGGAGCACAGTCATCGCAGAT
GACACCCTTGCTGGAACCGTCACCATCACTCTGAAGAACCTCCAAGCCGGTGAC
20 GCGGGCCTCTACCAGTGTGAGAGTCTCCGAGGCCGAGAGGCTGAGGTCCTGCAG
AAAGTACTGGTGGAGGTGCTGGAGGACCCTCTAGATGACCAAGATGCTGGAGAT
CTCTGGGTCCCCGAGGAGTCATCGAGTTTCGAGGGGTGCCCAAGTGGAACACAGC
ACCTCCAGGCAGGTTTCATCCTGTGGGTACCTCTAGCCTACCACCTTCCCTCCTCT
TTCCAAGGAATCAAGAGACCTCCTTCCCACCCACCTCCATTCTTCTCCTCCTGGCC
25 TGCGTTCTCCTGAGCAAGTTTCTTGCAGCCAGCATCCTCTGGGCTGTGGCCAGGG
GCAGGCAGAAGCCGGGAACACCTGTGGTCAGAGGGCTGGACTGTGGCCAAGATG
CTGGGCACCAACTTCAGATCCTCACTGGACCCGGAGGTACGTGAGAGAATTCTG
AGTGGGAGGAGAACTACAGCTTAAGTCCAGCCAGGAGTCAATCCAGCCTGCATG
CTCTCCCCCTCCTCCACCAAGACTTCTGTTTCTGCTACTTTTGCTTCAGAGGCCGCC
30 TCTGCCTCAAGCCACCTATCCTGGGAGCAGGAATACTGGTGTGTACATCTGTGT
TGAGTGGGGAAGACAGCTGGATGGTTGTCTGTCAACTTCTGCACTTTGGACATTA
AACATTCTCCACACACCAA

[00200] SEQ ID NO:7: Trem2 CRISPR guide

35 GAAGCACTGGGGGAGACGCA

[00201] SEQ ID NO:8: Trem2 repair oligo (183 nucleotides) containing a nucleotide G>A point mutation (at nucleotide 89 in this oligo sequence) for amino acid sequence change at R47H and 2 silent mutations (lysine AAG>AAA (at nucleotide 93 in this oligo sequence) and alanine GCC>GCA (at nucleotide 96 in this oligo sequence)) into the gene to prevent re-cutting of the donor sequence in homologous directed repair:

40

GCCCTCAACACCACGGTGCTGCAGGGCATGGCCGGCCAGTCCTTGAGGGTGTCA
TGTAATTATGACGCCTTGAAGCACTGGGGGAGACACAAGCaTGGTGTGCGGCAGC

TGGGTGAGGAGGGCCCATGCCAGCGTGTGGTGAGCACACACGGTGTGTGGCTGC
TGGCCTTCCTGAAGAAGCGG

[00202] SEQ ID NO:9: 5' homology arm (4980 nucleotides: mouse Apoe4 exon 1 and
5 757 nucleotides of mouse Apoe4 intron 2 sequence) included in the "humanized" mouse
ApoE construct inserted into the mouse genome.

CCTGTATCTCAGGGTTGAGAGGGAAGAGAGTGGGGTTTCCAGATGCCACATCC
CTTGATACCTAGTCCTCACCAACTCTGCTCTCCTAGTGAACAACCTGGTTGGCTAC
AGTAACGCTGGGCCAGGCAGGCATGCATGCGACGTATTACCACAAAGCCAGTGA
10 CCAGGTGAGCCGGAGGGAGCGCCTAGCTGTGGGTCCCAGGCTGGGTTTGTCTGGT
GCAGTTGGTATGCCAGGAGTCTAATGGGCCACTCACATGTGTGCCGGGGCCCTC
TCTCCCCCAGCTGCAGGTGGGTGTGGAGTTTGAGGCCAGCACAGGATGCAGGA
CACCAGTGCCCTCCTTTGGGTATCAGCTGGACCTGCCCAAGGCCAACTTCCTTTTAA
AAGGTAAGGAAGGCCTCAGCTTCCCTCCTGGGGAACAGGCCAGATAAGACTCAG
15 CTGTCTGTGGTAGAGTCCATGGGAAATAGGGAGGTTGAACATGTGCTGGTGGAG
TGGGCGGGGACTCTGTGCAGCTCCAAATTACTCTGGGTGGCTTGTCAAACAGTGG
GGCTCCTACCCTGGCATGTTTAGTACATGTTGGGGGCCTCGCTTTAAGCCCTCTCT
TCCCATTTCCATCTAGCAAGCTCTCTGGCCCTCCCCACTCACTCTTACCTTACTTG
GAGTTCTTCTATTGTGTGATGAAACACTATGATGGTAAACAGCTTAGGGAGCAAA
20 GAGGTTATGTTGGGTTACAACCTCTCAGGTGGCATGCCTACCACTGAGGAGAAGAT
GGGGCAGGACTCAGCAGAAAGCTGAAGGCAAGCTGATGCAGAAGGCCTTGTGG
GAGTGCTGCTTGTGGCTTGTCTCCTTATGGCTTCCTCAGCCTGCTCTTATAGCCTC
CGGACCATTAGCCCAGGGTGCCCCACTGAAAATAATCTGGGTACTCCACATCA
ATCACTTAGAAAGTGCCCTACAGGCTTGCTGTGCTGCCCTAGCTAATGGAGACATA
25 TGTATTGAGGTTCCCTCAGCTGGATCTCTTGAGTTCAAGACCAGCCTGGTCTACA
GAGCAAGTTCTGGGACAGCCAGGGCTACCCAGAGAAACCCTGTCTCAGAAAAGA
AAAAAAAGAAAAAGGTGGGGGTGGGGTGACTAGCTTGTATAAAACTAGCCAGC
ACAGCAGGGAAGCTGTGTGAATAGTGACAGCCAGGTTTCAAGACCTCATTCTGCG
CAGTGACATGGGTTTGTCAAGCCTGGGCGGTGTTGAGCCACTTAAAGGGTTGCTG
30 TGATGGTCTGGAGTGGCCTTGGTTGTGACTTAGGACATACGGGTCCGTTGTGGCT
ACCATAGAGATGGGTGGCCAGGCACATCAAGCCACCCAGTCTCTGCCCCGCTCTC
GGCCACAGGCTCTGTGAACAGTAACTGGATCGTGGGCGCCACGCTGGAGAAGA
AGCTTCCGCCCTTGCCCTGACACTGTCCCTCTGCGCCTTCCTGAACCACCGCAA
GAATAAGTTCTGTGTGGCTTCGGCCTCACCATCGGCTGAGCCCTCCTGTCTTCC
35 TCTGCAGACCATCGCTGGGCGGGCTGCCCTCCCCCTCCTCTCCCTCTCTCTTGGGGT
TGGGGCAGTGGGAAGGAGGGGACCTCCCATGCCCAAGGATCCCCAGCGCCAGGG
GACAGTGCCAGGGGGGCTGGGGTCCCGGAGGGAGTCTGGGATCTGAAGGGCA
TTCGATTGTGAGCGCCCAGGCAGAGGCGCAGAGGCGGCTGTACACAGGCTCAGA
AAGGAAAGACTTGATGTCTCCTCTGAGGGCAGCAGAGGAGCGCCGAGCCGCTGT
40 CACTTCCCCCTCCACCCCTCCATAGAAATCATGTTTATAAGTTATGGAAAACCGG
GACATTTTACAGAAAAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATA
AAAATAGGATCTGGGAGGCCTCGGTTTTCTCCAGTTGTTGACATGGTTGCCAGCA
GGCGGCGCCGAGGGTTCAGAAAGCACAGCAGCACCAAGCAGTTTAGAGAAAGCT
TGGCCAGGCATGGTCACACCCTCTGCTCTTGGGGACTTACACTGCCGGAACATCA
45 GAGGCCTGGCCTCACCAGGAGGGTGGCTCCAGGTCACCTCGCCTCTGTGCAGTCTG
GCCCCGAGAGCTGGCAGAGGACTTGTCTCTGTAAACAGGGTGGGGGCAGGGAG
ACGGGGCTCAGGAGCCTCCCTGTCCCAAACGGGCTGAGGTGGTAGCTTGTGCT

- 50 -

GACTTTCTCCCAGTGGGAAGGTCTCAGAGGTCTCAGAACTTCAGGAAGAAACGGA
GTTCTGGAAGTTTCAGCACATAAGGAAAGTTACTCTGGGAGGAACGGGCCCTA
GCACCTTCCCAGGCTGAAACAGGAAATGTCAAGTTGTTTTGTTTTTAAATTTTGT
TGAAGATGTAGCTCTGGGCCTCACGTGTCAGGCAGGTGCTGCTGGGTTCCTATA
5 GTGCTTTTCCGTGAGGCCTGCTCTGGGGTGTGCGATAAGGGCCTCAGATTGGGCT
CTGCATCTCACTGCTGCACCTCATGGCATCCCAAGGGAAGCAAAGACTCACGAT
GAACTGGTCAGTGTCTAGACCGCAGCACTAAGACCCTCTCTACTGCCTGGGCTG
GAGATGGGAGCTGGCCCTTAGCAACCCATGAAAATCATCTCACCACACCCAGTC
CTTGCCAGTGTCTTCTGAAGCCAAAGCTAACAGGCCTGGGCCTGGCCAGGCACCC
10 TGTACGTACCCTTGAGGCCAGGTGTTCCGCCTCTGCCCATCCTGCAGAATCATGT
TTTGCCGTGTCTGGTGCCAAACACTGCTATGTGGCTTCTCTCCTGCCATCAACAGC
TGGAACAGGGAACCTTGTGCAGGCAGTGCTTCTAGCAAGCTTGCTGTGGTCTCT
GAGCCCCTTGTCTACCTGACTTCCCAGGTACAATGGCTTTCCCACTTTTTGGGGG
TTTTGTTGTTGTTGGGTTTTTTTTTTTGTTTTTTCAAGACAGGGTTTCTCTGTGTAGTCC
15 TGTCGGTCTGGAACCTACTTTGTAGACCAGGCTGGCCTCCAACCTCAGAAATTCA
CCTGCCTCTGCCTCCAAGTGCTGGGATTATGGGATTAAAGGCATGTGCCACCACG
CCCAGCTGGCTTTTCCACTTTTTAGCCAGGACTTCATTCTATTACCTGAGCTCGGG
ATCTTCTGCCTCAGCTTTGCATATGGCTAGCACTATAGACCCATGTTCCAGTGA
ATGACTTATGGCTTGTCTTTTTTTTTTTTTTTTTTTTTTATGTGCATTAGTGTTT
20 TGCTGCATGTATGCCTTCGTGAGGGTAGCAGATCTTGGTGTTACAGTTGTGAGC
TGCTGTGTGGGTGCTGCGATTTTGAACCTAGGTCCTGTGAAATGCAGTCAGTGCT
CCTAACCTCTGAGTCATCTCTCCAGCTCCTGCTCTTCTGCTTTTATGAGGAAAAAG
AAAAGAGAAGTGGCTTGAGAGTGGAAAATGCACATGCAGGGGTGCACACCTGCA
GTCCCAGCATGCTACAGCAGAGGCAGAAGGACCTTTGTGGGTAGAGGGCAGCC
25 TGAGAATCTTATCTCAAAACAACCTTTTAAATGTGCTCTGTAGGGGTAGCTCTT
CCCTCCAAGGTGACACATCTGGCAATCGCCAGAAACAGATCAGGAGCATCAAC
GCTTGGTTTCCCAGGGCTTGGCTTAATGTATGGCTTCAAACCCATCGGGAGCCAC
CACTGAACAGCTCCTGAAGGAACTGGAGCACGTCCCAGCCTTGGAATGGAAAGA
GTTACCTGTGGTGGAGGAATCAACAACGAGGGATCCCAGAACACGATCTTCA
30 CCCCAGAAGCTGAGCCTCTTAGCCCCCACCACCCATTTCATTAGGCTGCCAG
CTCTTTTCTTTACAATGCACCAGACCCCGCGGGGAAAGGGAAGGAGCGGTTCTCA
GTGCCCCAGTACCAAGGCCTGGATTATTCAATGAGGTGTCCGCTCCCTTTGTTGG
CGGGGGAGGGGAGCGGGGGGTACAAAGGCATCCAAACTCCACCTCTTTCCTCTG
CCCTGCTGTGAAGGGGGAGAGAACACCCCGCCTCGTGACAGGGGGGCTGGCACAG
35 CCGCCCTAGCCCTGAGGAGGGGGCGGGACAGGGGGAGTCCTATAATTGGACCG
GTCTGGGATCCGATCCCTGCTCAGACCCTGGAGGCTAAGGACTTGTTCGGAAG
GAGCTGGTAAGACAAGCTGGGCTGGGGATTACCCAGGGACCTTGGTAGGATGT
GGGCTGGGAACCTTGAGATCCCCCGGAGTCCAGGAAACAGGCACAAGAATTGGA
AAAGCAGGCAGCACGATAGAAGTCTTGGGGGACAACTAAGGACTCGAGGTAA
40 CTAGCCTTTGCCAGAGTCAGAGCAGGTGGAGGGGTACCTCCAGGAAGGAGTAC
GGGACTGTCGGTGCACGGCGTACCGGCTCAACTAGGAACCATCCTATGGCGAAA
AAACTCGGGATGAGCCTTAGGCTGCTTTTATATAAATACCTACTGATTTCCATCA
CAGTCCCCAAGTAACCCGGACTGGTTTCAAACCTGTGGCTCCTCATGGCTGAGCTC
CCTAAGTTCTGTAGTTGTGGGAGGGTACCACTTCGCAGGGATGGAGGACGATTA
45 AAAATCGTGTTAAATTAACACAAAATGGAAAGCAGGACTTAGCCGGGAAGAAAG
AGGAATGTAAGCTGGACCACCCGCTGGCCCTCTGTGAAGTGGAATTTGAACCCTA
GGAGAGGGAGCTGGAATTTTTGGCAGCGGATCCACCCCGGGGTGCCGAGATAGC
GAACTCGGCAAGGGGAGGTAAACAGACCTTTGGGAAGAGCGGGTGCTCTGTTTT
GGAGATGTTTGTGATGGCTCACAGATCTGAGAAGGGAAGATGGGGTTCTCTGGG

- 51 -

TGGCCGGAGTCCCTCCACCCCCGCCCCCTGGTGTTCAAAGACAATTTTCCCTCC
GCAG

[00203] SEQ ID NO:10: DNA sequence including exons 2, 3 and 4 of the human APOE4
5 gene and 1500 nucleotides 3'UTR of the human APOE4 gene after exon 4 (4292
nucleotides) included in the "humanized" mouse ApoE construct inserted into the mouse
genome.

ACTGGCCAATCACAGGCAGGAAGATGAAGGTTCTGTGGGCTGCGTTGCTGGTCA
CATTCCTGGCAGGTATGGGGGCGGGGCTTGCTCGGTTCCCCCGCTCCTCCCCCT
10 CTCATCCTCACCTCAACCTCCTGGCCCCATTCAGGCAGACCCTGGGGCCCCCTCTTC
TGAGGCTTCTGTGCTGCTTCCTGGCTCTGAACAGCGATTTGACGCTCTCTGGGCCCT
CGGTTTCCCCCATCCTTGAGATAGGAGTTAGAAGTTGTTTTGTTGTTGTTGTTTGT
TGTTGTTGTTTGTGTTTTTTTGAGATGAAGTCTCGCTCTGTGCGCCAGGCTGGAGTG
CAGTGGCGGGATCTCGGCTCACTGCAAGCTCCGCTCCCAGGTCCACGCCATTCT
15 CCTGCCTCAGCCTCCCAAGTAGCTGGGACTACAGGCACATGCCACCACACCCGA
CTAACTTTTTTGTATTTTCAGTAGAGACGGGGTTTCACCATGTTGGCCAGGCTGGT
CTGGAACCTCCTGACCTCAGGTGATCTGCCCCGTTTCGATCTCCCAAAGTGCTGGGA
TTACAGGCGTGAGCCACCGCACCTGGCTGGGAGTTAGAGGTTTCTAATGCATTGC
AGGCAGATAGTGAATACCAGACACGGGGCAGCTGTGATCTTTATTCTCCATCACC
20 CCCACACAGCCCTGCCTGGGGCACACAAGGACACTCAATACATGCTTTTCCGCTG
GGCGCGGTGGCTCACCCCTGTAATCCCAGCACTTTGGGAGGCCAAGGTGGGAGG
ATCACTTGAGCCCAGGAGTTCAACACCAGCCTGGGCAACATAGTGAGACCCTGT
CTCTACTAAAAATACAAAAATTAGCCAGGCATGGTGCCACACACCTGTGCTCTCA
GCTACTCAGGAGGCTGAGGCAGGAGGATCGCTTGAGCCCAGAAGGTCAAGGTTG
25 CAGTGAACCATGTTTCAGGCCGCTGCACTCCAGCCTGGGTGACAGAGCAAGACCC
TGTTTATAAATACATAATGCTTTCCAAGTGATTAAACCGACTCCCCCTCACCTG
CCCACCATGGCTCCAAAGAAGCATTTGTGGAGCACCTTCTGTGTGCCCTAGGTA
CTAGATGCCTGGACGGGGTCAGAAGGACCCTGACCCACCTTGAACCTGTTCCACA
CAGGATGCCAGGCCAAGGTGGAGCAAGCGGTGGAGACAGAGCCGGAGCCCGAG
30 CTGCGCCAGCAGACCGAGTGGCAGAGCGGCCAGCGCTGGGAACTGGCACTGGGT
CGCTTTTGGGATTACCTGCGCTGGGTGCAGACACTGTCTGAGCAGGTGCAGGAGG
AGCTGCTCAGCTCCCAGGTCAACCAGGAAGTGAAGTGTCCCCATCCTGGCC
CTTGACCTCCTGGTGGGCGGCTATACCTCCCCAGGTCCAGGTTTCATTCTGCCCC
TGTCGCTAAGTCTTGGGGGGCCTGGGTCTCTGCTGGTTCTAGCTTCCTCTTCCCAT
35 TTCTGACTCCTGGCTTTAGCTCTCTGGATATCTCTCTCTCAGCTTTGTCTCTCTC
TTCCCTTCTGACTCAGTCTCTCACACTCGTCTTGCTCTGTCTCTGTCTTCCCTAG
CTCTTTTATATAGAGACAGAGAGATGGGGTCTCACTGTGTTGCCAGGCTGGTCT
TGAACCTTCTGGGCTCAAGCGATCCTCCCGCTCGGCCTCCCAAAGTGCTGGGATT
AGAGGCATGAGCCACCTTGCCCCGGCCTCCTAGCTCCTTCTTCGTCTCTGCCTCTGC
40 CCTCTGCATCTGCTCTCTGCATCTGTCTCTGTCTCCTTCTCTCGGCCTCTGCCCCGT
TCCTTCTCTCCCTCTTGGGTCTCTCTGGCTCATCCCCATCTCGCCCGCCCCATCCC
AGCCCTTCTCCCCGCCTCCCACTGTGCGACACCCTCCCGCCCTCTCGGCCGCAGG
GCGCTGATGGACGAGACCATGAAGGAGTTGAAGGCCTACAAATCGGAACTGGAG
GAACAACCTGACCCCGGTGGCGGAGGAGACGCGGGCACGGCTGTCCAAGGAGCT
45 GCAGGCGGCGCAGGCCCGGTGGGCGCGGACATGGAGGACGTGCGCGGCCGCC
TGGTGCAGTACCGCGGCGAGGTGCAGGCCATGCTCGGCCAGAGCACCGAGGAGC

- 52 -

TGCGGGTGC GCCTCGCCTCCCACCTGCGCAAGCTGCGTAAGCGGCTCCTCCGCGA
 TGCCGATGACCTGCAGAAGCGCCTGGCAGTGTACCAGGCCGGGGCCCGCGAGGG
 CGCCGAGCGCGGCCTCAGCGCCATCCGCGAGCGCCTGGGGCCCCCTGGTGGAACA
 GGGCCGCGTGC GGGGCCGCACTGTGGGCTCCCTGGCCGGCCAGCCGCTACAGGA
 5 GCGGGCCCAGGCCTGGGGCGAGCGGCTGCGCGCGCGGATGGAGGAGATGGGCA
 GCCGGACCCGCGACCGCCTGGACGAGGTGAAGGAGCAGGTGGCGGAGGTGCGC
 GCCAAGCTGGAGGAGCAGGCCCCAGCAGATACGCCTGCAGGCCGAGGCCTTCCAG
 GCGCGCCTCAAGAGCTGGTTCGAGCCCCCTGGTGGAAGACATGCAGCGCCAGTGG
 GCGGGGCTGGTGGAGAAGGTGCAGGCTGCCGTGGGCACCAGCGCCGCCCTGTG
 10 CCCAGCGACAATCACTGAACGCCGAAGCCTGCAGCCATGCGACCCACGCCACC
 CCGTGCCTCCTGCCTCCGCGCAGCCTGCAGCGGGAGACCCTGTCCCCGCCCCAGC
 CGTCCTCCTGGGGTGGACCCTAGTTTAATAAAGATTACCAAGTTTCACGCATCT
 GCTGGCCTCCCCCTGTGATTTCTCTAAGCCCCAGCCTCAGTTTCTCTTTCTGCCC
 ACATACTGGCCACACAATTCTCAGCCCCCTCCTCTCCATCTGTGTCTGTGTGTATC
 15 TTTCTCTCTGCCCTTTTTTTTTTTTTTTAGACGGAGTCTGGCTCTGTACCCAGGCTA
 GAGTGCAGTGGCACGATCTTGGCTCACTGCAACCTCTGCCTCTTGGGTTCAAGCG
 ATTCTGCTGCCTCAGTAGCTGGGATTACAGGCTCACACCACCACACCCGGCTAAT
 TTTTGTATTTTAGTAGAGACGAGCTTTCACCATGTTGGCCAGGCAGGTCTCAA
 CTCCTGACCAAGTGATCCACCCGCCCGGCCTCCCAAAGTGCTGAGATTACAGGCCT
 20 GAGCCACCATGCCCGGCCTCTGCCCCCTCTTTCTTTTTTAGGGGGCAGGGAAAGGT
 CTCACCCTGTCACCCGCCATCACAGCTCACTGCAGCCTCCACCTCCTGGACTCAA
 GTGATAAGTGATCCTCCCGCCTCAGCCTTTCAGTAGCTGAGACTACAGGCGCAT
 ACCACTAGGATTAATTTGGGGGGGGGGGGTGGTGTGTGTGGAGATGGGGTCTGGC
 TTTGTTGGCCAGGCTGATGTGGAATTCCTGGGCTCAAGCGATACTCCACCTTGG
 25 CCTCCTGAGTAGCTGAGACTACTGGCTAGCACCACCACACCCAGCTTTTTATTAT
 TATTTGTAGAGACAAGGTCTCAATATGTTGCCAGGCTAGTCTCAAACCCCTGGG
 CTCAAGAGATCCTCCGCCATCGGCCTCCCAAAGTGCTGGGATTCCAGGCATGGG
 GCTCCGAGCCCGGCCTGCCCAACTTAATAATACTTGTTCCTCAGAGTTGCAACTC
 CAAATGACCTGAGATTGGTGCCTTTATTCTAAGCTATTTTCATTTTTTTCTGCTGT
 30 CATTATTCTCCCCCTTCTCTCCTCCAGTCTTATCTGATATCTGCCTCCTTCCCACCC
 ACCCTGCACCCCATCCACCCCTCTGTCTCTCCCTGTTCTCTCAGGAGACTCTGG
 CTTCCTGTTTTCTCCACTTCTATCTTTATCTCTCCCTCCTACGGTTTCTTTTCTTT
 CTCCCCGGCCTGCTTGTTCCTCCCCCAACCCCTTCATCTGGATTCTTCTTCTGCC
 ATTCAGTTTGGTTTGAGCTCTCTGCTTCTCCGGTTCCTCTGAGCTAGCTGTCCCT
 35 TCACCCACTGTGAACTGGGTTTCCCTGCCCAACCTCATTCTCTTTCTTTCTTTCTT
 TTTTTTTTTTTTTTTTTTTTTTTTTTTTGTAGACAGAGTCTTGCTCTGTGCCCAGCC
 TGGAGTGCAGTGGTGCAATCTTGGTTCAGTGCACCTCCACTCCAGATTCAAG
 CAATTCTCCTGCCTCAGCCTCCAGAGTAGCTGGGATTACAGGCGTGTCCACCAC
 ACCCGACTAATTTTTGTATTTTGGTAGAGACAAGGCTTCGGCATTGTT
 40

[00204] SEQ ID NO:11: a Frt PGKneo Frt cassette followed by an NdeI restriction enzyme site (CATATG) (1834 nucleotides) inserted in the “humanized” mouse ApoE construct between nucleotides 9272 and 9273 to allow for selection prior to recombinase-mediated removal of this cassette.

45 GAAGTTCCTATTCTCTAGAAAGTATAGGAACTTCAGGTCTGAAGAGGAGTTTACG
 TCCAGCCAAGCTAGCTTGGCTGCAGGTCGTCGAAATTCTACCGGGTAGGGGAGG

- 53 -

CGCTTTTCCCAAGGCAGTCTGGAGCATGCGCTTTAGCAGCCCCGCTGGGGCACTTG
 GCGCTACACAAGTGGCCTCTGGCCTCGCACACATTCCACATCCACCGGTAGGCGC
 CAACCGGCTCCGTTCTTTGGTGGCCCCCTTCGCGCCACCTTCTACTCCTCCCCTAGT
 CAGGAAGTTCCCCCCCCGCCCCGCAGCTCGCGTCGTGCAGGACGTGACAAATGGA
 5 AGTAGCACGTCTCACTAGTCTCGTGCAGATGGACAGCACCGCTGAGCAATGGAA
 GCGGGTAGGCCTTTGGGGCAGCGGCCAATAGCAGCTTTGCTCCTTCGCTTTCTGG
 GCTCAGAGGCTGGGAAGGGGTGGGTCCGGGGGCGGGCTCAGGGGCGGGCTCAG
 GGGCGGGGCGGGCGCCCCGAAGGTCTCCGGAGGCCCCGGCATTCTGCACGCTTCA
 AAAGCGCACGTCTGCCGCGCTGTTCTCCTCTTCTCATCTCCGGGCCTTTCGACCT
 10 GCAGCCTGTTGACAATTAATCATCGGCATAGTATATCGGCATAGTATAATACGAC
 AAGGTGAGGAATAAACCATGGGATCGGCCATTGAACAAGATGGATTGCACGCA
 GGTCTCCGGCCCGCTTGGGTGGAGAGGCTATTCGGCTATGACTGGGCACAACAG
 ACAATCGGCTGCTCTGATGCCGCGGTGTTCCGGCTGTCAGCGCAGGGGCGCCCCG
 TTCTTTTGTCAAGACCGACCTGTCCGGTGCCCTGAATGAACTGCAGGACGAGGC
 15 AGCGCGGCTATCGTGGCTGGCCACGACGGGCGTTCCCTTGCGCAGCTGTGCTCGAC
 GTTGTCACTGAAGCGGGAAGGGACTGGCTGCTATTGGGCGAAGTGCCGGGGCAG
 GATCTCCTGTCATCTCACCTTGCTCCTGCCGAGAAAGTATCCATCATGGCTGATG
 CAATGCGGCGGCTGCATACGCTTGATCCGGCTACCTGCCCCATTGACCACCAAGC
 GAAACATCGCATCGAGCGAGCACGTACTCGGATGGAAGCCGGTCTTGTCGATCA
 20 GGATGATCTGGACGAAGAGCATCAGGGGCTCGCGCCAGCCGAAGTGTTCGCCAG
 GCTCAAGGCGCGCATGCCCGACGGCGATGATCTCGTCGTGACCCATGGCGATGC
 CTGCTTGCCGAATATCATGGTGGAAAATGGCCGCTTTTCTGGATTTCATCGACTGT
 GGCCGGCTGGGTGTGGCGGACCGCTATCAGGACATAGCGTTGGCTACCCGTGAT
 ATTGCTGAAGAGCTTGGCGGCGAATGGGCTGACCGCTTCCTCGTGCTTTACGGTA
 25 TCGCCGCTCCCGATTTCGCAGCGCATCGCCTTCTATCGCCTTCTTGACGAGTTCTTC
 TGAGGGGATCAATTCTCTAGAGCTCGCTGATCAGCCTCGACTGTGCCTTCTAGTT
 GCCAGCCATCTGTTGTTTGCCCCCTCCCCCGTGCCCTTCCTTGACCCTGGAAGGTGCC
 ACTCCCCTGTCTTTTCTTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTA
 GGTGTCAATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATT
 30 GGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGGCTTCTGAGG
 CGGAAAGAACCAGCTGGGGCTCGACTAGAGCTTGCGGAACCCCTTCGAAGTTCCT
 ATTCTCTAGAAAGTATAGGAACTTCCATATG

[00205] SEQ ID NO:12: 3' homology arm (5166 nucleotides) included in the
 35 "humanized" mouse ApoE construct inserted into the mouse genome.

AAACCTGATGGAGAAGATACAGGCCTCTGTGGCTACCAACCCCATCATCACCCC
 AGTGGCCCAGGAGAATCAATGAGTATCCTTCTCCTGTCTGCAACAACATCCATA
 TCCAGCCAGGTGGCCCTGTCTCAAGCACCTCTCTGGCCCTCTGGTGGCCCTTGCTT
 AATAAAGATTCTCCGAGCACATTCTGAGTCTCTGTGAGTGATTCCAATCAGCTTC
 40 AGCCTCAGTTTATTGTTTTTTGTCCTTACCTAGCACACATTCCATGGCCCTGTCACT
 ATCTGTAGAGGGAGGTGGTTTTGTCAGCAATAGAAATGAAGCCTAGGACCTAGCA
 ACATAAAAGAACAAGTGATCTACCACTGAGCCACGCCCACAGCCCCTCACTGGG
 GGATTCTAGGCAGGGGCTCTACCACTGAGCCACCCGCGAGCCCCTCACTGGGGAA
 TCATATCTACCACTGAGTCACGCCCTCCAGCCCCTCACTACGGGAATTCTAGTC
 45 AGTAGCTCTACCACTGAGCCACACCCACAGCCTCTGGGGCTCTTACCGCCCCCT
 ACCCCTGGATTCTAGGCATGGGCTCATTTTATTTATTTATTTATTTAAGATTGT
 ATCTTATGTATAAGGTACACTGCAGCTGTCTTCAGGCGTCAGGTCCATTACAGA

- 54 -

TGGTTGTGAGCCACCATGTGGTTGCTGGGAATTGAACTCAGGACTTATAGAAGAG
TAGTCAGTGCTCTTAAGTCTGAGCCATCTCTCCAGCACCCAGTACAGGCTCTTCT
ATTTAGCTATATCCACCCTTCTTTTCTAGTCTGAAATAGGATCTCAACTGATTTTCC
TTGCACTCCCTCTAGCCTAGTTTGGTCTTGAATATTTGAATCTTTGTTTTCAAATC
5 AATCTCTACAGGAACTGAGAAAGGCATGTACCACTTCATGTGGGTCAGTTGGGCT
ACTTTTCCCAACTTCCCAAGCACCCACTGCACAGCTATGCCTTGAATCAATCAAC
ATGTAAGAGACCAGGGTCGCCAGGGCGGTGTTTACTTTTCTGGTTGTCTTATCTCTC
CTCCTCCGCTCTAGTCTTATCTGACACCCTCTCCTTGCCTTGTCTCTCCTCTTTTTC
CCTTCTAGGCTTCCTTTTCTGGGCTTCCTGTTTTCTGATCCTCTGTTATCTCACCT
10 CCCGCGGTTTCTTTTGTCTCTGGGCCTTTGGTTGGCGGTTTCTACGGTTTCTACGTG
GCTTTTGGAACTCAGCCTTTCTCCCTTGTCTCTGAAGTTAGCTGGATCTTTGCTCC
CTCTGGGTCATGGGGCCTTAGCCCCATTCTTTCTCCCTGCCTGTGCTGCATGCCT
TTTGACTTTCCAGCAAGTGTATGGAGAGTGAGTTCAGGCTGGGGACACAAAAC
CATTCCTCCCCATGTCTTGGTACTCAAAGGGGTCATGGTGAAGCTGGAGAGCCCC
15 TGGCTGGCTTCTCCTCCCACCCCCCTCAGTTCTCAGGGACTCAGCAGGGCTCCCAC
TAACAGGGGCAGGCTAGGGCTTGAGCTGTGTCTTGGGTCCGGGCCAAGGCTTCAG
AACTCAACTGCCTCTGGCACACCCCGAGCCTGCAGCTTTTCTGGCATCAAATC
AGCATTATCTGGAGGCAGGCACCACTCCCACACATGACTCATTAGGCCCAATGA
GAAGATGGGTCCGTGGGCTAGTGACAGGGCCCTAGACAGCCACACTTCATGCCC
20 AGGGGCTAGGAGCACACCCCCAGAGCCTCACTACTCTCAAATATCAAGATGAGG
GGAGAGTATAGAGGGAATGTCTCCCTCTGAAGACCTGAATTATTGTGATGTTATT
TGAGCCACGCTGGCCTTGAAGTCTGAACCCTCCTGCCTCATCTTCAAAGGCTGGA
ATTACAGGTTCCGCGCCACTAGGCCTATCTGAGAACTTAGTTAATTCTACAGAAGA
GAGTTTGTTTTCACTGGTTTGAACGAGGCCTCGTGTACCCAGAGCTACTCTTTTG
25 CCAACTCACTGTAGAGCCAAGGATGACCTTGAAGTCTGGTCTTCTGGTCCGAG
TCCTCGGTACTGGGTAGACAATGTGTGATCCTAACCCCCAGTTTTATGTGGTGCT
ATACAGATGGCATCCAGGGTTTCTTGCATGCTGGACAGGTCATCAACCAACCGA
GCCACATCCTCCTCATCATCATCACTTTGTTGTTGGTTTTCAATCCAGAGCTCATG
GAGCCCAAGCTGGCCTCAATCTATATAACCAAGACTGTGCCTGGTCTTCTGTCT
30 CTACCTAACAAATGATGGTGGGATGCAGGGATGTACAACCAGGAGCAGAGCCTT
ACTTCTAAACGAAGAAGGAACCCACCTCCCTGTGGGCAGACCTGGAGGTGGGG
CAAGGACCACAGAAAGACATTACAGAACTAGGATCGTGAAGGAAGTCATGGAG
GCCAGCCTGTTGTACAGAGTGAGTTCAGGACAGCCAGGGCTACACAGAGGAAA
ACAAGAAGGAAAAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAA
35 ACCTTAGCTGTGTGCTTCCCGTACCCTACCTGTGGCACAGGAAGCCCTTGTTGCT
AAGAGTAGGATGACACTGGAAGCACCAAGCACTGGGCAGAGTAAGGGGGAAAT
CTGTTACATTATTCAGATGGGCGCTTGAGGACTGAGCAGGACTCCTTTCAAGAAG
CAAAAGGGTCAGGCCTGGTGCCACAGGGACTGGAAGCTAGCTAGCGCCGAGTT
GGCCCCAGAGATGTCGCAACCCAGCCAGGGTCGAGAATCTGTTCCACCCCTTTCA
40 CAACCATCCCCCTGTTGTCGTCGTCCTCCACCCACCCCGCCCCAAGTACACG
TGGGTTGCAGGGGCACCAGGCCAGCCAACCTAGAGTCTGGGCCCCCTTAGCCACC
AGCTGCCAGGGGGTCACTGTCGGTCAATGACAGCTCTGGGGGAGGGGGGGAGAA
GGGCCTTGACTCTAGCCTGAGAGAAAGGATGTTGTGGAAGGAGGGGGCAGGGA
GGCAAGTTTAGGGCCTGCAGGGGCCTAGGAGGCCCCACAAGACCTAAAAACGGG
45 GGAAGGGGGGTTGTGCCAGTTAGGGGACACTATGGAGCTCTGCAAGCTAAGAGG
CTCTTAGCTTCTTTGCAGTTTGAAGTACTGAGTGAAGAGGCAACTTCTAAGGAAGGGA
GATGAGGGGATGCCAAGATCCCAGAGAGCATCCGAGGAGGTCTGAGGGTGTGCA
GATGCAAAGGCATTGGAGGTGAAGGGAGCCAGGGTGCAGCATCCGGGACAGAA
TGTGAGCTGAGGCTCCTGGTCAAGGAGAAGGTAGAGAAGAGCTAACCTGAGGAT

- 55 -

GCAGTGTGAGCTAGGGGTGAGATGGGGGTGAGGGGAGTTGTTTGTAAAGACCCCC
 CCCCTTAAGGTGGGACAGCCTCAGAGAGAGAGTGTAGTAGGCAGAGCAGCCAAG
 GCTGGGTGGAGATCAATGAGATTTGGAAGTGAGGATGCTGACCAGTGACGAGCC
 TTGGGCCTAAATAAAAAAGCCTGGATGTGGGATCTGCCTCCCAGTATCGACCAGA
 5 ATGACAGAAGAGAGTGGGCTGGTTGTGTTGGTGTGTTGGTGCATGCCTGTAATCCCA
 GCAACTCACTAGAGAGGCAGAGGCAGGAGCATCACAAATTCCAGGCCAGCCAA
 AAAGCCTATGTAAAAAAAAAAAAAAAAAGAGAAAAAAGAAAAAGAAAAAGTAGGT
 GGACACAGAGACAAGGGGGAGGCTCAGGGGGAGGGCGACCAGCTTGCTCCGCC
 CCCTCCCCAACCGGTTAAACCTCTGTGCAGGATCCTCCCACCGCCATGGGCCTCC
 10 TGAGAGATCCTTAGATCCAGGTTAGTGCATAGGAAAGTGTCCCCCCTACTACCTAC
 AGCTAAGGGATTGGGGTGGTGGGATCATGGTGGAGGGCGGTGGTGAATACTAGC
 GATGTCCCCCGCTACCCGTGCGTCTGCCTCCAGGGTGCCCCCTCAACCAGGATGA
 GGCTCTTCATCGCTCTTCCTGTCCTGATTGTGGTTCGTAGCCATGACCTTGGAAGGT
 AAGAAAGAGCCTTGGAAGGTAAGAAAGAGGCTTGGAAGTGTGAAGTTGGCCTTG
 15 TGCCTGCGGCCAGGCTTAGAAGACCCTCGAGGAGGGCTCTGAGGTCCCTTTCTG
 TGTCATCATTCCACTACCGCCCTCCCATCGTCCCCCATCCCACCTGCCAGGTGCCT
 TATTTTTGTGTCAAAGTGGGTGCTGAAGGAGGCAACTCTGTCCAGAAAAGACGC
 AGTAACCAATGACCTAGGATACCACCCTTTGGAATTGGCTAATCTTCCTAGAAGG
 GGCGGAGCGTAAAAACAAGGAGGTGAGAGGTGCAGTAAATCAAGTGTCCAAT
 20 ACCCTCCCCCATGCTAATGAGTTTGCTCGCAACCCTCTCGCGGCAGGCCAGCCC
 CCGCCCAGGCGGCCCGGATTTGTCCGGAACATTGGAGAGCATACCGGATAAAC
 TGAAGGAGTTTGGGAACACTTTGGAAGACAAGGCCCGGGCAGCCATTGAACATA
 TCAAACAGAAGGAAATTTTGACCAAGACCCGGTTAGGACCTTTCAGGGCACGGG
 CGGGTGGTGTGTGTGTGTGTGCGTGC GCGCGCGCCCGTGTGTAAAGCCCTAGCA
 25 GACAGTTCCACACTGACACAATGGGGAAACTGCACCAGAGTGTTTGACACTTTCC
 CTGAAGTCATAGAACTGTATCTGAAGTCATTGAACTGGATGTCAAAGTGCTCGTA
 GTGTGGAGACAGGCGGTGTAACCTCCAGCCAACTGTTAGAGATGTTTCCAAGTCC
 TAGTGAAGGGCCAAGCTAGGCGGCTGACTGGTTAGGACAGACCCTGACCCCTCC
 CTGTGTACTCTTGAGACAGGTCATGACTTGAGTCTCCGAGACAGAGAAAGAATGT
 30 AGGAGAGTTGGGGCAGGGGCACAGCAGAAGCTGTACAGGCCTGGGCTCTGCAGT
 TTACACTGGCCAAAGAGAGATTAGGGCATGCTGGGTAAAGAACTAGCCAGGCAG
 TGGTGGCGCACACCTTTGATCCAGTATTCATGAGGCAGAGGCAGGCAGATCTCT
 TTGAGGCCAGCCTGATTGGAGCTAGTTCTAGGAAAGCCAGGGCTACACAGAGAA
 ACCCTGTCTCAACACCACCACCACCCCC

35

[00206] SEQ ID NO:13: wild-type amino acid sequence-mouse Apoe

MKALWAVLLVTLTGLAEGEPEVTDQLEWQSNQPWEQALNRFWDYLRWVQTLS
 DQVQEELQSSQVTQELTALMEDTMTEVKAYKKELEEQLGPVAEETRARLGKEVQA
 AQARLGADMEDLRNRLGQYRNEVHTMLGQSTEEIRARLSTHLRKMRLMRDAED
 40 LQKRLAVYKAGAREGAERGVSAIRERLGPLVEQGRQRTANLGAGAAQPLRDRAQA
 FGDRIRGRLEEVGNQARDRLVEVREHMEEVRSKMEEQTQQIRLQAEIFQARLKGWFE
 PIVEDMHRQWANLMEKIQASVATNPITPVAQENQ

45 [00207] SEQ ID NO:14: amino acid sequence-human APOE3

MKVLWAALLVTFLAGCQAKVEQAVETEPEPELRQQTEWQSGQRWELALGRFWDY
 LRWVQTLSEQVQEELLSSQVTQELRALMDETMKELKAYKSELEEQLTPVAEETRAR
 LSKELQAAQARLGADMEDVCGRVLQYRGEVQAMLGQSTEELRVRLASHLRKLKRK

- 56 -

LLRDADDLQKRLAVYQAGAREGAERGLSAIRERLGPLVEQGRVRAATVGSLAGQPL
QERAQAWGERLRARMEEMGSRTDRDLDEVKEQVAEVRKLEEQAAQQIRLQAEAFQ
ARLKSWFEPLVEDMQRQWAGLVEKVQAAVGTSAAPVPSDNH

5 [00208] SEQ ID NO:15: APOE4p (299 amino acids)

KVEQAVETEPEPELRQQTEWQSGQRWELALGRFWDYLRWVQTLSEQVQEELLSSQ
VTQELRALMDETMKELKAYKSELEEQLTPVAEETRARLSKELQAAQARLGADMED
VRGRLVQYRGEVQAMLGQSTEELRVRLASHLRKLRKRLLRDADDLQKRLAVYQAG
AREGAERGLSAIRERLGPLVEQGRVRAATVGSLAGQPLQERAQAWGERLRARMEE
10 MGSRTDRDLDEVKEQVAEVRKLEEQAAQQIRLQAEAFQARLKSWFEPLVEDMQRQ
WAGLVEKVQAAVGTSAAPVPSDNH

[00209] Any patents or publications mentioned in this specification are incorporated
herein by reference to the same extent as if each individual publication is specifically and
15 individually indicated to be incorporated by reference.

[00210] The genetically modified mice and methods of use described herein are presently
representative of preferred embodiments, exemplary, and not intended as limitations on the
scope of the invention. Changes therein and other uses will occur to those skilled in the art.
Such changes and other uses can be made without departing from the scope of the invention
20 as set forth in the claims.

11 Jan 2024
2018239433

WHAT IS CLAIMED IS:

1. A genetically modified mouse comprising:
a transgene encoding a humanized APOE4 protein (APOE4p), wherein the transgene comprises exon 1 of a mouse *ApoE4* gene and exons 2, 3 and 4 of a human *APOE4* gene; and
a mouse gene encoding a mouse Trem2 protein comprising a p.R47H mutation (Trem2p),
wherein the humanized APOE4p and mouse Trem2p are expressed in the genetically modified mouse, and the genetically modified mouse exhibits one or more characteristic(s) of non-familial late-onset Alzheimer's disease selected from (a) microglia, amyloid plaques, tau aggregates, inflammation, synaptic and/or neuronal loss, cognitive deficit, or blood flow deficit in the brain of the genetically modified mouse (b) cerebrovascular leakage and (c) cholesterol metabolism.
2. The genetically modified mouse of claim 1, wherein the humanized APOE4p comprises an amino acid sequence of: SEQ ID NO:1, or the humanized APOE4p is encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:2 under highly stringent hybridization conditions.
3. The genetically modified mouse of claim 1, wherein the mouse Trem2p comprises an amino acid sequence of: SEQ ID NO:3, or the mouse Trem2p is encoded by the complement of a nucleic acid which hybridizes to SEQ ID NO:4 under highly stringent hybridization conditions.
4. A method for screening a putative treatment for human Alzheimer's disease, comprising:
administering a compound to a genetically modified mouse of any one of claims 1 to 3;
assessing an effect of the compound on one or more characteristic(s) of non-familial late-onset Alzheimer's disease selected from (a) microglia, amyloid plaques, tau aggregates, inflammation, synaptic and/or neuronal loss, cognitive deficit, or blood flow deficit in the brain of the genetically modified mouse, (b) cerebrovascular leakage, and (c) cholesterol metabolism; and
comparing the effect to a control mouse.

5. The method of claim 4, wherein the control mouse is a wild-type C57BL/6J mouse.
6. The method of claim 4, wherein the control mouse is an APOE3-expressing mouse.




FIG. 1




FIG. 2




FIG. 3A




FIG. 3B




FIG. 3C





FIG. 4



47JLA12252WO_ST25.txt
SEQUENCE LISTING

<110> The Jackson Laboratory
<120> A GENETICALLY MODIFIED MOUSE EXPRESSING HUMAN APOE4 AND MOUSE
Trem2 p.R47H
<130> 47JLA12252WO
<150> 62/474,358
<151> 2017-03-21
<160> 17
<170> PatentIn version 3.5
<210> 1
<211> 317
<212> PRT
<213> Homo sapiens
<400> 1

Met Lys Val Leu Trp Ala Ala Leu Leu Val Thr Phe Leu Ala Gly Cys
1 5 10 15

Gln Ala Lys Val Glu Gln Ala Val Glu Thr Glu Pro Glu Pro Glu Leu
20 25 30

Arg Gln Gln Thr Glu Trp Gln Ser Gly Gln Arg Trp Glu Leu Ala Leu
35 40 45

Gly Arg Phe Trp Asp Tyr Leu Arg Trp Val Gln Thr Leu Ser Glu Gln
50 55 60

Val Gln Glu Glu Leu Leu Ser Ser Gln Val Thr Gln Glu Leu Arg Ala
65 70 75 80

Leu Met Asp Glu Thr Met Lys Glu Leu Lys Ala Tyr Lys Ser Glu Leu
85 90 95

Glu Glu Gln Leu Thr Pro Val Ala Glu Glu Thr Arg Ala Arg Leu Ser
100 105 110

Lys Glu Leu Gln Ala Ala Gln Ala Arg Leu Gly Ala Asp Met Glu Asp

115

120

125

Val Arg Gly Arg Leu Val Gln Tyr Arg Gly Glu Val Gln Ala Met Leu
 130 135 140

Gly Gln Ser Thr Glu Glu Leu Arg Val Arg Leu Ala Ser His Leu Arg
 145 150 155 160

Lys Leu Arg Lys Arg Leu Leu Arg Asp Ala Asp Asp Leu Gln Lys Arg
 165 170 175

Leu Ala Val Tyr Gln Ala Gly Ala Arg Glu Gly Ala Glu Arg Gly Leu
 180 185 190

Ser Ala Ile Arg Glu Arg Leu Gly Pro Leu Val Glu Gln Gly Arg Val
 195 200 205

Arg Ala Ala Thr Val Gly Ser Leu Ala Gly Gln Pro Leu Gln Glu Arg
 210 215 220

Ala Gln Ala Trp Gly Glu Arg Leu Arg Ala Arg Met Glu Glu Met Gly
 225 230 235 240

Ser Arg Thr Arg Asp Arg Leu Asp Glu Val Lys Glu Gln Val Ala Glu
 245 250 255

Val Arg Ala Lys Leu Glu Glu Gln Ala Gln Gln Ile Arg Leu Gln Ala
 260 265 270

Glu Ala Phe Gln Ala Arg Leu Lys Ser Trp Phe Glu Pro Leu Val Glu
 275 280 285

Asp Met Gln Arg Gln Trp Ala Gly Leu Val Glu Lys Val Gln Ala Ala
 290 295 300

Val Gly Thr Ser Ala Ala Pro Val Pro Ser Asp Asn His
 305 310 315

<210> 2

47JLA12252WO_ST25.txt

<211> 2792

<212> DNA

<213> Homo sapiens

<400> 2

actggccaat cacaggcagg aagatgaagg ttctgtgggc tgcgttgctg gtcacattcc	60
tggcaggtat gggggcgggg cttgctcggt tcccccgct cctccccctc tcacctcac	120
ctcaacctcc tggccccatt caggcagacc ctgggcccc tcttctgagg cttctgtgct	180
gcttcctggc tctgaacagc gatttgacgc tctctgggcc tcggtttccc ccatccttga	240
gataggagtt agaagttggt ttgttggtgt tgtttgttgt tgttgttttg tttttttgag	300
atgaagtctc gctctgtcgc ccaggctgga gtgcagtggc gggatctcgg ctactgcaa	360
gctccgcctc ccaggctcac gccattctcc tgcctcagcc tcccaagtag ctgggactac	420
aggcacatgc caccacacc gactaacttt tttgtatttt cagtagagac ggggtttcac	480
catgttggcc aggctggtct ggaactcctg acctcaggtg atctgcccgt ttcgatctcc	540
caaagtgctg ggattacagg cgtgagccac cgcacctggc tgggagttag aggtttctaa	600
tgcattgcag gcagatagtg aataccagac acggggcagc tgtgatcttt attctccatc	660
acccccacac agccctgcct ggggcacaca aggacactca atacatgctt ttccgctggg	720
cgcggtggct caccctgta atcccagcac tttgggaggc caaggtggga ggatcacttg	780
agcccaggag ttcaacacca gcctgggcaa catagtgaga ccctgtctct actaaaaata	840
caaaaattag ccaggcatgg tgccacacac ctgtgctctc agctactcag gaggctgagg	900
caggaggatc gcttgagccc agaaggtcaa ggttgacagt aaccatgttc aggccgctgc	960
actccagcct gggtgacaga gcaagaccct gtttataaat acataatgct ttccaagtga	1020
ttaaaccgac tccccctca ccctgcccac catggctcca aagaagcatt tgtggagcac	1080
cttctgtgtg cccctaggta ctagatgcct ggacggggtc agaaggacct tgaccacct	1140
tgaacttggt ccacacagga tgccaggcca aggtggagca agcggaggag acagagccgg	1200
agcccagagct gcgccagcag accgagtggc agagcggcca gcgctgggaa ctggcactgg	1260
gtcgcttttg ggattacctg cgctgggtgc agacactgtc tgagcagggt caggaggagc	1320
tgctcagctc ccaggtcacc caggaactga ggtgagtgtc cccatcctgg cccttgacct	1380
tcctgggtggg cggctatacc tccccaggtc caggtttcat tctgcccctg tcgctaagtc	1440

47JLA12252WO_ST25.txt

ttggggggcc tgggtctctg ctggttctag cttcctcttc ccatttctga ctctggctt	1500
tagctctctg gatatctctc tctcagcttt gtctctctct cttcccttct gactcagtct	1560
ctcacactcg tcctggctct gtctctgtcc ttccctagct cttttatata gagacagaga	1620
gatggggtct cactgtgttg cccaggctgg tcttgaactt ctgggctcaa gcgacacctc	1680
cgcctcggcc tcccaaagtg ctgggattag aggcatgagc caccttgccc ggccctcctag	1740
ctccttcttc gtctctgcct ctgccctctg catctgctct ctgcatctgt ctctgtctcc	1800
ttctctcggc ctctgccccg ttccttctct ccctcttggg tctctctggc tcatcccat	1860
ctgccccgcc ccatcccagc ctttctcccc gcctcccact gtgcgacacc ctccccccct	1920
ctcggccgca gggcgctgat ggacgagacc atgaaggagt tgaaggccta caaatcgga	1980
ctggaggaac aactgacccc ggtggcggag gagacgcggg cacggctgtc caaggagctg	2040
caggcggcgc agggccggct gggcgcggaac atggaggacg tgcgcggccg cctggtgcag	2100
taccgcggcg aggtgcaggc catgctcggc cagagcaccg aggagctgcg ggtgcgcctc	2160
gcctcccacc tgcgcaagct gcgtaagcgg ctctcccgcg atgccgatga cctgcagaag	2220
cgcctggcag tgtaccaggc cggggcccgcg gagggcgccg agcgcggcct cagcgccatc	2280
cgcgagcgcc tggggccctt ggtggaacag ggccgcgtgc gggccgccac tgtgggctcc	2340
ctggccggcc agccgctaca ggagcgggccc caggcctggg gcgagcggct gcgcgcgcgg	2400
atggaggaga tgggcagccg gaccgcgac cgcctggacg aggtgaagga gcaggtggcg	2460
gaggtgcgcg ccaagctgga ggagcaggcc cagcagatac gcctgcaggc cgaggccttc	2520
caggccccgc tcaagagctg gttcgagccc ctggtggaag acatgcagcg ccagtgggcc	2580
gggctggtgg agaaggtgca ggctgccgtg ggcaccagcg ccgcccctgt gccagcgac	2640
aatcactgaa cgccgaagcc tgcagccatg cgacccacg ccaccccgct cctcctgcct	2700
ccgcgcagcc tgcagcggga gaccctgtcc ccgcccagc cgtcctcctg ggggtggacc	2760
tagtttaata aagattcacc aagtttcacg ca	2792

<210> 3
 <211> 249
 <212> PRT
 <213> Artificial Sequence

47JLA12252W0_ST25.txt

<220>

<223> Mouse Trem2 protein having the R47H point mutation

<400> 3

Met Gly Pro Leu His Gln Phe Leu Leu Leu Leu Ile Thr Ala Leu Ser
1 5 10 15

Gln Ala Leu Asn Thr Thr Val Leu Gln Gly Met Ala Gly Gln Ser Leu
20 25 30

Arg Val Ser Cys Thr Tyr Asp Ala Leu Lys His Trp Gly Arg His Lys
35 40 45

Ala Trp Cys Arg Gln Leu Gly Glu Glu Gly Pro Cys Gln Arg Val Val
50 55 60

Ser Thr His Gly Val Trp Leu Leu Ala Phe Leu Lys Lys Arg Asn Gly
65 70 75 80

Ser Thr Val Ile Ala Asp Asp Thr Leu Ala Gly Thr Val Thr Ile Thr
85 90 95

Leu Lys Asn Leu Gln Ala Gly Asp Ala Gly Leu Tyr Gln Cys Gln Ser
100 105 110

Leu Arg Gly Arg Glu Ala Glu Val Leu Gln Lys Val Leu Val Glu Val
115 120 125

Leu Glu Asp Pro Leu Asp Asp Gln Asp Ala Gly Asp Leu Trp Val Pro
130 135 140

Glu Glu Ser Ser Ser Phe Glu Gly Ala Gln Val Glu His Ser Thr Ser
145 150 155 160

Arg Gln Val Ser Ser Cys Gly Ser Pro Leu Ala Tyr His Leu Pro Pro
165 170 175

Leu Ser Lys Glu Ser Arg Asp Leu Leu Pro Thr His Leu His Ser Ser
180 185 190

47JLA12252WO_ST25.txt

Pro Pro Gly Leu Arg Ser Pro Glu Gln Val Ser Cys Ser Gln His Pro
195 200 205

Leu Gly Cys Gly Gln Gly Gln Ala Glu Ala Gly Asn Thr Cys Gly Gln
210 215 220

Arg Ala Gly Leu Trp Pro Arg Cys Trp Ala Pro Thr Ser Asp Pro His
225 230 235 240

Trp Thr Arg Arg Tyr Val Arg Glu Phe
245

<210> 4
<211> 1056
<212> DNA
<213> Artificial Sequence

<220>
<223> DNA encoding mouse Trem2 protein having the R47H point mutation

<400> 4
acttcaaggg aaaagcaaga tcttgcacaa ggtcccctcc ggctggctgc tggcaaagga 60
aaggtgccat gggacctctc caccagtttc tcctgctgct gatcacagcc ctgtcccaag 120
ccctcaacac cacggtgctg cagggcatgg ccggccagtc cttgaggggtg tcatgtactt 180
atgacgcctt gaagcactgg gggagacaca aagcatgggtg tcggcagctg ggtgaggagg 240
gcccattgcca gcgtgtgggtg agcacacacg gtgtgtggct gctggccttc ctgaagaagc 300
ggaatgggag cacagtcatt gcagatgaca cccttgctgg aaccgtcacc atcactctga 360
agaacctcca agccgggtgac gcgggcctct accagtgtca gagtctccga ggccgagagg 420
ctgaggtcct gcagaaagta ctggtggagg tgctggagga ccctctagat gaccaagatg 480
ctggagatct ctgggtcccc gaggagtcatt cgagtttcga ggggtgccc aa gtggaacaca 540
gcacctccag gcaggtttca tcctgtgggt cacctctagc ctaccacctt cctcctcttt 600
ccaaggaatc aagagacctc cttcccaccc acctccattc ttctcctcct ggcctgcgtt 660
ctcctgagca agtttcttgc agccagcatc ctctgggctg tggccagggg caggcagaag 720
ccgggaacac ctgtggtcag agggctggac tgtggccaag atgctgggca ccaacttcag 780

47JLA12252W0_ST25.txt

atcctcactg gacccggagg tacgtgagag aattctgagt gggaggagaa ctacagctta 840
 agtccagcca ggagtcaatc cagcctgcat gctctcccct cctccaccaa gacttctgtt 900
 tctgctactt ttgcttcaga ggccgcctct gcctcaagcc cacctatcct gggagcagga 960
 atactggtgt gtacatctgt gttgagtggg gaagacagct ggatggttgt ctgtcaactt 1020
 ctgcactttg gacattaaac attctccaca caccaa 1056

<210> 5
 <211> 249
 <212> PRT
 <213> Mus musculus

<400> 5

Met Gly Pro Leu His Gln Phe Leu Leu Leu Leu Ile Thr Ala Leu Ser
 1 5 10 15

Gln Ala Leu Asn Thr Thr Val Leu Gln Gly Met Ala Gly Gln Ser Leu
 20 25 30

Arg Val Ser Cys Thr Tyr Asp Ala Leu Lys His Trp Gly Arg Arg Lys
 35 40 45

Ala Trp Cys Arg Gln Leu Gly Glu Glu Gly Pro Cys Gln Arg Val Val
 50 55 60

Ser Thr His Gly Val Trp Leu Leu Ala Phe Leu Lys Lys Arg Asn Gly
 65 70 75 80

Ser Thr Val Ile Ala Asp Asp Thr Leu Ala Gly Thr Val Thr Ile Thr
 85 90 95

Leu Lys Asn Leu Gln Ala Gly Asp Ala Gly Leu Tyr Gln Cys Gln Ser
 100 105 110

Leu Arg Gly Arg Glu Ala Glu Val Leu Gln Lys Val Leu Val Glu Val
 115 120 125

Leu Glu Asp Pro Leu Asp Asp Gln Asp Ala Gly Asp Leu Trp Val Pro

130

135

140

Glu Glu Ser Ser Ser Phe Glu Gly Ala Gln Val Glu His Ser Thr Ser
 145 150 155 160

Arg Gln Val Ser Ser Cys Gly Ser Pro Leu Ala Tyr His Leu Pro Pro
 165 170 175

Leu Ser Lys Glu Ser Arg Asp Leu Leu Pro Thr His Leu His Ser Ser
 180 185 190

Pro Pro Gly Leu Arg Ser Pro Glu Gln Val Ser Cys Ser Gln His Pro
 195 200 205

Leu Gly Cys Gly Gln Gly Gln Ala Glu Ala Gly Asn Thr Cys Gly Gln
 210 215 220

Arg Ala Gly Leu Trp Pro Arg Cys Trp Ala Pro Thr Ser Asp Pro His
 225 230 235 240

Trp Thr Arg Arg Tyr Val Arg Glu Phe
 245

<210> 6
 <211> 1056
 <212> DNA
 <213> Mus musculus

<400> 6
 acttcaaggg aaaagcaaga tcttgcacaa ggtccctcc ggctggctgc tggcaaagga 60
 aaggtgccat gggacctctc caccagtttc tcctgctgct gatcacagcc ctgtcccaag 120
 ccctcaacac cacggtgctg cagggcatgg ccggccagtc cttgagggtg tcatgtactt 180
 atgacgcctt gaagcactgg gggagacgca aggcctggtg tcggcagctg ggtgaggagg 240
 gcccattgcca gcgtgtggtg agcacacacg gtgtgtggct gctggccttc ctgaagaagc 300
 ggaatgggag cacagtcata gcagatgaca cccttgctgg aaccgtcacc atcactctga 360
 agaacctcca agccggtgac gcgggcctct accagtgtca gagtctccga ggccgagagg 420
 ctgaggtcct gcagaaagta ctggtggagg tgctggagga ccctctagat gaccaagatg 480

47JLA12252WO_ST25.txt

ctggagatct ctgggtcccc gaggagtcac cgagtttcga ggggtgcccac gtggaacaca	540
gcacctccag gcagggtttca tcctgtgggt cacctctagc ctaccacctt cctcctcttt	600
ccaaggaatc aagagacctc cttcccaccc acctccattc ttctcctcct ggcctgcgtt	660
ctcctgagca agtttcttgc agccagcatc ctctgggctg tggccagggg caggcagaag	720
ccgggaacac ctgtgggtcag agggctggac tgtggccaag atgctgggca ccaacttcag	780
atcctcactg gacccggagg tacgtgagag aattctgagt gggaggagaa ctacagctta	840
agtccagcca ggagtcaatc cagcctgcat gctctcccct cctccaccaa gacttctgtt	900
tctgctactt ttgcttcaga ggccgcctct gcctcaagcc cacctatcct gggagcagga	960
atactggtgt gtacatctgt gttgagtggg gaagacagct ggatgggtgt ctgtcaactt	1020
ctgcactttg gacattaaac attctccaca caccaa	1056

<210> 7
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Trem2 CRISPR guide

<400> 7	
gaagcactgg gggagacgca	20

<210> 8
 <211> 183
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Trem2 repair oligonucleotide containing a nucleotide G>A point mutation (at nucleotide 89 in this oligo sequence) for R47H and 2 silent mutations (lysine AAG>AAA (at nucleotide 93) and alanine GCC>GCA (at nucleotide 96))

<400> 8	
gccctcaaca ccacggtgct gcagggcacg gccggccagt ccttgagggt gtcattgtact	60
tatgacgcct tgaagcactg ggggagacac aaagcatggt gtcggcagct gggtgaggag	120
ggcccatgcc agcgtgtggt gagcacacac ggtgtgtggc tgctggcctt cctgaagaag	180

cgg

183

<210> 9

<211> 4980

<212> DNA

<213> Mus musculus

<400> 9

cctgtatctc agggttgaga gggaagagag tggggtttcc agatgcccac atcccttgat	60
acctagtcct cacccaactc tgctctccta gtgaacaact ggttggctac agtaacgctg	120
ggccaggcag gcatgcatgc gacgtattac cacaaagcca gtgaccaggt gagccggagg	180
gagcgcctag ctgtgggtcc caggctgggt ttgctggtgc agttggtatg cccaggagtc	240
ctaattgggcc actcacatgt gtgccgggcc ctctctcccc cagctgcagg tgggtgtgga	300
gtttgaggcc agcaccagga tgcaggacac cagtgcctcc tttgggtatc agctggacct	360
gccaaggcc aacttccttt ttaaaggtaa ggaaggcctc agcttcctc ctggggaaca	420
ggccagataa gactcagctg tctgtggtag agtccatggg aaataggag gttgaacatg	480
tgctggtgga gtgggcgggg actctgtgca gtcctcaaatt actctgggtg gcttgtcaaa	540
cagtggggct cctaccctgg catgtttagt acatgttggg ggcctcgctt taagccctct	600
cttcccattc ccatctagca agctctcttg cctccccac tcactcttac cttacttgga	660
gttcttctat tgtgtgatga aacactatga tggtaaacag cttaggaggc aaagaggtta	720
tgttgggtta caactctcag gtggcatgcc taccactgag gagaagatgg ggcaggactc	780
agcagaaagc tgaaggcaag ctgatgcaga aggcttgtg ggagtgtctg ttgttggtt	840
gctccttatg gcttcctcag cctgctctta tagcctccgg accattagcc cagggtgccc	900
cactgaaaat aatctgggta ctccacatc aatcacttag aaagtgccct acaggcttgc	960
ctgctgccct agctaattga gacatatgta ttgaggttcc ctcagctgga tctcttgagt	1020
tcaagaccag cctggtctac agagcaagtt ctgggacagc cagggtacc cagagaaacc	1080
ctgtctcaga aaagaaaaaa aagaaaaagg tgggggtggg gtgactagct tgtataaaac	1140
tagccagcac agcagggaag ctgtgtgaat agtgacagcc aggttcagaa cctcattctg	1200
cgcagtgaca tgggtttgtc aagcctgggc ggtgttgagc cacttaaagg gttgctgtga	1260
tggctctggag tggccttgggt tgtgacttag gacatacggg tccgttgtgg ctaccataga	1320

47JLA12252WO_ST25.txt

gatgggtggc caggcacatc aagccacca gtctctgccc cgctctcggc ccacaggctc	1380
tgtgaacagt aactggatcg tgggcgccac gctggagaag aagcttccgc ctttgcccct	1440
gacactgtcc ctctgcgcct tcctgaacca ccgcaagaat aagttcctgt gtggcttcgg	1500
cctcaccatc ggctgagccc tcctgtcctt cctctgcaga ccatcgctgg gccggctgcc	1560
ctccccctct ctccctctct cttgggggttg gggcagtggg aaggagggga cctcccatgc	1620
ccaaggatcc ccagcgccag gggacagtgc ccagggggcc tgggggtccc gagggagtcc	1680
tgggatctga agggcattcg attgtgagcg cccaggcaga ggcgcagagg cggctgtaca	1740
caggctcaga aaggaaagac ttgatgtcct cctgagggca gcagaggagc gccgagccgc	1800
ctgtcacttc cccctccacc cctccataga aatcatgttt ataagttatg gaaaaccggg	1860
acattttaca gaaaaaaaa aacttaaaaa acaaaaaata tacgtggaaa aaaaaatagg	1920
atctgggagg cctcggtttt ctccagttgt tgacatgggt gccagcaggc ggcgccgagg	1980
gttcagaaaag cacagcagca ccaagcagtt tagagaaagc ttggccaggc atggtcacac	2040
cctctgctct tggggactta cactgccgga acatcagagg cctggcctca ccaggagggt	2100
ggctccaggt cactcgcctc tgtgcagtct ggccccgaga gctggcagag gactttgtct	2160
ctgtaaacag ggtgggggca gggagacggg gctcaggagc ctccctgtcc caaacgggc	2220
tgagggtggt gcttgtgctg actttctccc agtgggaagg tcagaggctc cagaaacttc	2280
aggaagaaac ggagttcctg gaagttcagc acaataagga aagttactct gggaggaacg	2340
ggccctagca ctttcccagg ctgaaacagg aaatgtcaag ttgttttggt ttttaaattt	2400
tgttgaagat gtagctctgg gcctcacgtg tcaggcaggt gctgctgggt tccctatagt	2460
gcttttccgt gaggcctgct ctgggggtgt cgataagggc ctcagattgg gctctgcatc	2520
tcactgctgc acctcatggc atcccaaggg aagcaaagac tcacgatgaa ctggtcagtg	2580
tcctagaccg cagcactaag accctctcta ctgcctgggc tggagatggg agctggccct	2640
tagcaacca tgaaaatcat ctcaccacac ccagtccttg ccagtgtttt ctgaagccaa	2700
agctaacagg cctgggcctg gccaggcacc ctgtacgtac ctttgagacc aggtgttccg	2760
cctctgcca tcctgcagaa tcatgttttg ccgtgtctgg tgccaaacac tgctatgtgg	2820
cttctctcct gccatcaaca gctgggaaca gggaaccttg tgcaggcagt gcttctagca	2880

47JLA12252WO_ST25.txt

agcttgctgt ggtctctgag ccccttgtcc tacctgactt cccaggtaca atggctttcc	2940
cactttttgg gggttttggt gttgttgggt tttttttgt ttttcaagac agggtttctc	3000
tgtgtagtcc tgtcggtcct ggaactcact ttgtagacca ggctggcctc caactcagaa	3060
attcacctgc ctctgcctcc aagtgtctggg attatgggat taaaggcatg tgccaccacg	3120
cccagctggc ttttccactt tttagccagg acttcattct attacctgag ctcgggatct	3180
tcctgcctca gctttgcata tggctagcac tatagacca tgttccagt aatgacttat	3240
ggcttgtctt tttttttttt tttttttttt tttatgtgca ttagtgtttt gcctgcatgt	3300
atgccttcgt gagggtagca gatcttgggt ttacagttgt gagctgctgt gtgggtgctg	3360
cgattttgaa cctaggtcct gtgaaatgca gtcagtgtc ctaacctctg agtcattctt	3420
ccagctcctg ctcttctgct tttatgagga aaaagaaaag agaagtggct tgagagtgga	3480
aaatgcacat gcaggggtgc acacctgcag tcccagcatg ctacagcaga ggcagaagga	3540
cctttgtggg ttagagggca gcctgagaat cttatctcaa aacaactttt taaaatgtgc	3600
tctgtagggg tagctcttcc ctccaaggt gacacatctg gcaatcgcca gaaacagatc	3660
aggagcatca acgcttggtt tcccagggt tggcttaatg tatggcttca aacccatcgg	3720
gagccaccac tgaacagctc ctgaaggaac tggagcacgt cccagccttg gaatggaaag	3780
agttcacctg tgggtggagga atcaacaacg agggatccca gaacaacgat cttacccca	3840
gaagctgagc ctcttagccc ccaccaccc atttccattt aggctgccag ctcttttctt	3900
tacaatgcac cagacccgc ggggaaaggg aaggagcggg tctcagtgcc ccagtaccaa	3960
ggcctggatt attcaatgag gtgtccgctc cctttgttgg cgggggaggg gagcgggggg	4020
tcacaaggca tccaaactcc acctctttcc tctgccctgc tgtgaagggg gagagaacaa	4080
ccgcctcgt gacagggggc tggcacagcc cgccctagcc ctgaggaggg ggcgggacag	4140
ggggagtcct ataattggac cggtctggga tccgatcccc tgctcagacc ctggaggcta	4200
aggacttggt tcggaaggag ctggtaagac aagctgggct ggggattcac ccagggacct	4260
tggtaggatg tgggctggga accttgagat cccccggagt ccaggaaaca ggcacaagaa	4320
ttggaaaagc aggcagcacg atagaagtct tgggggacaa actaaggact cgaggtaact	4380
agcctttgcc agagtcagag caggtggagg ggttacctcc aggaaggagt acgggactgt	4440

47JLA12252WO_ST25.txt

cggtgcacgg cgtaccggct caactaggaa ccatcctatg gcgaaaaaac tcgggatgag	4500
ccttaggctg cttttatata aatacctact gatttccatc acagtcccca agtaaccg	4560
actggtttca aactgtggct cctcatggct gagctcccta agttctgtag ttgtgggagg	4620
gtaccacttc gcagggatgg aggacgatta aaaatcgtgt taaattaaca caaaatggaa	4680
agcaggactt agccgggaag aaagaggaat gtaagctgga ccacccgctg gccctctgtg	4740
aagtggaatt tgaaccctag gagagggagc tggaatTTTTT ggcagcggat ccacccggg	4800
gtgccgagat agcgaactcg gcaaggggag gtaaacagac ctttgggaag agcgggtgct	4860
ctgttttgga gatgtttgtg atggctcaca gatctgagaa gggaagatgg ggttctctgg	4920
gtggccggag tccctccacc cccgccccct ggtgttcaaa gacaatTTTTT ccctccgcag	4980

<210> 10
 <211> 4292
 <212> DNA
 <213> Homo sapiens

<400> 10	
actggccaat cacaggcagg aagatgaagg ttctgtgggc tgcgttgctg gtcacattcc	60
tggcaggtat gggggcgggg cttgctcggt tcccccgct cttccccctc tcattctcac	120
ctcaacctcc tggccccatt caggcagacc ctgggcccc tcttctgagg cttctgtgct	180
gcttcttggc tctgaacagc gatttgacgc tctctgggcc tcggtttccc ccatccttga	240
gataggagtt agaagttggt ttgttgttgt tggttgttgt tggttgtttg tttttttgag	300
atgaagtctc gctctgtcgc ccaggctgga gtgcagtggc gggatctcgg ctactgcaa	360
gctccgcctc ccaggtccac gccattctcc tgcctcagcc tccaagtag ctgggactac	420
aggcacatgc caccacaccc gactaacttt tttgtatTTTt cagtagagac ggggtttcac	480
catgttggcc aggctggtct ggaactcctg acctcaggtg atctgcccgt ttcgatctcc	540
caaagtgctg ggattacagg cgtgagccac cgcacctggc tgggagttag aggtttctaa	600
tgcattgcag gcagatagtg aataccagac acggggcagc tgtgatcttt attctccatc	660
acccccacac agccctgcct ggggcacaca aggacactca atacatgctt ttccgctggg	720
cgcggtggct caccctgta atcccagcac tttgggaggc caaggtggga ggatcacttg	780

47JLA12252WO_ST25.txt

agcccaggag	ttcaacacca	gcctgggcaa	catagtgaga	ccctgtctct	actaaaaata	840
caaaaattag	ccaggcatgg	tgccacacac	ctgtgctctc	agctactcag	gaggctgagg	900
caggaggatc	gcttgagccc	agaaggtcaa	ggttgacagt	aaccatgttc	aggccgctgc	960
actccagcct	gggtgacaga	gcaagaccct	gtttataaat	acataatgct	ttccaagtga	1020
ttaaaccgac	tccccctca	ccctgcccac	catggctcca	aagaagcatt	tgtggagcac	1080
cttctgtgtg	cccctaggta	ctagatgcct	ggacggggtc	agaaggaccc	tgaccacact	1140
tgaacttggt	ccacacagga	tgccaggcca	aggtggagca	agcggaggag	acagagccgg	1200
agcccgagct	gcgccagcag	accgagtggc	agagcggcca	gcgctgggaa	ctggcactgg	1260
gtcgcttttg	ggattacctg	cgctgggtgc	agacactgtc	tgagcagggt	caggaggagc	1320
tgctcagctc	ccaggtcacc	caggaactga	ggtgagtgtc	cccatcctgg	cccttgaccc	1380
tcctgggtggg	cggctatacc	tccccaggtc	caggtttcat	tctgcccctg	tcgctaagtc	1440
ttggggggcc	tgggtctctg	ctggttctag	cttcctcttc	ccatttctga	ctcctggctt	1500
tagctctctg	gatatctctc	tctcagcttt	gtctctctct	cttcccttct	gactcagtct	1560
ctcacactcg	tcctggctct	gtctctgtcc	ttccctagct	cttttatata	gagacagaga	1620
gatgggggtct	cactgtgttg	cccaggctgg	tcttgaactt	ctgggctcaa	gcgacccctc	1680
cgctcggcc	tcccaaagtg	ctgggattag	aggcatgagc	caccttgccc	ggcctcctag	1740
ctccttcttc	gtctctgcct	ctgccctctg	catctgctct	ctgcatctgt	ctctgtctcc	1800
ttctctcggc	ctctgccccg	ttccttctct	ccctcttggg	tctctctggc	tcatcccat	1860
ctgccccgcc	ccatcccagc	ccttctcccc	gcctccact	gtgcgacacc	ctcccgccct	1920
ctcggccgca	gggcgctgat	ggacgagacc	atgaaggagt	tgaaggccta	caaatcggaa	1980
ctggaggaac	aactgacccc	ggtggcggag	gagacgcggg	cacggctgtc	caaggagctg	2040
caggcggcgc	aggcccggct	gggcgcggac	atggaggacg	tgcgcggccg	cctgggtgcag	2100
taccgcggcg	aggtgcaggc	catgctcggc	cagagcaccg	aggagctgcg	ggtgcgcctc	2160
gcctcccacc	tgcgcaagct	gcgtaagcgg	ctcctccgcg	atgccgatga	cctgcagaag	2220
cgcctggcag	tgtaccaggc	cggggcccgc	gagggcgccg	agcgcggcct	cagcgccatc	2280
cgcgagcgcc	tggggcccct	ggtggaacag	ggccgcgtgc	gggccgccac	tgtgggctcc	2340

47JLA12252WO_ST25.txt

ctggccggcc agccgctaca ggagcgggcc caggcctggg gcgagcggct gcgcgcgcgg	2400
atggaggaga tgggcagccg gacccgcgac cgcctggacg aggtgaagga gcaggtggcg	2460
gaggtgcgcg ccaagctgga ggagcaggcc cagcagatac gcctgcaggc cgaggccttc	2520
cagggccgcc tcaagagctg gttcgagccc ctggtggaag acatgcagcg ccagtgggcc	2580
gggctgggtg agaaggtgca ggctgccgtg ggcaccagcg ccgcccctgt gcccagcgac	2640
aatcactgaa cgccgaagcc tgcagccatg cgacccacg ccaccccgct cctcctgcct	2700
ccgcgcagcc tgcagcggga gaccctgtcc ccgcccagc cgtcctcctg ggggtggacc	2760
tagtttaata aagattcacc aagtttcacg catctgctgg cctccccctg tgatttcctc	2820
taagccccag cctcagtttc tctttctgcc cacatactgg ccacacaatt ctacagcccc	2880
tcctctccat ctgtgtctgt gtgtatcttt ctctctgccc tttttttttt ttttagacgg	2940
agtctggctc tgtcaccag gctagagtgc agtggcacga tcttggctca ctgcaacctc	3000
tgcctcttgg gttcaagcga ttctgctgcc tcagtagctg ggattacagg ctcacaccac	3060
cacaccggc taatTTTTgt atTTTTagta gagacgagct ttcaccatgt tggccaggca	3120
ggtctcaaac tcctgaccaa gtgatccacc cgccggcctc ccaaagtgt gagattacag	3180
gcctgagcca ccatgcccgg cctctgcccc tctttctttt ttagggggca gggaaaggtc	3240
tcaccctgtc acccgccatc acagctcact gcagcctcca cctcctggac tcaagtata	3300
agtgatcctc ccgcctcagc ctttccagta gctgagacta caggcgcata ccactaggat	3360
taatttgggg ggggggggtg tgtgtgtgga gatggggctt ggctttgttg gccaggctga	3420
tgtggaattc ctgggctcaa gcgatactc caccttggcc tcctgagtag ctgagactac	3480
tggctagcac caccacacc agctttttat tattatttgt agagacaagg tctcaatatg	3540
ttgccaggc tagtctcaaa cccctgggct caagagatcc tccgccatcg gcctcccaaa	3600
gtgctgggat tccaggcatg gggctccgag cccggcctgc ccaacttaat aatacttgtt	3660
cctcagagtt gcaactcaa atgacctgag attggtgcct ttattctaag ctattttcat	3720
ttttttctg ctgtcattat tctccccctt ctctcctcca gtcttatctg atatctgcct	3780
ccttcccacc caccctgcac cccatccac ccctctgtct ctccctgttc tcctcaggag	3840
actctggctt cctgttttcc tccacttcta tcttttatct ctccctccta cggtttcttt	3900

47JLA12252WO_ST25.txt

tctttctccc cggcctgctt gtttctcccc caacccccctt catctggatt tcttcttctg	3960
ccattcagtt tggtttgagc tctctgcttc tccggttccc tctgagctag ctgtcccttc	4020
accactgtg aactggggtt ccctgccccaa ccctcattct ctttctttct ttcttttttt	4080
tttttttttt tttttttttt ttttgagaca gagtcttgct ctgttgccca gcctggagtg	4140
cagtggtgca atcttggttc actgcaacct ccacttccca gattcaagca attctcctgc	4200
ctcagcctcc agagtagctg ggattacagg cgtgtcccac cacacccgac taatttttgt	4260
atttttggta gagacaaggc ttcggcattg tt	4292

<210> 11

<211> 1834

<212> DNA

<213> Artificial Sequence

<220>

<223> A Frt PGKneo Frt cassette followed by an Nde1 restriction enzyme site (CATATG)

<400> 11

gaagttccta ttctctagaa agtataggaa cttcaggtct gaagaggagt ttacgtccag	60
ccaagctagc ttggctgcag gtcgtcgaaa ttctaccggg taggggaggc gcttttccca	120
aggcagtctg gagcatgcgc tttagcagcc ccgctgggca cttggcgcta cacaagtggc	180
ctctggcctc gcacacattc cacatccacc ggtaggcgcc aaccggctcc gttctttggt	240
ggccccttcg cgccaccttc tactcctccc ctagtcagga agttcccccc cgccccgcag	300
ctcgcgtcgt gcaggacgtg acaaattgaa gtagcacgtc tcactagtct cgtgcagatg	360
gacagcaccg ctgagcaatg gaagcgggta ggcctttggg gcagcggcca atagcagctt	420
tgctccttcg ctttctgggc tcagaggctg ggaaggggtg ggtccggggg cgggctcagg	480
ggcgggctca ggggcggggc gggcgcccga aggtcctccg gagggccggc attctgcacg	540
cttcaaaagc gcacgtctgc cgcgctgttc tcctcttcct catctccggg cttttcgacc	600
tgcagcctgt tgacaattaa tcatcggcatt agtatatcgg catagtataa tacgacaagg	660
tgaggaacta aaccatggga tcggccattg aacaagatgg attgcacgca ggttctccgg	720
ccgcttgggt ggagaggcta ttcggctatg actgggcaca acagacaatc ggctgctctg	780
atgccgccgt gttccggctg tcagcgcagg ggcgcccgt tctttttgtc aagaccgacc	840

47JLA12252WO_ST25.txt

tgtccggtgc cctgaatgaa ctgcaggacg aggcagcgcg gctatcgtgg ctggccacga	900
cgggcgttcc ttgcgcagct gtgctcgacg ttgtcactga agcgggaagg gactggctgc	960
tattgggcga agtgccgggg caggatctcc tgtcatctca ccttgctcct gccgagaaag	1020
tatccatcat ggctgatgca atgcggcggc tgcatacgct tgatccggct acctgccccat	1080
tcgaccacca agcgaaacat cgcatacgagc gagcacgtac tcggatggaa gccggtcttg	1140
tcgatcagga tgatctggac gaagagcatc aggggctcgc gccagccgaa ctgttcgcca	1200
ggctcaaggc gcgcatgccc gacggcgatg atctcgtcgt gacccatggc gatgcctgct	1260
tgccgaatat catggtggaa aatggccgct tttctggatt catcgactgt ggccggctgg	1320
gtgtggcgga ccgctatcag gacatagcgt tggctacccg tgatattgct gaagagcttg	1380
gcggcgaatg ggctgaccgc ttcctcgtgc tttacgggat cgccgctccc gattcgagc	1440
gcatcgcctt ctatcgcctt cttgacgagt tcttctgagg ggatcaattc tctagagctc	1500
gctgatcagc ctcgactgtg ctttctagtt gccagccatc tgttgtttgc ccctcccccg	1560
tgccttcctt gaccctggaa ggtgccactc ccactgtcct ttcctaataa aatgaggaaa	1620
ttgcatcgca ttgtctgagt aggtgtcatt ctattctggg ggggtggggtg gggcaggaca	1680
gcaaggggga ggattgggaa gacaatagca ggcatgctgg ggatgcggtg ggctctatgg	1740
cttctgaggc ggaaagaacc agctggggct cgactagagc ttgcggaacc cttcgaagtt	1800
cctattctct agaaagtata ggaacttcca tatg	1834

<210> 12
 <211> 5166
 <212> DNA
 <213> Mus musculus

<400> 12 aaacctgatg gagaagatac aggcctctgt ggctaccaac cccatcatca cccagtggc	60
ccaggagaat caatgagtat ctttctcctg tcctgcaaca acatccatat ccagccaggt	120
ggccctgtct caagcacctc tctggccctc tgggtggccct tgcttaataa agattctccg	180
agcacattct gagtctctgt gagtgattcc aatcagcttc agcctcagtt tattgttttt	240
tgccttacct agcacacatt ccatggccct gtcactatct gtagaggag gtggttttgc	300

47JLA12252WO_ST25.txt

agcaatagaa atgaagccta ggacctagca acataaaaaga acaagtgatc taccactgag	360
ccacgcccac agcccctcac tgggggattc taggcagggg ctctaccact gagccacccg	420
cagcccctca ctggggaatc atatctacca ctgagtcacg cccctccagc ccctcactac	480
gggaattcta gtcagtagct ctaccactga gccacacca cagcctctgg ggctcttcac	540
cgccccctac ccctggattc taggcatggg ctcatTTTTat ttattttattt atttaagatt	600
tgtttatctt atgtataagg tacactgcag ctgtcttcag gcgtcaggtc ccattacaga	660
tggttgtagag ccaccatgtg gttgctggga attgaactca ggacttatag aagagtagtc	720
agtgtcttta actgtcgagc catctctcca gcaccagta caggctcttc tatttagcta	780
tatccaccct tcttttttagt ctgaaatagg atctcaactg attttccttg cactccctct	840
agcctagttt ggtcttgaat atttgaatct ttgttttcaa atcaatctct acaggaactg	900
agaaaggcat gtaccacttc atgtgggtca gttgggctac ttttcccaac ttccaagca	960
cccactgcac agctatgcct tgaatcaatc aacatgtaag agaccagggt cgccaggcgg	1020
tgtttacttt tctggttgtc ttatctctcc tcctccgctc tagtcttatc tgacaccctc	1080
tccttgccct gtctctcctc tttttccctt ctaggcttcc ttttctggct tcctgttttc	1140
ctgatcctct gttatctcac cctcccgcgg tttcttttgc tctgggcctt tggttggcgg	1200
tttctacggg ttctacgtgg cttttggaac ctacgccttt ctcccttgct ctgaagttag	1260
ctggatcttt gctccctctg ggtcatgggg ccttagcccc attctttctc ccctgcctgt	1320
gctgcatgcc ttttgacttt ccagcaagt gtatggagag tgagttcagg ctggggacac	1380
aaaaccattc tccccatgtc ctggtactca aaggggtcat ggtggaagct ggagagcccc	1440
tggctggctt ctctccac cccctcagtt ctacagggact cagcagggt cccactaaca	1500
ggggcaggct agggcttgag ctgtgtcttg ggtcgggcca aggcctcaga actcaactgc	1560
ctctggcaca cccgagcct gcagcttttc ctggcatcaa actcagcatt atctggaggc	1620
aggcaccact cccacacatg actcattagg cccaatgaga agatgggtcg gtgggctagt	1680
gacagggccc tagacagcca cacttcatgc ccaggggcta ggagcacacc ccagagcct	1740
cactactctc aaatatcaag atgaggggag agtatagagg gaatgtctcc ctctgaagac	1800
ctgaattatt gtgatgttat ttgagccacg ctggccttga actctgaacc ctctgcctc	1860

47JLA12252WO_ST25.txt

atcttcaaag gctggaatta caggttcgcg ccactaggcc tatctgagaa cttagttaat	1920
tctacagaag agagtttgtt ttcactgggt tgaaacgagg cctcgtgtac ccagagctac	1980
tcttttgcca actcactgta gagccaagga tgaccttgaa ctctggctctt cctggctccg	2040
agtcctcggg actgggtaga caatgtgtga tcctaacccc cagttttatg tgggtgtata	2100
cagatggcat ccagggtttc ctgcatgctg gacaggctcat caaccaaccg agccacatcc	2160
tcctcatcat catcactttg ttgttgggtt tcaatccaga gctcatggag cccaagctgg	2220
cctcaatcta tataaccaag actgtgcctg gtcttcctgt ctctaccta caaatgatgg	2280
tgggatgcag ggatgtacaa ccaggagcag agccttactt ctaaacgaag aaggaacccc	2340
acctccctgt gggcagacct ggagggtggg caaggaccac agaaagacat tacagaacta	2400
ggatcgtgaa ggaagtcag gaggccagcc tgttgtacag agtgagttcc aggacagcca	2460
gggctacaca gaggaaaaca agaaggaaaa aaaaaaaaaa aaaaagaact gaatgactag	2520
cagttttaga accttagctg tgtgcttccc gtaccctacc tgtggcacag gaagcccttg	2580
ttgctaagag taggatgaca ctggaagcac caagcactgg gcagagtaag ggggaaatct	2640
gttacattat tcagatgggc gcttgaggac tgagcaggac tcctttcaag aagcaaaagg	2700
gtcaggcctg gtgcccacag ggactggaag ctagctagcg ccgagttggc cccagagatg	2760
tcgcaacca gccagggtcg agaattctgtt ccaccccttt cacaaccatc cccctgttgt	2820
cgctgtcccc acccccaccc ccgccccaac tgacacgtgg gttgcagggg caccaggcca	2880
gccaacctag agtctgggcc ccttagccac cagctgccag ggggtcactg tcggtcaatg	2940
acagctctgg gggagggggg gagaagggcc ttggactcta gcctgagaga aaggatgttg	3000
tggaaggagg gggcaggag gcaagtttag ggcctgcagg ggcctaggag gccccacaag	3060
acctaaaaac gggggaagg gggttgtgcc agttagggga cactatggag ctctgcaagc	3120
taagaggctc ttagcttctt tgcagttttg actagctgaa gaggcaactt ctaaggaagg	3180
gagatgaggg gatgccaaga tcccagagag catccgagga ggtctgaggg tgtgcagatg	3240
caaaggcatt ggaggtgaag ggagccaggg tgcagcatcc gggacagaat gtgagctgag	3300
gctcctgggtc aaggagaagg tagagaagag ctaacctgag gatgcagtgt gagctagggg	3360
tgagatgggg gtgaggggag ttgtttgtaa gaccccccc ctttaagggtg gacagcctca	3420

47JLA12252W0_ST25.txt

gagagagagt	gagtaggcag	agcagccaag	gctgggtgga	gatcaatgag	at ttggaagt	3480
gaggatgctg	accagtgcg	agccttgggc	ctaaataaaa	agcctggatg	tgggatctgc	3540
ctcccagtat	cgaccagaat	gacagaagag	agtgggctgg	ttgtgttggg	gttggtgcat	3600
gcctgtaatc	ccagcaactc	actagagagg	cagaggcagg	agcatcaca	attccaggcc	3660
agccaaaaag	cctatgtaaa	aaaaaaaaaa	agagaaaaaa	gaaaaaagaa	aaagtaggtg	3720
gacacagaga	caagggggag	gctcaggggg	agggcgacca	gcttgctccg	ccccctcccc	3780
aaccggttaa	acctctgtgc	aggatcctcc	caccgccatg	ggcctcctga	gagatcctta	3840
gatccagggt	agtgcatagg	aaagtgtccc	cccactacct	acagctaagg	gattgggggtg	3900
gtgggatcat	ggtggagggc	ggtggtgaat	actagcgatg	tcccccgcta	cccgtgcgtc	3960
tgctccagg	gtgcccctcc	aaccaggatg	aggctcttca	tcgctcttcc	tgtcctgatt	4020
gtggtcgtag	ccatgacctt	ggaaggtaag	aaagagcctt	ggaaggtaag	aaagaggctt	4080
ggaagtgtga	agttggcctt	gtgcctgcgg	cccaggctta	gaagaccctc	gaggagggct	4140
ctgagggtccc	tttctgtgtc	atcattccac	taccgccctc	ccatcggtccc	ccatcccacc	4200
tgccagggtgc	cttatttttg	tgtcaaagtg	ggtgctgaag	gaggcaactc	tgtccagaaa	4260
agacgcagta	accaatgacc	taggatacca	ccctttggaa	ttggctaata	ttcctagaag	4320
gggcgggagcg	taaaaacaag	gaggtgagag	gtgcagtaaa	atcaagtgtc	caataccctc	4380
ccccatgcta	atgagtttgc	tcgcaaccct	ctcgcggcag	gcccagcccc	cgcccaggcg	4440
gccccggatt	tgtccggaac	attggagagc	ataccggata	aactgaagga	gtttgggaac	4500
actttggaag	acaaggcccg	ggcagccatt	gaacatatca	aacagaagga	aattttgacc	4560
aagacccggt	taggaccttt	cagggcacgg	gcgggtgggtg	tgtgtgtgtg	tgcgtgcgcg	4620
cgcgcccgtg	tgtaaaagcc	ctagcagaca	gttccacact	gacacaatgg	ggaaactgca	4680
ccagagtgtt	tgacactttc	cctgaagtca	tagaactgta	tctgaagtca	ttgaactgga	4740
tgtcaaagtg	ctcgtagtgt	ggagacaggc	ggtgtaactc	ccagccaact	gttagagatg	4800
tttccaagtc	ctagtgaagg	gccaagctag	gcggctgact	ggttaggaca	gaccctgacc	4860
cctccctgtg	tactcttgag	acaggtcatg	acttgagtct	ccgagacaga	gaaagaatgt	4920
aggagagttg	gggcaggggc	acagcagaag	ctgtacaggc	ctgggctctg	cagtttacac	4980

47JLA12252WO_ST25.txt

tggccaaaga gagattaggg catgctgggt taagaactag ccaggcagtg gtggcgacaca	5040
cctttgatcc cagtattcat gaggcagagg caggcagatc tctttgaggc cagcctgatt	5100
ggagctagtt ctaggaaagc cagggctaca cagagaaacc ctgtctcaac accaccacca	5160
cccccc	5166

<210> 13
 <211> 311
 <212> PRT
 <213> Mus musculus

<400> 13

Met	Lys	Ala	Leu	Trp	Ala	Val	Leu	Leu	Val	Thr	Leu	Leu	Thr	Gly	Cys
1			5						10					15	

Leu	Ala	Glu	Gly	Glu	Pro	Glu	Val	Thr	Asp	Gln	Leu	Glu	Trp	Gln	Ser
		20						25					30		

Asn	Gln	Pro	Trp	Glu	Gln	Ala	Leu	Asn	Arg	Phe	Trp	Asp	Tyr	Leu	Arg
		35					40					45			

Trp	Val	Gln	Thr	Leu	Ser	Asp	Gln	Val	Gln	Glu	Glu	Leu	Gln	Ser	Ser
	50					55					60				

Gln	Val	Thr	Gln	Glu	Leu	Thr	Ala	Leu	Met	Glu	Asp	Thr	Met	Thr	Glu
65					70					75					80

Val	Lys	Ala	Tyr	Lys	Lys	Glu	Leu	Glu	Glu	Gln	Leu	Gly	Pro	Val	Ala
				85					90					95	

Glu	Glu	Thr	Arg	Ala	Arg	Leu	Gly	Lys	Glu	Val	Gln	Ala	Ala	Gln	Ala
			100					105					110		

Arg	Leu	Gly	Ala	Asp	Met	Glu	Asp	Leu	Arg	Asn	Arg	Leu	Gly	Gln	Tyr
		115					120					125			

Arg	Asn	Glu	Val	His	Thr	Met	Leu	Gly	Gln	Ser	Thr	Glu	Glu	Ile	Arg
	130					135					140				

47JLA12252WO_ST25.txt

Ala Arg Leu Ser Thr His Leu Arg Lys Met Arg Lys Arg Leu Met Arg
145 150 155 160

Asp Ala Glu Asp Leu Gln Lys Arg Leu Ala Val Tyr Lys Ala Gly Ala
165 170 175

Arg Glu Gly Ala Glu Arg Gly Val Ser Ala Ile Arg Glu Arg Leu Gly
180 185 190

Pro Leu Val Glu Gln Gly Arg Gln Arg Thr Ala Asn Leu Gly Ala Gly
195 200 205

Ala Ala Gln Pro Leu Arg Asp Arg Ala Gln Ala Phe Gly Asp Arg Ile
210 215 220

Arg Gly Arg Leu Glu Glu Val Gly Asn Gln Ala Arg Asp Arg Leu Glu
225 230 235 240

Glu Val Arg Glu His Met Glu Glu Val Arg Ser Lys Met Glu Glu Gln
245 250 255

Thr Gln Gln Ile Arg Leu Gln Ala Glu Ile Phe Gln Ala Arg Leu Lys
260 265 270

Gly Trp Phe Glu Pro Ile Val Glu Asp Met His Arg Gln Trp Ala Asn
275 280 285

Leu Met Glu Lys Ile Gln Ala Ser Val Ala Thr Asn Pro Ile Ile Thr
290 295 300

Pro Val Ala Gln Glu Asn Gln
305 310

<210> 14
<211> 317
<212> PRT
<213> Homo sapiens

<400> 14

Met Lys Val Leu Trp Ala Ala Leu Leu Val Thr Phe Leu Ala Gly Cys

1	5	10	15
Gln Ala Lys Val Glu Gln Ala Val Glu Thr Glu Pro Glu Pro Glu Leu	20	25	30
Arg Gln Gln Thr Glu Trp Gln Ser Gly Gln Arg Trp Glu Leu Ala Leu	35	40	45
Gly Arg Phe Trp Asp Tyr Leu Arg Trp Val Gln Thr Leu Ser Glu Gln	50	55	60
Val Gln Glu Glu Leu Leu Ser Ser Gln Val Thr Gln Glu Leu Arg Ala	65	70	75
Leu Met Asp Glu Thr Met Lys Glu Leu Lys Ala Tyr Lys Ser Glu Leu	85	90	95
Glu Glu Gln Leu Thr Pro Val Ala Glu Glu Thr Arg Ala Arg Leu Ser	100	105	110
Lys Glu Leu Gln Ala Ala Gln Ala Arg Leu Gly Ala Asp Met Glu Asp	115	120	125
Val Cys Gly Arg Leu Val Gln Tyr Arg Gly Glu Val Gln Ala Met Leu	130	135	140
Gly Gln Ser Thr Glu Glu Leu Arg Val Arg Leu Ala Ser His Leu Arg	145	150	155
Lys Leu Arg Lys Arg Leu Leu Arg Asp Ala Asp Asp Leu Gln Lys Arg	165	170	175
Leu Ala Val Tyr Gln Ala Gly Ala Arg Glu Gly Ala Glu Arg Gly Leu	180	185	190
Ser Ala Ile Arg Glu Arg Leu Gly Pro Leu Val Glu Gln Gly Arg Val	195	200	205
Arg Ala Ala Thr Val Gly Ser Leu Ala Gly Gln Pro Leu Gln Glu Arg			

210

215

220

Ala Gln Ala Trp Gly Glu Arg Leu Arg Ala Arg Met Glu Glu Met Gly
 225 230 235 240

Ser Arg Thr Arg Asp Arg Leu Asp Glu Val Lys Glu Gln Val Ala Glu
 245 250 255

Val Arg Ala Lys Leu Glu Glu Gln Ala Gln Gln Ile Arg Leu Gln Ala
 260 265 270

Glu Ala Phe Gln Ala Arg Leu Lys Ser Trp Phe Glu Pro Leu Val Glu
 275 280 285

Asp Met Gln Arg Gln Trp Ala Gly Leu Val Glu Lys Val Gln Ala Ala
 290 295 300

Val Gly Thr Ser Ala Ala Pro Val Pro Ser Asp Asn His
 305 310 315

<210> 15
 <211> 299
 <212> PRT
 <213> Homo sapiens

<400> 15

Lys Val Glu Gln Ala Val Glu Thr Glu Pro Glu Pro Glu Leu Arg Gln
 1 5 10 15

Gln Thr Glu Trp Gln Ser Gly Gln Arg Trp Glu Leu Ala Leu Gly Arg
 20 25 30

Phe Trp Asp Tyr Leu Arg Trp Val Gln Thr Leu Ser Glu Gln Val Gln
 35 40 45

Glu Glu Leu Leu Ser Ser Gln Val Thr Gln Glu Leu Arg Ala Leu Met
 50 55 60

Asp Glu Thr Met Lys Glu Leu Lys Ala Tyr Lys Ser Glu Leu Glu Glu
 65 70 75 80

47JLA12252W0_ST25.txt

Gln Leu Thr Pro Val Ala Glu Glu Thr Arg Ala Arg Leu Ser Lys Glu
85 90 95

Leu Gln Ala Ala Gln Ala Arg Leu Gly Ala Asp Met Glu Asp Val Arg
100 105 110

Gly Arg Leu Val Gln Tyr Arg Gly Glu Val Gln Ala Met Leu Gly Gln
115 120 125

Ser Thr Glu Glu Leu Arg Val Arg Leu Ala Ser His Leu Arg Lys Leu
130 135 140

Arg Lys Arg Leu Leu Arg Asp Ala Asp Asp Leu Gln Lys Arg Leu Ala
145 150 155 160

Val Tyr Gln Ala Gly Ala Arg Glu Gly Ala Glu Arg Gly Leu Ser Ala
165 170 175

Ile Arg Glu Arg Leu Gly Pro Leu Val Glu Gln Gly Arg Val Arg Ala
180 185 190

Ala Thr Val Gly Ser Leu Ala Gly Gln Pro Leu Gln Glu Arg Ala Gln
195 200 205

Ala Trp Gly Glu Arg Leu Arg Ala Arg Met Glu Glu Met Gly Ser Arg
210 215 220

Thr Arg Asp Arg Leu Asp Glu Val Lys Glu Gln Val Ala Glu Val Arg
225 230 235 240

Ala Lys Leu Glu Glu Gln Ala Gln Gln Ile Arg Leu Gln Ala Glu Ala
245 250 255

Phe Gln Ala Arg Leu Lys Ser Trp Phe Glu Pro Leu Val Glu Asp Met
260 265 270

Gln Arg Gln Trp Ala Gly Leu Val Glu Lys Val Gln Ala Ala Val Gly
275 280 285

Thr Ser Ala Ala Pro Val Pro Ser Asp Asn His
 290 295

<210> 16
 <211> 7
 <212> PRT
 <213> Simian virus 40

<400> 16

Pro Lys Lys Lys Arg Lys Val
 1 5

<210> 17
 <211> 14
 <212> PRT
 <213> Xenopus laevis

<400> 17

Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln Ala Lys Lys Lys
 1 5 10